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Abstract 
Background 
Heart failure has become a global public health issue because of the rising global burden, high 
cost of care, frequent rehospitalisation and poor prognosis. 
Compared to other regions of the world, there are limited data on contemporary clinical 
profile, outcome, and economic cost of heart failure in Sub-Saharan Africa in general and 
Nigeria (Africa’s most populous country) in particular. We examined these in patients admitted 
with acute heart failure to a tertiary hospital in Nigeria. 
Methods 
This was a hospital based, prospective, observational study conducted at the Federal Medical 
Centre, Idi-Aba, Abeokuta, Nigeria. Detailed clinical documentation on cases of acute heart 
failure was carried out. The following data were obtained: demographic data, pre-admission 
history (previous heart failure related admissions). Others include NYHA functional class, 
symptoms, signs, self-reported cardiovascular risk factors, aetiology of heart failure, 
precipitating factors, co-morbidities, blood investigations, 12-lead ECG, echocardiography, 
medications and intra-hospital and 6-month outcomes.  
The study cohort was prospectively followed up for 6 months post initial hospitalisation. The 
subjects were contacted through clinic visits or telephone calls at one and six months. 
Information obtained during follow-up included their wellbeing, prescribed pharmacotherapy, 
history of re-hospitalization and deaths (from next of kin if they died at home). In addition to 
patient or relation’s telephone interviews, where necessary referring physicians were 
contacted for additional information.  
The following health outcomes were documented - 1) length of initial hospital stay (LoS) in 
days, 2) survival status on discharge (dead or alive), 3) short-term case-fatality (30 days), 4) 
medium-term case-fatality (180 days), and 5) re-hospitalization status (180 days) 
 
xiii  
Heath economic data were extracted from the registry. Outpatient and inpatient costs were 
computed from the cohort of HF cases admitted in 2010 including personnel, diagnostic and 
treatment resources used for their management over a 12-month period. Indirect costs were 
also calculated. The annual cost per person was then calculated. 
Results 
The mean age of the subjects was 56.6±15.3 years (57.3±13.4 for men, 55.7±17.1 for women) 
and 204 (45.1%) were women. Overall, 415 (91.8%) subjects presented with de novo acute 
heart failure. The most common risk factor for HF was hypertension (pre-existing in 64.3% of 
cases). Type 2 diabetes mellitus was present in 41(10.0%). Hypertensive HF was the 
commonest aetiological cause of heart failure being responsible for 78.5% of cases. Dilated 
cardiomyopathy (7.5%), cor-pulmonale (4.4%), pericardial disease (3.3%), rheumatic heart 
disease (2.4%) and ischemic heart disease were less common (0.4%) causes. The majority 
(71.2%) of subjects presented with left ventricular dysfunction (mean left ventricular ejection 
fraction 43.9 ± 9.0%) and valvular dysfunction and abnormal left ventricular geometry were 
frequently documented. Mean duration of hospital stay was 11.4± 9.1 days and intra-hospital 
mortality was 3.8%. 
Case fatality at 30-days was 4.2% (95%CI, 2.4-7.3%) for the cohort of newly presenting acute 
HF subjects that were followed up [3.9% (95%CI, 1.7-8.5%) in men and 4.5% (95%CI 2.1-9.3%) 
in women]. At 180-days, case-fatality was 7.3% (95%CI, 4.7-11.2%) [7.1% (95%CI, 3.8-12.7%) in 
men and 7.5% (95%CI 3.9-14.0%) for women] Patients with pericardial diseases had the 
highest early mortality. Mortality was related to some socio-demographic and clinical 
characteristics.  
Thirty two denovo HF subjects (12.2%) were rehospitalised at least once. There were 21 men 
(65.6%) and 11(34.4%) women. Worsening heart failure was the commonest reason for 
readmission. Among others, factors associated with rehospitalization include presence of 
mitral regurgitation (OR, 2.37; 95%CI, 1.26-4.46), age greater than 60 years (OR, 2.04; 95%CI, 
xiv  
0.96-3.29), presence of tricuspid regurgitation (OR, 1.77; 95% CI, 0.86-3.61), and presence of 
atrial fibrillation (OR, 1.34; 95%CI, 0.59-3.03). 
The total computed cost of care of HF in Abeokuta was 76, 288,845 Naira (US$508, 595) 
translating to 319,200 Naira (US$2,128 US Dollars) per patient per year. Inpatient and out-
patient care contributed 46% and 54% of total cost respectively. The high cost of outpatient 
care was largely due to cost of transportation for monthly follow up visits. Payments were 
mostly made through out-of-pocket spending. 
 Conclusions 
Compared to high income countries, individuals presenting with AHF in Abeokuta, Nigeria are 
relatively younger and still of a working age. It is also commoner in men and associated with 
severe symptoms because of late presentation.  
Intra-hospital mortality is similar to other parts of the world. Rehospitalization after admission 
for HF is relatively common within 6-months.  
The economic burden of heart failure in the study setting is high considering the minimum 
wage of 18,000 Naira (120 US dollars) per month in the country. This calls for financing reforms 
for the control of the disease, which may include a reduction or waiver of user fees in 
government hospitals, scaling up of financial risk protection pre-payment mechanisms such as 
health insurance and use of primary healthcare centres for follow-up visits for mild cases. The 
development and adequate funding of community HF care programmes in the country is also a 
possible panacea. 
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Chapter 1: Introduction 
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1.1 Introduction 
In the last 20-25 years, heart failure (HF) has emerged a major global public health problem. 
Although recognized as a more significant health problem in high income countries,(Sidney et 
al., 2013, Mosterd and Hoes, 2007) the syndrome both in its acute(Mosterd and Hoes, 2007) 
and chronic(Mosterd and Hoes, 2007) forms has emerged as an  issue of global  importance. It 
has been established that the burden of HF doubles with each passing decade after the age of 
40 years especially in industrialized countries of the world due to aging population and 
increasing burden of risk factors including; hypertension, diabetes mellitus, ischaemic heart 
disease and, more recently obesity .(Cowie et al., 1997)  
HF affects over 26 million people worldwide.(Bui et al., 2011) It is a highly symptomatic 
syndrome that affects 2-3% of the population in high income countries especially in people 
above the age of 65 years.(Redfield et al., 2003, Mosterd et al., 1999)  Approximately 15 
million (out of 900 million) Europeans and 5.8 million (out of 300 million) Americans are 
affected by HF.(Wijeysundera et al., 2010, McMurray et al., 2012) In the United States of 
America (USA) alone, up to 2.4 million hospital admissions can be attributed to HF as primary 
or secondary diagnoses.(Roger et al., 2011) It is the primary reason for 12-15 million office 
visits and 6.5 million hospital-days each year.(Roger et al., 2011) About 670,000 new cases 
occur in the USA yearly. 
Over 39 million dollars is spent annually in the USA for the care of HF patients.  In Europe, over 
60% of economic cost of HF is related to hospital admissions.(Stewart et al., 2001a) This is 
because HF is associated with high rates of hospital admissions, readmissions and frequent 
clinic visits. Data from developed countries show that half of HF patients are rehospitalised 
within 6-months of discharge(Butler and Kalogeropoulos, 2008) and 70% of these are due to  
worsening of previously diagnosed HF.(Gheorghiade et al., 2005) In a recent report, Jencks et 
al(Jencks et al., 2009) showed that HF is the number one reason for readmission in the USA. HF 
readmission is associated with higher mortality compared to the index admission. 
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HF related admission and re-admission has been projected to rise in the coming years due to 
aging of the world population. By 2050, 1 in 5 Americans will be elderly and 80% of patients 
hospitalized for HF in that country are usually above 65 years.(2005) 
HF is associated with shorter life expectancy, greater morbidity and impaired quality of life 
than most common diseases. About 30% of people die within 3 months of diagnosis of HF. 
Annual mortality is 10% thereafter. Those with severe HF have an annual mortality of 
>50%.(Murray-Thomas and Cowie, 2003) 
Although there have been many therapeutic gains in the management of  chronic HF(Scott and 
Jackson, 2013) leading to improved overall survival rates(Scalvini and Giordano, 2013), there 
has been very little parallel success  in respect to AHF. This is particularly important when one 
considers the high proportion of patients who still require hospitalization for acute HF and 
associated high levels of in-patient case-fatality and poor short-to-medium term health 
outcomes. 
1.2 Definitions/Nomenclature  
There is no generally accepted definition of HF. The current definition of HF by major 
international/national societies of HF is as follows: 
The European Society of Cardiology (ESC) defined HF as “an abnormality of cardiac structure 
or function leading to failure of the heart to deliver oxygen at a rate commensurate with the 
requirements of the metabolizing tissues, despite normal ﬁlling pressures (or only at the 
expense of increased ﬁlling pressures)”(Dickstein et al., 2008) or “clinically as “a syndrome in 
which patients have typical symptoms (e.g. breathlessness, ankle swelling, and fatigue) and 
signs (e.g. elevated jugular venous pressure, pulmonary crackles, and displaced apex beat) 
resulting from an abnormality of cardiac structure or function”.(McMurray et al., 2012) 
The American Heart Association/ American College of Cardiology (AHA/ACC) defined the 
condition as “a complex clinical syndrome that results from any structural or functional 
4  
impairment of ventricular filling or ejection of blood”(Yancy et al., 2013) while the Heart 
failure society of America  defined HF as a “syndrome caused by cardiac dysfunction, generally 
resulting from myocardial muscle dysfunction or loss and characterized by either LV dilation or 
hypertrophy or both.”(Heart Failure Society of et al., 2010) 
The earliest definition of HF may be probably that by Thomas Lewis in 1933. He defined HF as 
“a condition in which the heart fails to discharge its content adequately”. (Lewis, 1933b)He 
opined that the very essence of cardiovascular practice is the early detection of HF. 
At various times in history, several authorities have provided definitions such as Wood 
(1950)(Wood, 1950), Denolin et al (1983)(Denolin et al., 1983), Poole-Wilson (1985)(Poole-
Wilson, 1985), Harris (1987)(Harris et al., 1987), Braunwald(1988)(Braunwald, 1988) and Cohn 
(1988).(Cohn, 1988) These definitions are shown are shown in table 1.1. 
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Table 1.1:Various definitions of HF failure by different individuals and authorities 
SNO Person/Authority Year Definition 
1.  Lewis(Lewis, 1933a) 1933 “A condition in which the heart fails to discharge its contents 
adequately”. 
2.  Wood(Wood, 1950)  1950 “A state in which the heart fails to maintain an adequate 
circulation for the needs of the body despite a satisfactory 
filling pressure”. 
3.  Denolin(Denolin et al., 
1983)   
1983 “Heart failure is the state of any heart disease in which, 
despite adequate ventricular filling, the heart’s output is 
decreased or in which the heart is unable to pump blood at a 
rate adequate for satisfying the requirements of the tissues 
with function parameters remaining within normal limits”.  
4.  Harris(Harris et al., 
1987)  
1987 “A syndrome which arises when the heart is chronically unable 
to maintain an appropriate blood pressure without support”.  
5.  Braunwald(Braunwald, 
1988) 
1988 “A pathophysiological state in which an abnormality of cardiac 
function is responsible for the failure of the heart to pump 
blood at a rate commensurate with the requirements of the 
metabolizing tissues”.  
6.  Cohn (Cohn, 1988) 1988 “A syndrome in which cardiac dysfunction is associated with 
reduced exercise tolerance a high incidence of ventricular 
arrhythmias and shortened life expectancy”.  
7.  Poole-Wilson(Poole-
Wilson, 1996)  
1996 “A clinical syndrome caused by an abnormality of the heart 
and recognized by a characteristic pattern of haemodynamic, 
renal, neural and hormonal responses”. 
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1.3 Classification of HF 
1.3.1 Acute and chronic HF 
Acute HF: This is defined as “the sudden or gradual onset of the signs and symptoms of HF 
requiring unplanned office visits, emergency room visits, or hospitalization”. “Irrespective of 
the precipitating factor, pulmonary and systemic congestion due to elevated right or left heart 
filling pressures is an almost universal feature of acute decompensated heart failure (ADHF). 
This may present in the form of acute pulmonary oedema due to LV failure, cardiogenic shock 
especially in the setting of acute myocardial infarction (usually characterized by hypotension, 
oliguria and peripheral vasoconstriction) 
Chronic HF: This is a clinical syndrome resulting from chronic cardiac decompensation 
associated with left-sided or right-sided heart failure 
1.3.2 Systolic and diastolic HF 
Systolic HF: HF due to impaired LV systolic function (usually echocardiographically determined 
EF of <45%). 
Diastolic HF: HF due to the need for higher filling pressures to obtain normal LV end diastolic 
volume. It is also called HF with normal or preserved ejection fraction (EF >45%). These terms 
are not mutually exclusive as most patients with systolic dysfunction have different forms of 
diastolic dysfunction. HF with normal EF (HFNEF) is more common in the elderly, women, 
diabetics, and individuals with long standing hypertension. It has a better prognosis than heart 
failure with LV systolic dysfunction although in the Canadian study there was no difference in 
outcome between these forms of HF.(Owan and Redfield, 2005, Rutten et al., 2003) There is 
still no consensus on the definition of HFNEF. Some workers even believe that it is over 
estimated. Table 1.2 shows the differences between SHF and DHF).  
1.3.3 Symptomatic and asymptomatic LV dysfunction. 
It is now known that more than half of individuals with left ventricular systolic dysfunction 
(EF<35-40%) are asymptomatic. This is commoner in people with coronary artery disease 
(RR=12.5, 95%Cl = 4.5-33.3), hypertension (RR=3.5, 95%Cl = 1.4-8.5) and abnormal ECG (RR 7.1, 
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95%Cl 2.8-16.7). Asymptomatic LV systolic dysfunction is a precursor for the development of 
HF and CV events.(Wang et al., 2003) Since HF is characterized by symptoms and signs, 
asymptomatic LV dysfunction is not the same as HF. 
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Table 1.2. Differences between diastolic and systolic HF.  
Characteristic Diastolic HF Systolic HF 
Age Frequently elderly All ages, typically 50-70 years 
Sex Frequently female More often males 
LV ejection fraction Preserved or normal, 
approximately 40% or 
higher 
Depressed, approximately 40% 
or lower 
LV cavity size Usually normal, often with 
concentric LVH 
Usually dilated 
LVH on 12 lead ECG Usually present Sometimes present 
Chest radiography Congestion without 
cardiomegaly 
Congestion and cardiomegaly 
Heart sound Fourth heart sound present Third heart sound present 
Co-existing conditions 
Hypertension +++ ++ 
Diabetes mellitus +++ ++ 
Previous myocardial infarction + +++ 
Obesity +++ + 
Chronic lung disease ++ 0 
Sleep apnoea ++ ++ 
Long term dialysis ++ 0 
Atrial fibrillation + 
(usually paroxysmal) 
+ 
(usually persistent) 
(Table adapted from Aurigemma et al(31) and Meyer et al(32) 
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1.4 Historical perspective  
The concept of HF has been known by man from time immemorial. History shows that there 
were descriptions of HF in ancient Egypt, Greece and India. The Romans were known to have 
used the Foxglove as a medicine in heart disease. It was not until the description of human 
circulation by William Harvey that the nature of the condition became clearer. Other major 
advances in medicine and science led to improvement in the understanding of the 
pathophysiology, and management of HF. These include the discovery of x-rays by Roentgen, 
electrocardiography by Einthoven, echocardiography by Inge Edler as well as cardiac 
catheterization and nuclear medicine. 
Blood-letting and leeches were used in ancient times for the treatment of HF. In 1785, William 
Withering published the benefits of digitalis. Doctors used Southey tubes in the 19th and 20th 
centuries to let-out fluid from oedematous peripheries of HF patients. In 1985, thiazide 
diuretics were introduced. Prior to this mercurial agents were used as diuretics but these were 
associated with toxicity. In 1967 Christian Barnard performed the human heart transplantation 
for the treatment of end stage intractable HF in the Republic of South Africa. 
The use of vasodilators in HF started with the discovery of angiotensin converting enzyme 
inhibitor in the 70s. The first co-operative West Scandinavian Enalapril Survival Study 
(CONSENSUS – 1) was the landmark study that demonstrated the unequivocal benefits of 
enalapril in patients with HF. Table 1.3 shows the landmark events in the evolution of man’s 
understanding of HF since 1628 when human circulation was described while Table 1.4 shows 
landmarks in the advancement of HF treatment. According to Katz(Katz, 2008), since the 5th 
century BC, physicians and scientists have approached the syndrome of HF in at least nine 
different ways: ‘A clinical syndrome’ circulatory disorder, altered architecture of the heart, 
abnormal haemodynamics ,disordered fluid balance, biochemical abnormalities, maladaptive 
hypertrophy, genomics and epigenetics’  
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Table 1.3. Landmark events in the evolution of man’s understanding of HF 
Period  Landmark event 
5th century BC (Ancient 
Greek & Romans) 
Hippocrates corpus described “rales” 
3rd century BC Centre of medical science moved to Alexandria in Egypt. Human anatomy 
and physiology were studied by Herophilus and Erasistratus. Recognized 
that the human heart contracts and understood the role of semblance 
values. Held that arteries contain air  and that blood flows from the right 
ventricle into veins   
2nd century BC Galen, 
Greek physician 
Viewed heart as source of heat. Failed to understand that the heart is a 
pump. Palpated the arterial pulse but believed it was transmitted along 
the arterial wall rather than by blood flow. Probably the first to describe 
atrial fibrillation.  
Galen’s erroneous view that the main role of the heart is to distribute heat 
by ebb and flow dominated Western medical science for over 1500 years. 
Treatment for dyspnea and dropsy during this period was based on this 
humoral belief. 
17th century William Harvey describes human circulation in 1628.  
In 1668, Richard Lower noted that the ejection function of the heart was 
impaired in cardiac tamponade 
Raymond Vieussens described the physiological basis for the signs and 
symptoms in mitral stenosis 
18th century  In 1745, Giovanni Hancisi described eccentric LVH in aortic regurgitation 
and concentric LVH in aortic stenosis. Noted that LV dilatation weakens 
the heart. 
Nicholas Corvisat and John Bell documented that eccentric LVH carried 
worse prognosis than concentric pattern.  
Corvisat also described two mode of death in HF: Progressive HF or sudden 
death. 
19th  century 1833: Joseph Hyaathe Bertin reported that LV dilatation weakens the 
myocardium. 
Austin Flint demonstrated that concentric LVH was an adaptive mechanism 
in pressure overload 
William Osler documented the adverse consequences of concentric LVH 
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1895: Roentgen discovered X-ray which allowed evaluation of cardiac size. 
20th century 1918: Ernest H Starling describes that Starlings law of the heart. 
1920: Inorganic mercurial substance was first used by Saxi and Heiling to 
achieve diuresis but this was associated with toxicity 
1920-30s: The concept of energetic thermodynamics in the study of 
cardiovascular pathophysiology was introduced by workers such as 
Helmholtz, Hill, Starling, Visscher and Oslen.   
1940: AndreCour and Dickinson W  Richard introduced cardiac 
catheterization which led to improvement in the understanding of cardiac 
haemodynamics 
1950: Felix Meerson confirmed the earlier observation by Osler that 
overload-induced hypertrophy is both beneficial and deleterious 
1960: Open heart surgery commenced 
1985: Janis Pfeiffer and his colleagues gave a clue to the mechanism of the 
survival benefit of ACEI;-slowing of cavity dilatation (remodeling) following 
myocardial infarction. 
1987: Eugene Braunwald and others introduced the field of molecular 
cardiology and genomics 
2000: Application of the field of epigenetics in the study of HF 
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Table 1.4. Landmark trials in the advancement of HF treatment 
a. Inhibition of the renin-angiotensin-
aldosterone system. 
 
The Cooperative North Scandinavia ENalapril Survival Study (CONSENSUS) 
showed that Enalapril improved symptoms as well as life expectancy in HF 
compared to placebo, but had no impact on sudden cardiac death.(1987)  
The vasodilator – Heart Failure trial II (V-HeFT – II). Tested Enalapril or 
hydralazine/isosorbide dinitrate in class II and III HF. Sudden death and mortality 
was reduced by 14 and 12% respectively in the Enalapril group compared to 23% 
and 10% respectively in the hydralazine/isosorbide dinitrate.(Cohn et al., 1991)  
The studies of Left Ventricular Dysfunction treatment (SOLVD – treatment) 
demonstrated a reduction of total mortality in HF patients by 8% as well as 
fewer deaths and hospitalizations due to HF in patients on Enalapril compared to 
placebo.(1991, 1992a)  
Others  
The Survival and Ventricular Enlargement (SAVE) trial (Used Captopril)(Pfeffer et 
al., 1992), the Acute Infarction Ramipril Efficacy (AIRE) trial  (used 
Ramipril)(1993) and the Trandolapril Cardiac Evaluation (TRACE) trial (Ref) (used 
Trandolapril)(Kober et al., 1995) All showed that ACE inhibition significantly 
improved survival and reduces morbidity and mortality associated with CV 
events in HF.  
b. Inhibition of Angiotensin Receptors 
 
These are used where ACE inhibitors are contraindicated. 
Valsartan Heart Failure trial (VAL-HeFT): Mortality at 2 years was 18 vs. 25%, 
RRR 28%.(Cohn et al., 2001) 
“Assessment of Reduction in mortality and morbidity in patients with LV 
dysfunction already taking ACE inhibitors “(CHARM – Added trial). The trial 
demonstrated that Candesartan significantly improved outcomes versus placebo 
in patients already taking ACE inhibitors or beta blockers.(Pfeffer et al., 2003) 
(McMurray et al., 2003) 
The CHARM – Alternative trial: in patients with LV dysfunction who do not 
tolerate ACE inhibitors, it was shown that Candesartan at 32mg/day significantly 
reduced CV related morbidity and hospitalization for HF in individuals who do 
not tolerate ACE inhibitors.(Granger et al., 2003) 
Valsartan in Acute Myocardial Infarction (VALIANT trial) 
The trial demonstrated that Valsartan (160mg) is as effective as Captopril 
(150mg) in the reduction of all-cause mortality in individuals with myocardial 
infarction complicated by HF. However combination of Captopril and Valsartan 
did not show additional benefit.(Pfeffer et al., 2000) 
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c. Aldosterone antagonists 
 
The Randomized Aldosterone Evaluation study (RALES).  In HF patients with 
systolic dysfunction (EF 25%) and who are in class III and IV NYHA class, 
aldactone compared to placebo was associated with a significant 30% reduction 
in relative risk of all-cause mortality.(Pitt et al., 1999) 
The Eplerenone Post-AMI Heart Failure Efficacy and Survival Study (EPHESUS). 
Eplerenone showed reductions in all-cause mortality as well as combined 
endpoint of CV mortality and hospitalization for CV events.(Pitt et al., 2006) 
Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure 
(EMPHASIS-HF). The study confirmed the previously observed findings with 
Eplerenone but in those with mild symptoms.(Zannad et al., 2011) 
d. Blockage of sympathetic nervous 
system with beta-blockers. 
 
The US Carvedilol Heart Failure Program.  This was the first study to 
demonstrate the benefit of beta blockers in the management of HF. The trial 
showed that Carvedilol reduced HF associated overall mortality by 65% and 
combined risk of death or rehospitalization by 38% compared to placebo.(Packer 
et al., 1996)  
The Cardiac Insufficiency Bisoprolol Study II (CIBIS II) In NYHA class IV HF and 
EF≤35%, bisoprolol was associated with lower overall mortality compared to 
placebo. Bisoprolol use was also associated with fewer HF related deaths and all 
cause hospital admissions.(1999a) 
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS 
trial). (Ref) The trial reported 27% reduction in the combined risk of death or 
hospitalization for a cardiovascular cause and 40% in the number of days in 
hospital for HF with carvedilol compared to placebo.(Packer et al., 2002)  
The study of the effects of Nebivolol Intervention on Outcomes and 
Rehospitalization in seniors with Heart Failure (SENIORS). 
The authors demonstrated that beta-blockage with Nebivolol is effective and 
safe in elderly patients with HF.(Flather et al., 2005) 
e. Sinus node inhibition 
 
The systolic Heart Failure treatment with HF inhibitor Ivabradine trial (SHIFT).  
The trial revealed a reduction in mortality from HF as well as HF related 
hospitalization.(Swedberg et al., 2010)  
Paradigm – HF trial. This is a randomized, double blind phase III study that demonstrated the 
efficiency and safety of angiotensin receptor Neprilysin inhibitor (LCZ696) in the 
treatment of HF. In patients with HF and reduced EF, LCZ969 was found to be 
superior to Enalapril. It reduced risk of death from CV causes by 20%, reduced HF 
hospitalization by 21% and all-cause mortality by 16%.(McMurray et al., 2014, 
McMurray et al., 2013) 
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Chapter 2: Literature review on acute heart failure
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Introduction and definition: Acute heart failure (AHF) can be defined as a rapid onset of or 
change in symptoms and signs of HF.(Metra et al., 2014, Yancy et al., 2013, McMurray et al., 2012) The 
syndrome is often life threatening, often requiring immediate medical care in the form of hospital 
admission due to the deterioration of individuals with pre-existing HF but can also be the first 
presentation of HF (denovo AHF). It is often precipitated by one or more factors such as infection, 
ischemia, hypertensive crisis, dietary indiscretion and non-compliance to medication.   
The presentation of AHF may vary and the syndrome is heterogeneous due to differences in economic 
development, genetic susceptibility, cultural practices and burden of CV risk factors. Worldwide, the 
hospitalization for AHF is common and a growing public health problem. 
Data from the USA suggests that AHF first admission occurs in about 400 per 100,000 populations. It is 
also approaching 1,000 per 100,000 populations for second hospitalization. More than 5.7 million 
people in that country who are aged 20 years and above are living with HF (2.7% prevalence) (Roger et 
al., 2012a, Roger et al., 2012b) There were 670,000 new cases in people aged 45 years and above in 
2008 in a population of about 304 million people. Incidence tripled between the year 1979 and 2004 and 
the prevalence is higher in men compared to women with heavy predominance with advancing 
age.(Roger et al., 2012a, Roger et al., 2012b) In Canada, approximately 500,000 persons are living with 
HF (1.5% prevalence). The annual incidence is approximately 50,000 new cases in a population of 32.7 
million people in 2006.(Ross et al., 2006) Table 2.1 shows the proportion of people living with HF in 
various countries. Table 2.2 depicts the proportion of AHF patients to total admission in some countries. 
This ranges from 0.65 in South Africa to 3.73 in some European countries. 
Registries of AHF have shown some characteristics and regional as well as continental differences in the 
mode of presentation, aetiology, burden and type of co-morbidities, precipitating factors, treatment and 
outcome of AHF syndrome. Some of the recent AHF registries include; the ADHERE(Fonarow, 2003), 
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OPTIMIZE(Fonarow et al., 2004), Euro HF survey I(Cleland et al., 2003) and II(Nieminen et al., 2006a), 
EFICA(Zannad et al., 2006), AHEAD(Spinar et al., 2011), ATTEND(Sato et al., 2010), THESUS-
HF(Damasceno et al., 2012) etc.  
Table 2.1. Proportion of population living with HF in some countries around the world. 
Continent  Country  Proportion of population with HF 
Africa(Damasceno et al., 
2007)  
None  No population based study 
Asia(Hung et al., 2000) (Ng 
and Niti, 2003, Koseki et al., 
2003) 
China  1.3% 
Japan   1% 
Malaysia  6.7% 
Singapore  4.3% 
Australasia(2011)  Australia  1.3% 
Europe(2012c, Galinier et al., 
2012, Nieminen et al., 2006a)  
International   1-2% 
France  2.2% 
United Kingdom  1.3% 
Middle East (Agarwal et al., 
2001) 
Oman  0.5% 
North America(Ross et al., 
2006, Roger et al., 2012a, 
Roger et al., 2012b, 
Heidenreich et al., 2013)  
Canada  1.5% 
United State  2.7% 
South America(Bocchi et al., 
2013) 
No data  No population based study  
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Table 2.2. shows the proportion of AHF patients to total admission in some countries 
Continent/Region Country No. of HF admissions HF admissions/Total 
admission  
Africa(Stewart et al., 2008) South Africa NA 0.65 Asia(2014e, 2014f, 2014d) Japan 174,957 1.24  Korea 57,147 0.78  Singapore 15,535 NA Australasia(2014e, 2014f, 2014d) Australia 53035 1.38  New Zealand 9876 1.53 Europe(2014e, 2014f, 2014d) International (22 countries)  0.32-3.73  International(18 countries) 626185 NA  France 159143 1.46  Germany 306250 1.54  Poland 229428 3.73  United Kingdom 73790 0.88 Middle East(2014e, 2014f, 2014d) Israel 19707 1.31 North America(2014e, 2014f, 2014d) Canada 49829 1.76  United states 1179151 3.04 
 Brazil 235692 2.11 South America(2014e, 2014f, 2014d) Chile 27607 1.70  Mexico 90695 1.64 
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2.1  Methods 
A Medline /Pubmed search was conducted from January 1, 2000 to December 31, 2014 to identify 
studies on acute HF worldwide. Manuscripts written in English language were reviewed. The search 
criteria were ‘heart failure’ or ‘cardiac failure’ AND ‘registry’ or ‘survey’. The reference lists of identified 
papers were critically reviewed for additional information. Data extracted were summarized or grouped 
as follows: brief description of each registry/survey, socio-demographic profile, clinical profile including 
major symptoms and signs, laboratory profile (blood and non-blood based), aetiological risk factors, 
precipitating factors, co-morbidities, hospital management and intra-hospital outcome (length of stay 
and discharge status) and post-discharge outcomes. Figure 2.1 is a flow diagram showing how the data 
were extracted. Figure 2.2 presents these registries and surveys in different continents. Tables 2.3-2.7 
were used to summarise the information 
A separate search was done specifically for HF in Sub-Saharan Africa (SSA) from 1 January 1950 to 31 
December 2014. 
The search criteria include: “heart disease”, “cardiovascular disease”, heart failure”, “cardiac failure”, 
“hypertension”, “rheumatic heart disease”., “cardiomyopathy”, “dilated cardiomyopathy” 
“endomyocardial fibrosis”, “peripartum cardiomyopathy” “pericarditis/ pericardial effusion”, “cor-
pulmonale”, “coronary artery disease” “ischaemic heart disease” and “sub-Saharan Africa”. Literatures 
published in English language were retrieved. English abstracts of articles written in other languages 
were also retrieved.  This was supplemented with search of other database such as African index 
medicus, African journals on-line (AJOL) World Bank database, WHO global infobase as well as the global 
cardiovascular infobase and global health library. 
We also consulted additional papers as well as book chapters referenced through this search strategy. 
Articles that focused on epidemiology and aetiology of heart disease in SSA have been reviewed. 
 19  
One thousand six hundred and twenty six (1,626) articles were initially retrieved. Thereafter, studies 
that were not relevant to the review were excluded such as case reports, studies on pathophysiology of 
heart disease and studies carried outside the sub-region. We conducted a review of the remaining 102 
articles. These are categorized into the regions of SSA and presented as clinical studies (Table 2.8 ) 
We identified a total of 71 studies involving 72,971 patients that described the pattern of heart disease 
in SSA during the period 1950 - 2014. Most studies on heart disease in the region were hospital based (n 
= 100) with few population based studies (n = 2). More were focused on urban centres. We retrieved 71 
clinical studies (as summarized in Table 2.8) Ten (10) were from Southern Africa, 32 from West Africa, 
11 from East Africa and 9 each from central and the horn of Africa) 
2.2  Sociodemographic characteristics 
2.2.1  Age at presentation 
AHF syndrome is a disease of the elderly in high-income countries of Europe, North America and Japan. 
Mean age ranges from 70-75 years.(Adams et al., 2005a, Fonarow et al., 2007b, Sato et al., 2010, 
Nieminen et al., 2006a) Patients are younger in South America(Bocchi et al., 2013), South Asia and sub-
Saharan Africa.(Damasceno et al., 2012) Figure 2.3 shows the mean age of AHF in different reports 
across the world regions. 
2.2.2 Gender distribution 
The sex ratio varies from region to region. The proportion of men in the different registries ranges from 
49% to 67%. (Figure 2.3) The rate is generally commoner in men except in the THESUS-HF and ADHERE 
registry. This may be due to selection bias. 
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Figure 2.1: Flow chart showing how the literatures were extracted 
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Figure 2.2. Acute HF registries /surveys in different parts of the world 
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Table 2.3 shows the characteristics of AHF patients in different regions of the world. 
Characteristics  ADHERE(Adams et al., 2005a) 
EHFS-I(Cleland et al., 2003) 
EHFS-II(Nieminen et al., 2006a) 
Italian(Tavazzi et al., 2006) 
E&W Survey(Nicol et al., 2008) 
EFICA(Zannad et al., 2006) 
ATTEND(Sato et al., 2010)  
AHEAD(Spinar et al., 2011) 
OPTIMIZE(Fonarow et al., 2004) 
THESUS-HF(Damasceno et al., 2012) 
KorAHF(Choi et al., 2011) 
HIJC-HF(Kawashiro et al., 2008) 
Country/Region US Europe Europe Italy UK FRANCE Japan Europe US SSA KOREA JAPAN No of patients  187,565 11,327 3580 2807  581 1110  48,612 1006 3,200 3,578 
Mean age  72 71 69.9 73  73 73  73 52 67.6 69.8 
Male (%) 49 53 61.3 60.5  59 59  48 49.4 50 59.3 
Body mass index NA  26.8 NA  NA NA  NA 25.2 23.2 21.4 
Obesity             
ESC Clinical class of HF             Denovo 24  37.1 NA  22    16.3   
Decompensated  NA  65.4 NA         
Acute pulmonary oedema NA  16.2 NA  65 63  13 NA 70.4 35.5 Cardiogenic shock 3 <1 3.9 7.7  29 NA  NA NA 29.6 65.5 
Hypertensive heart failure  NA  11.4   NA NA  NA NA NA NA Right heart failure  NA  3.2 NA  NA NA  NA NA NA NA 
New-onset AHF (%) NA  37.1 NA  NA NA  NA 45.4 36.7 11.5 
Hospitalization for HF within last 12 months (%)  
NA 65 44.5 NA  NA NA  NA NA NA NA 
NYHA (III or IV) 47.2  NA NA         
Clinical history/Co-morbidities             Coronary artery disease (%) 5.7 68 53.6 (54) NA  31 39.1  39.1 34.6 74 6.4 
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Previous MI (%) 31 39 NA 36.5  46 1.4  1.4 NA NA 33.5 
Previous revascularization (%) 
NA NA NA 19.1  22 NA  NA NA NA NA 
Hypertension  74 53 62.5 65.6  33 NA  NA NA NA NA 
Diabetes mellitus  44 27 32.8 38.4  60 71  71 55.4 46.5 54.1 
Atrial fibrillation/flutter  31 9 38.7 NA  27 34  42 11.4 30.5 31.4 Previous stroke or TIA 17 NA 13.3 9.2  25 40  31 18.3 NA 36.4 Renal failure  NA 17 16.8 24.7  1 12  16 NA 18.9 NA 
Dyspnoea 32    40 NA       
Dyspnoea on exertion 44    35 NA       Rales  68     34  77.6     
Oedema orthopnea  66    23 59  68     HFpEF 46(40)    55(40) 34 27(45) 43.69(>40)     
HFrEF 75    65 56 66      
EF 34   40         
LVSD 63 53  50    53     
             
Valvular disease  NA 29 34.4 11.4  53 NA  NA 7.7 9.2 22.8 
Anaemia  NA NA 14.7 NA  NA NA  NA NA NA 23.1 
COPD 29(31) 32 19.3 29.7  NA 10  NA 15.2 NA 44.2 
Dilated cardiomyopathy  NA NA 19.3 NA  NA 9  28 NA 3.5 NA Peripheral vascular disease (%) NA NA NA 12  NA NA  NA NA NA 20.8 Pacemaker implanted  4.7 NA 9.1 12.4  NA NA  NA NA NA NA Implanted cardiac defibrillator (%) NA NA NA 4.5  NA 4.7  4.7 NA NA NA Active smoker (%) NA NA NA 14.5  34 NA  NA NA NA NA 
HIV positive NA NA NA NA  NA NA  NA 9.8 NA NA 
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Etiologic profile   NA NA  NA NA  NA NA NA NA 
Ischaemic (%) 57  53.6 46  NA NA  NA NA NA NA 
Hypertensive (%) NA  11.4 14.9  NA NA  NA 13 NA NA 
Valvular  NA  34.4 11.4  NA NA  NA NA NA NA 
Dilated cardiomyopathy NA  19.3 NA  61 33  46 7.7 52.3 33.5 Corpulmonale NA  3.2 NA  15 18  23 45.4 36.7 11.5 
Precipitating factors (on admission)            ACS (%) NA  30.2 NA  21 NA  NA 14.3 12.7 23.1 
Arrhythmia (%) NA  32.4 NA  15 NA  NA 18.8 26.5 20.8 
Valvular cause (%) NA  26.8 NA  NA NA  NA NA NA NA 
Infection (%) NA  17.6 NA  NA NA  NA NA NA NA 
Non-compliance with therapy (%) NA  22.2 NA  NA NA  NA NA NA NA Inadequate diuretic therapy NA NA NA NA NA NA NA  NA NA 0.4 NA Hypertensive crisis NA NA NA NA NA NA NA NA NA NA NA NA 
Hypertension 37     NA 42 NA NA NA NA NA 
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Table 2.4. shows more data the characteristics of AHF patients in different regions of the world. 
Characteristics  EFICA(Zannad et al., 2006)  
ATTEND (Sato et al., 2010) 
AHEAD(Spinar et al., 2011) OPTIMIZE(Fonarow et al., 2007b) THESUS-HF(Damasceno et al., 2012) 
KORHF(Choi et al., 2011) HIJC-HF(Kawashiro et al., 2008) 
FINN-AKVA(Siirila-Waris et al., 2006) POLISH (Venskutonyte et al., 2009) 
ESC_PILOT(Maggioni et al., 2010) ALARM(Follath et al., 2011) RO_AHFS(Chioncel et al., 2011) IN-HF(Oliva et al., 2012) 
FINN-AKVA POLISH 
Country/Region FRANCE Europe Europe US SSA KOREA JAPAN FINLAND POLAND Europe Europe Romania Italy FINLAND POLAND 
Study period    2006-2009 2003-2004 2006-2009 2004-2009  2004  2009-2010 2006-2007 2008-2009   
Year of publication    2011 2006  2011  2006  2010  2011  620 270 
No of patients  581 1110 4153 48,612 1006 3,200 3,578 620 270 1,892 4,953 3,224  75.1 68 
Age  73 73 74 73 52 67.6 69.8 75.1 68 70  69  50.4 71 
Male (%) 59 59 58 48 49.4 50 59.3 50.4 71 63 62 58    
Body mass index NA NA  NA 25.2 23.2 21.4 27.7 NA     27.7 NA 
Obesity 22    16.3           
ESC clinical class of HF                 
Denovo 65 63  13 NA 70.4 35.5 49 27  36.2   49 27 
Decompensated  35 NA  NA NA 29.6 65.5 51 73  63.8   51 73 
Acute pulmonary oedema NA NA  NA NA NA NA NA 20  36.7   NA 20 
Cardiogenic shock NA NA  NA NA NA NA NA 2  11.7   NA 2 
Hypertensive heart failure  NA NA  NA 45.4 36.7 11.5 NA 11  7.4   NA 11 
Right heart failure  NA NA  NA NA NA NA NA 11  4.5   NA 11 
NYHA (III or IV) 31 39.1  39.1 34.6 74 6.4 NA NA       
Clinical history/Co-morbidities              NA NA 
Hospitalization for HF within last 12 month (%) 
     29.6     36.4     
Coronary artery disease (%) 51 NA 51 1.4 NA NA 33.5 55.2 54  30.7   55.2 54 
Previous MI (%) 22 NA  NA NA NA NA 27.7 37   17  27.7 37 
Previous revascularization (%) 33 NA  NA NA NA NA NA 22     NA 22 
Hyperlipidaemia     32        40  54.7 60 
Hypertension  60 71  71 55.4 46.5 54.1 54.7 60 62 43.5 67 58 32.3 39 
Diabetes mellitus  27 34  42 11.4 30.5 31.4 32.3 39 35 45 33 40 29.4 44 
Atrial fibrillation/flutter  25 40 27 31 18.3 NA 36.4 29.4 44 44 24.4 44 38 17.4 13 
Dyspnoea at rest   63 44         44   
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Dyspnoea on exert                
Orthopnoea   53 27            
PND   53 15            
Rales   66 64            
Oedema    67 65            
Previous stroke or TIA 1 12  16 NA 18.9 NA 17.4 13       
Renal failure  53 NA  NA 7.7 9.2 22.8 9.4 39 26 21 33    
Valvular disease  NA NA  NA NA NA 23.1 12.1 21  14.4     
Anaemia  NA NA  NA 15.2 NA 44.2 NA 17  24.8 30  9.4 39 
COPD NA 9  28 NA 3.5 NA 12.6 NA  12.6   12.1 21 
Dilated cardiomyopathy  NA NA  NA NA NA 20.8 9.9 NA     NA 17 
Peripheral vascular disease (%) NA NA  NA NA NA NA NA NA     12.6 NA 
Pacemaker implanted  NA 4.7  4.7 NA NA NA NA NA  5.5   9.9 NA 
Implanted cardiac defibrillator (%) NA NA  NA NA NA NA NA NA     NA NA 
Active smoker (%) 34 NA  NA 9.8 NA NA NA NA     NA NA 
Cancer NA NA  NA NA NA NA NA 3     NA NA 
Thyroid disease NA NA  NA NA NA NA NA 12     NA NA 
HIV positive NA NA  NA 13 NA NA NA NA     NA 3 
Etiologic profile              NA 12 
Ischaemic (%) 61 33  46 7.7 52.3 33.5 55.2 55 51 61 61  NA NA 
Hypertensive (%) 15 18  23 45.4 36.7 11.5 54.7 24  44 44  NA NA 
Valvular  21 NA  NA 14.3 12.7 23.1 12.1 21     55.2 55 
Dilated cardiomyopathy 15 NA  NA 18.8 26.5 20.8 9.9      54.7 24 
Corpulmonale NA NA  NA NA NA NA NA NA     12.1 21 
Toxic NA NA  NA NA NA NA NA 4     9.9 NA 
myocarditis/infection NA NA  NA NA NA NA NA 8     NA NA 
Infiltrative NA NA  NA NA 0.4 NA NA NA     NA 4 
Precipitating factors (on admission)              NA 
ACS (%) 42 NA  NA NA NA NA 31.9 8  36.9   NA NA 
Arrhythmia (%) 25 NA  NA NA NA NA 34 18  26.9   NA NA 
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Valvular cause (%) NA NA  NA NA NA NA 12.1 NA     31.9 8 
Infection (%) 20 NA  NA NA NA NA 23.5 9  16.3   34 18 
Non-compliance with therapy (%) 7 NA  NA NA NA NA NA NA  13.4   12.1 NA 
Inadquate diuretic therapy NA NA  NA NA NA NA NA 43     23.5 9 
Hypertensive crisis 8 NA  NA NA NA NA NA NA     NA NA 
 
 28  
Table 2.5. Shows data on the outcome of HF in different parts of the world 
Outcome Indonesia(Siswanto et al., 2010) 
ADHERE (Adams et al., 2005a) 
ADHERE-AP (Atherton et al., 2012) 
OPTIMIZE (Fonarow et al., 2007b)  
ARGENTINA (Perna et al., 2006) 
EHFS-I(Cleland et al., 2003) 
EHFSII (Nieminen et al., 2006a) 
Italian (Tavazzi et al., 2006)  
EFICA (Zannad et al., 2006) 
ATTEND (Sato et al., 2010) 
Poland (Venskutonyte et al., 2009) 
KorHF (Choi et al., 2011) 
THESUS-HF(Damasceno et al., 2012) 
AHEAD (Spinar et al., 2011) 
Length of hospital stay (LOS)  
              
Median 7.1 4.2 6.0 NA  11 9 9 15.1 21 NA NA 9.2 7.1 
Mean    5.7 7-9.3  NA   31     
Intrahospital mortality (%) 9.0 4.0 4.8 3.8 4.6-12.1 6.9 6.7 7.3 27/43 7.7 8.5 6.4 4.2 12.7 Post-discharge outcome               i. Rehospitalisation (%) 
              
30-day  22.1             
90-day    29.6  24.2 NA        
180-day        38.1     17.8  
1-year  65.8  NA           
5-year               
ii. Mortality               
30-day  10       27.4      
90-day    8.6  13 NA        
180-day        13    15 17.8  
1-year  36       46.5      
5-year               
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Table 2.6. Shows more data on the outcome of HF in different parts of the world 
Outcome FINN-AKVA(Siirila-Waris et al., 2006) (FINLAND) 
Bueno et al(Bueno et al., 2010) (USA) 
Aranda et al(Aranda et al., 2009) (USA) 
Cutis et al(Curtis et al., 2008) (USA) 
Heidenreich et al(Heidenreich et al., 2010) (USA) 
ESC-HF Pilot(Maggioni et al., 2013) (Europe) 
INHF(Oliva et al., 2012) (Italy) 
Tavazi(Tavazzi et al., 2006) (Italy)  
EAHFE(Jacob Rodriguez et al., 2011) (Spain) 
HIJC-HF(Kawashiro et al., 2008) (Japan) 
Nicol et al(Nicol et al., 2008) (UK) 
Rudiger et al(Rudiger et al., 2005) (Switzerland) 
Klapholz et al(Klapholz et al., 2004) (USA) 
Logeart(Logeart et al., 2013) (France) 
Length of hospital stay (LOS)                Median 7 6.3 5.5  6.2 NA 10    8 9 6  
Mean              10.6 
Intrahospital mortality (%) 7.1 4.2 4.4  2.8 3.8 6.4    15 8 4.2 8 Post-discharge outcome               i. Rehospitalisation (%) 
              
30-day  24.8/21.9 26.9 22.7 16.7      NA NA NA  
90-day           NA NA NA  
180-day   60     38.1   NA NA NA  
1-year    67  43.9 30.7  27.2      
5-year               
ii. Mortality               
30-day  10.9   5.0      NA  NA  
90-day 15          18  NA  
180-day           NA  NA  
1-year 20.0    24.3  24   11.4 NA    
5-year 60.3              
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Table 2.7. shows more data on the outcome of HF in different parts of the world 
   
ALARM-HF(Follath et al., 2011) 
ATTEND (Sato et al., 2010) (Japan) 
OFICA(Oliva et al., 2012) (France) 
Dharmorajan et al(Dharmarajan et al., 2013) (USA) 
Jencks et al(Jencks et al., 2009) (USA) 
Rodriguez et al(Jacob Rodriguez et al., 2011) (Spain) 
Pei et al (China) 
Tseng et al (Taiwan) 
Ng et al(Ng and Niti, 2003) (Singapore) 
Tsutsui et al(Tsutsui et al., 2006a) (Japan) 
Hamaguchi et al(Tsuchihashi-Makaya et al., 2009) (Japan) 
Nicol et al(Nicol et al., 2008) (UK) 
Lee  et al(Lee et al., 2004) Joffe(Joffe et al., 2013) 
Ng et al(Ng et al., 2008) 
IMPACT-HF(O'Connor et al., 2005) 
Length of hospital stay (LOS)  
                
Median 6 21 13            8.7  
Mean  31              6 
Intrahospital mortality (%) 
12 7.7 8.2   5.3   2.5 6.30 8.8 12 9.5 5.5 7.1 2.8 
Post-discharge outcome 
                
i. Rehospitalisation (%) 
                
30-day    24.8 19.6 27.2       8.7    
90-day     34        14.1    
180-day                 
1-year     56.1     40 33.1  23.8    
5-year                 
ii. Mortality                 
30-day      8.9 5.30 3.90     11.4-men 11.8-women    90-day                 
180-day                 
1-year              34-men 32.3-women 
37.3  
5-year               78.5  
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Figure 2.3. Shows mean age of AHF and proportion of men in different reports across the world regions (2A)(Damasceno et al., 2012, Siswanto et al., 2010, Choi et al., 2011, Chioncel et al., 2011, Nieminen et al., 2006a, Peraa et al., 2011, Adams et al., 2005a, Sato et al., 2010, Siirila-Waris et al., 2006, Fonarow et al., 2007b), spectrum of AHF syndrome (2B)(Spinar et al., 2011, Venskutonyte et al., 2009, Follath et al., 2011, Nieminen et al., 2006a), mean ejection fraction (EF) in some registries (2C)(Damasceno et al., 2012, Spinar et al., 2011, Chioncel et al., 2011, Oliva et al., 2012, Nieminen et al., 2006a, Adams et al., 2005a), pattern of heart disease in different regions of the world (2D)(Nieminen et al., 2006a, Zannad et al., 2006, Damasceno et al., 2012, Choi et al., 2011, Siirila-Waris et al., 2006, Atherton et al., 2012)  
A B 
C D 
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2.2.3 Ethnic/racial distribution 
Large registries from the United States and Canada where different groups were represented afford the 
opportunity to examine the ethnic or racial differences in the characteristics, clinical presentation and 
outcome of AHF. In the US and Canada, ethnic minorities constitute 36.3% and 16.2% of the population 
respectively. Differences in risk factor burden as well as access to care, severity of disease influence the 
outcome among the different races.  
Blacks constitute 12.6% and 2.5% of the population in USA and Canada respectively. Data from the 
ADHERE registry shows that black patients are younger than Caucasians (63.5 years vs. 72.5 
years).(Adams et al., 2005a) They are less likely to have HF secondary to coronary heart disease (CHD) 
(30,0 vs. 56.1%), more likely to have left ventricular ejection fraction <40% (58.4 vs. 49.7%) and more 
likely to have diabetes mellitus (DM), hypertension, obesity and renal failure at presentation. They are 
also more likely to have higher initial blood pressure (BP) and a narrow QRS complex on ECG. 
Alternatively, they have lower rates of in-hospital mortality (2.8 vs. 4.5%) compared to whites.(Adams et 
al., 2005a) 
Furthermore, compared to whites even after adjusting for major co-variates in the non-ischemic arm but 
not in the ischaemic group, African Americans have higher rates of readmission within 1-year of 
discharge (68.2 vs. 63.0%, p<0.001) but lower 30-day  (6.3 vs. 10.7%, p<0.001) and 1-year  mortality 
rates (31.5% vs.40.1%, p<0.001) compared to white patients.(Rathore et al., 2003)  
The ARIC study which had a long-term follow up revealed that there was no difference in age-adjusted 
30-day and 1-year case fatality. However at 5-years, African Americans demonstrated greater case 
fatality in both men and women compared to whites (p=0.02 and 0.03 respectively)(Loehr et al., 2008) 
African Americans also have the highest incidence of HF (3.0/1000 person years followed up)  and are 
the youngest at presentation compared to other ethnic groups in America.(Rathore et al., 2003) 
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In Canada, the black population has the highest prevalence of 2 or more CV risk factors but paradoxically 
have lower prevalence of heart disease compared to other ethnic groups (3.4% vs. 5.0% for Caucasians 
5.2% for South Asians and 3.2% for Chinese.(Chiu et al., 2010) 
The Hispanics have the second highest incident rate of HF in the United States (3.5/1000 person years).  
The rate for white Americans and Chinese is 2.4 and 1.0 per 1000 person years respectively.(Bahrami et 
al., 2008) Hispanics have the highest rate of DM, dyslipidemia and renal dysfunction. Paradoxically 
Hispanic Americans have favorable mortality and quality of life compared to other groups.(Bahrami et 
al., 2008) 
South Asians constitute 4% of the general population in Canada. IHD is particularly prevalent and occur 
at a younger age in this population compared to other races. They have higher rate of DM, central 
obesity and smoking in that country.(Joshi et al., 2007) In one study, South Asians were found to have 
more extensive disease, present almost one hour later and but show similar short and long term 
outcomes to that of Canadian whites.(Khan et al., 2010) 
The Chinese HF patient in Canada are relatively older, have lower rates of CHD, multi-vessel disease and 
HF but they have higher rates of valvular heart disease compared to whites. They are also more likely to 
have HF with preserved ejection fraction (HFpEF) as well as limited insight on their disease status and CV 
risk factors.(Chow et al., 2008) The group makes up about 3.9% of the Canadian population. 
CHD and HF is also becoming a major problem among the Aboriginal population in Canada. This is 
because of increasing rates of CV risk factors in the population over a period of 17 years.(Shah et al., 
2000) 
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The group is particularly disadvantaged in the country. They are more likely to live in crowded homes as 
well as in houses that need major repairs. They also have 7.4 and 5.2 years shorter life expectancy in 
men and in women respectively compared to other ethnic groups. 
2.3  Clinical profile 
2.3.1 Symptoms and signs 
Dyspnoea at rest was reported in 32-63% of patients while dyspnoea on exertion was documented in 
35-44%. 27-53% had orthopnea while rales were reported in 34-77.6% of the subjects. Oedema was 
present in 23-68%. (Table 2.3, Table 2.4) 
2.3.2 Clinical class of AHF 
Acute presentation of decompensated chronic HF is the common form of AHF in high-income countries. 
In the THESUS-HF and Korean HF registry, denovo presentation of acute HF was commoner. It has been 
documented that 7-59% are admitted through the intensive care unit (ICU) but this depends on the 
inclusion criteria for the registry. The proportion who present in cardiogenic shock ranges from less than 
1% to 32%.  Acute pulmonary oedema, hypertensive heart failure, right heart failure and high output HF 
are present in 1.8-37%, 4.3-11.4%, 3.2-11% and 1.2-3.2% respectively. Previous history of HF has been 
documented in 51-75% while 20-45% has had at least one previous AHF admission. (Table 2.3, Table 
2.4) 
2.3.3  Aetiological risk factors 
Figure 2.3-D shows the relative importance of the different aetiological risk factors for HF in different 
regions of the world. Ischaemic heart disease is by far the commonest risk factor for HF in high income 
countries of Europe and North America. In SSA, the prominent aetiological risk factors are non-ischaemic 
such as hypertension, dilated cardiomyopathy and rheumatic heart disease. Degenerative valve disease 
is also common in high income countries. 
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2.3.4 CV risk factors and co-morbidities 
CV risk factors and co-morbidities (both cardiac and non-cardiac) are common in AHF patients. (Table 
2.3, Table 2.4) 
  
About 7.7% of AHF patients in SSA and 68% in Europe have coronary artery disease (CAD). The 
proportion with previous myocardial infarction (MI) ranges from 17-39%. History of hypertension is 
present in 43.5-76%. Diabetes mellitus (DM), atrial fibrillation (AF), chronic kidney disease (CKD) and 
anemia is present in 11.4-44%, 9-44%, 14.4-17% and 16.8-53% respectively. Apart from the impact on 
the pathophysiology of the condition, co-morbidities also affect the drug therapy, outcome as well as 
the cost of treatment of AHF patients. Furthermore some co-morbidity such as psychosomatic disorders 
may be under-reported. 
2.3.5 Precipitating factors 
Commonly reported precipitating factors include acute coronary syndromes (ACS), hypertensive crisis, 
valvular dysfunction and infections. Others include inadequate diuretic therapy, non-compliance with 
therapy and arrhythmias (Table 2.3, Table 2.4) (Zannad et al., 2006, Siirila-Waris et al., 2006, Follath et 
al., 2011, Venskutonyte et al., 2009) In the EFICA study(Zannad et al., 2006), ACS was responsible for 
42%, arrhythmias (25%), infections (20%), non-compliance with therapy (7%) and hypertensive crisis 
(8%) 
2.4 Laboratory findings  
2.4.1 Blood investigations 
Anaemia is present in about 50% of AHF patients, with about a quarter presenting with at least 
moderate degree of anaemia. One-fifth of patients have hyponatremia on admission (serum sodium of 
less than 135meq/L). The prevalence of hyponatremia is generally higher in individuals who were 
admitted into the intensive care or coronary care unit. Over 30% of AHF patients have an estimated 
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glomerular filtration rate of ≥90ml/min.1.73m2. About 20% have severe chronic kidney disease (CKD) 
(eGFR<30ml/min/1.73mZ). Biomarker such as natriuretic peptide is not generally available in many 
studies. 
2.4.2 Electrocardiography  
The prevalence of atrial fibrillation (AF) ranges from 9 to 44%. About 20% of AHF patient present with 
new onset AF. Over a third will have prolonged QRS complex. In the Romanian acute HF registry (RO-
AHFS) the following ECG abnormalities were observed at baseline: atrial fibrillation (44.3%) 
 , second or 3rd degree AV block (5.4%), right bundle branch block (RBBB) (10.6%), and left bundle 
branch block (LBBB)(16.7%) Others include pacemaker (3.8%), LVH (23.3%) and QRS complex >120ms 
(but no RBBB or LBBB) (4.3%)(Chioncel et al., 2011) 
2.4.3 Echocardiography 
Heart failure with preserved EF (HFPEF) in present in about half of patients. In the RO-AHFS 
registry(Chioncel et al., 2011), 23.8%, 19.8%, 7.1% and 1.1% had significant mitral valve disease, aortic 
valve disease, LV aneurysm and mechanical complications due to acute myocardial infarction 
respectively. 
The mean LV end-diastolic diameter, LV end-systolic diameter and LV ejection fraction were 61.7cm, 
47.1cm and 37.7% respectively. 
2.5 In-hospital care 
2.5.1 Drug Therapy 
Diuretics are widely used in all the regions of the world for the management of AHF, although the route, 
dosage and duration of therapy have been less studied. There is also regional variation in the use of 
vasodilators. The use of inotropes is more in Europe compared to North American and much less so in 
regions where the aetiology of HF is predominantly non-ischemic. However use of aldosterone 
antagonists e.g. spironolactone is low in North America. 
The dosage of medication, specific intolerance, contraindications to commencement or up-titration is 
not well documented. Comparison of use of these medications between specialized centres and 
primary/secondary centres is also less documented. 
 38  
2.5.2  Procedural interventions 
Data shows that less than 10% of patients with AHF in high income countries of Europe and America 
(where IHD is the predominant aetiology) undergo coronary angiography during index admission. 
Pulmonary artery catheters are not commonly placed during hospitalization. 
Use of evidence based therapies for HF appears to be highest in high income countries of Western 
Europe, Japan and North America compared to developing economies of Asia, Eastern Europe, South 
America and Africa. The frequency use of device therapies such as ICD and CRT in AHF is not well 
documented. 
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2.6  Outcomes in AHF  
2.6.1 Length of hospital stay (LOS) 
This generally ranges from 4 and 21 days.(2012c, Maggioni et al., 2013, Bueno et al., 2010, Joffe et al., 
2013, Aranda et al., 2009, Fonarow et al., 2007a, Abraham et al., 2008, Ng et al., 2008, Siirila-Waris et 
al., 2006, Nieminen et al., 2006a, Oliva et al., 2012, Logeart et al., 2013) (Figure 2.4)  The longest LOS has 
been reported from Japan and Brazil.(Bocchi et al., 2013, Sato et al., 2010) This could be related to 
policy of care as well as differences in insurance in different countries.(Sato et al., 2010) LOS is longer in 
Europe compared to the USA. Longer LOS appears to be beneficial to patients as it affords time for is 
aboutstabilization and reduces the incidences of early rehospitalisation. (2012c, Maggioni et al., 2013, 
Bueno et al., 2010, Joffe et al., 2013, Aranda et al., 2009, Fonarow et al., 2007a, Abraham et al., 2008, Ng 
et al., 2008, Siirila-Waris et al., 2006, Nieminen et al., 2006a, Oliva et al., 2012, Logeart et al., 2013) LOS 
has fallen in Europe by 1-2 days(Stewart et al., 2001b) and from 5.6 to 5.3 days in the USA in the last 
decade.(Bueno et al., 2010) LOS appears to increase with age.(Bueno et al., 2010) In one study, LOS was 
5.2 days for those aged 60-64 years compared to 7.2 days for patients aged 85 years and above.(2012c) 
(Table 2.5, Table 2.6, Table 2.7 ) 
2.6.2 HF related mortality 
Intrahospital mortality 
This ranges from a rate of 2.5% in one US study(Ng et al., 2008) to 27% in the EFICA study by Zannad et 
al(Zannad et al., 2006). The latter were patients admitted in the intensive care unit with most in 
cardiogenic shock. (Figure 2.5) 
Short- and medium-term mortality 
The 30-, 90-, 180-day and 12-month mortality associated with the development of AHF is shown figure 
2.6.  Short- and medium-term outcomes have improved in the last few years.(Bueno et al., 2010, Chen 
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et al., 2011, Curtis et al., 2008, Blackledge et al., 2003b, Schaufelberger et al., 2004) In one USA report, 
intrahospital mortality rates fell from 8.5% in 1993 to 4.3% in 2006, while 30-day mortality rate fell from 
12.8% to 10.7% during the same period. In another report intrahospital mortality fell from 5.1% to 4.2% 
between 2001 and 2005 although the 6-month and 12-month mortality rate remained fairly unchanged 
during same period.(Curtis et al., 2008) Chen et al(Chen et al., 2011) also analyzed Medicare 
data of 55 million patients between 1999 and 2008 and clearly showed reduction of 1-year mortality 
from 31.7% to 29.6%. 
Long-term mortality 
Long-term outcome for acute HF has remained poor despite improvement in HF management. The 
reported 5-year mortality rate is in the range of 70 %.(2012c, Joffe et al., 2013, MacIntyre et al., 2000, 
Cowie et al., 2000, Roger et al., 2004, Jhund et al., 2009) (figure  
 2.7) However community based reports from Scotland and the USA showed some improvement in 5-
year mortality rate.(Jhund et al., 2009, Roger et al., 2004, Joffe et al., 2013) The 5-year mortality rate in 
Scotland in 2004 was 65%.(Jhund et al., 2009) Between the period 1979-1984 and 1996 -2000, 5-year 
mortality fell according to one USA report.(Roger et al., 2004) In another report, 1-year and 5-year 
mortality rates fell from 57.4% and 80.3% to 45.3% and 70.5% respectively.(Joffe et al., 2013) 
2.6.3 Predictors of mortality 
The well described independent predictors of morbidity and mortality in AHF include age(Joynt et al., 
2013), co-morbidities (both cardiac and non-cardiac)(Kociol et al., 2010) heart rate(Kociol et al., 2010), 
blood pressure(Rodriguez and Marelli, 2014) renal function(Siirila-Waris et al., 2006), serum sodium(Ng 
et al., 2008), haemoglobin concentration(Abraham et al., 2008), natriuretic peptide 
concentration(Mosterd et al., 1999, McDonagh et al., 1997), troponin levels(McDonagh et al., 1997, 
Redfield et al., 2003), QRS duration(Nieminen et al., 2006a, McDonagh et al., 1997) and evidence based 
medications for AHF.(McMurray et al., 2012) 
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Both the ADHERE (Adams et al., 2005a) and OPTIMIZE-HF(Fonarow et al., 2007b) registries found systolic 
blood pressure and renal function as independent predictors of outcome. In the OPTIMIZE-HF registry, 
eight factors (such as age, body weight, systolic BP, serum sodium and creatinine as well as co-morbid 
conditions predicted the combined and point of death or readmission with a c-index of 0.72.(Fonarow et 
al., 2007b) In addition, combination of elevated B-type NP and positive troponin levels identified a 
subset of AHF patients who are at risk of short term mortality. These findings have been corroborated 
by many other studies globally. 
It is now well established that; AHF patients have relatively low intra-hospital mortality but higher risk of 
early out-of-hospital readmission and mortality, and the risk of readmission and mortality can now be 
predicted using some clinical and/or laboratory based models. This is better so with mortality than 
readmission model. Furthermore, the absence of high risk features does not really identify populations 
who are at absolute low risk. 
2.6.4 Hospital readmission 
Readmission after an initial or index case of HF is common (Maggioni et al., 2013, Kociol et al., 2010, 
Cleland et al., 2003, Aranda et al., 2009, Tavazzi et al., 2013, Tavazzi et al., 2006, Jacob Rodriguez et al., 
2011, Dharmarajan et al., 2013, Curtis et al., 2008, Jencks et al., 2009, Heidenreich et al., 2010)  and CV 
reasons are responsible in about 30% of cases.(Maggioni et al., 2013, Nieminen et al., 2006a, Aranda et 
al., 2009, Dharmarajan et al., 2013, Jencks et al., 2009) It has been shown that 30-day readmission in the 
USA ranges from 20-25%.(Maggioni et al., 2013, Dharmarajan et al., 2013, Jencks et al., 2009) Higher 
rates of 60-67% have been reported following longer follow up.(Kociol et al., 2010, Aranda et al., 2009, 
Curtis et al., 2008) In Europe this ranges from 24% at 90-days to 44% at 1-year after discharge from the 
hospital.(Cleland et al., 2003, Nieminen et al., 2006a, Maggioni et al., 2013) It is now known that timely 
readmission for HF is associated with better patients’ outcomes. This has been demonstrated by various 
HF programs in USA and Europe.(Rauh et al., 1999, Galvao et al., 2006)(Figure 2.8) 
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Ref. (Atherton et al., 2012, Adams et al., 2005a, Fonarow et al., 2007b, Klapholz et al., 2004, Follath et al., 2011, O'Connor et al., 
2005, Heidenreich et al., 2010, Bueno et al., 2010, Damasceno et al., 2012, Siirila-Waris et al., 2006, Siswanto et al., 2010, Choi 
et al., 2011, Spinar et al., 2011, Nicol et al., 2008, 2012c, Nieminen et al., 2006a, Tavazzi et al., 2006, Rudiger et al., 2005, Perna 
et al., 2006, Oliva et al., 2012, Cleland et al., 2000, Logeart et al., 2013, Zannad et al., 2006, Sato et al., 2010) 
Figure 2.4. Length of hospital stay in various studies around the world 
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Figure 2.5. Intrahospital mortality rate following admission for acute HF in various studies around the world.  
Ref(Ng et al., 2008, Heidenreich et al., 2010, O'Connor et al., 2005, Maggioni et al., 2013, Fonarow et al., 2007b, 
Adams et al., 2005a, Bueno et al., 2010, Klapholz et al., 2004, Damasceno et al., 2012, Aranda et al., 2009, Perna et 
al., 2006, Jacob Rodriguez et al., 2011, Atherton et al., 2012, Tsutsui et al., 2006a, Oliva et al., 2012, Choi et al., 
2011, Nieminen et al., 2006a, Joffe et al., 2013, Cleland et al., 2000, Siirila-Waris et al., 2006, Tavazzi et al., 2006, 
Sato et al., 2010, Logeart et al., 2013, Rudiger et al., 2005, Venskutonyte et al., 2009, Hamaguchi et al., 2009, 
Siswanto et al., 2010, 2012c, Follath et al., 2011, Spinar et al., 2011, Nicol et al., 2008, Zannad et al., 2006) 
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Figure 2.6. Mortality after admission for acute HF 
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 2.7. Five-year mortality after onset of acute HF 
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Figure 2.8. Rehospitalisation after admission for acute HF 
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2.7 The healthcare cost of HF 
The economic cost of treatment of HF is huge due to high level of hospital care especially in 
high income countries. HF is responsible for 1-2% of direct healthcare expenditure in high 
income countries. For instance, direct cost of HF was estimated as 2.9 billion Euros in Germany 
(60% due to in-patient care).(Neumann et al., 2009) HF was estimated to cost about 39.2 
billion Dollars in the USA in 2010 representing 2% of the budget allocated to health.(Roger et 
al., 2011) About 80% of direct cost for HF is due to hospital admissions.(Heidenreich et al., 
2013) Joynt et al(Joynt et al., 2013) estimated hospital admission in 2010 to cost about 91.9 
million Dollars (3.1% of the total expenditure) It has been projected that this cost will double in 
the next 20-years due to increasing number of people with the syndrome.(2012c, Heidenreich 
et al., 2013)  
2.8 Psychosocial impact of HF 
HF is associated with psychosocial dysfunction. Physical disability due to easy fatigability and 
shortness of breath affect activities like work, leisure and other social activities. Thus patients 
are often isolated. Psychological problems associated with HF include anxiety, fear and 
depression.(Jeon et al., 2010) Patients often experience guilt and frustration because of their 
dependence on others. Furthermore family members and caregivers also share in this 
psychosocial burden.(Stromberg, 2013, Brostrom et al., 2003) 
2.9 Trend in hospitalization for acute HF 
In most high income countries, it has been shown that hospitalizations for HF have increased in 
the last 10-years.(McMurray et al., 1993a, Stewart et al., 2001b) It rose by about 40% in 
Germany in a period of 7 years (2000-2007) while in the United Kingdom it rose by 57% since 
the year 2006.(Neumann et al., 2009, Stewart et al., 2001b, Stewart et al., 2003) On the other 
hand, the number of patients with primary diagnosis of HF is reported to be decreasing in the 
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USA (Chen et al., 2011), although the country’s national hospital discharge survey shows no 
appreciable change in HF admissions between 2000 and 2010.(Hall et al., 2012) 
In high income countries HF is a common cause of hospital admissions in those aged 65 years 
and above.(Rodriguez and Marelli, 2014) It is also responsible for 29% of emergency 
department visits in the USA (approximately 10.5 million visits) in those aged 40 years and 
above.(Hugli et al., 2005) About 5% of emergency admission in the UK is due to HF.(2012c) HF 
accounts for a large proportion of healthcare consumption and longer hospital stay.(Bueno et 
al., 2010) 
There are some limitations in the available data on acute HF globally. Geographical 
representation in many major AHF registries is lacking. Most studies are from Europe and 
North America which is just 15% of the global population. Findings therefore cannot be 
extrapolated to other regions especially middle and low income countries. 
 Most AHF data have been collected in a non-consecutive form. This can result in differential 
enrolment and may also not be truly representative of the population. 
Basic laboratory and clinical variables were captured in many registries such as haemoglobin, 
electrolyte and urea, bilirubin, ECG and echocardiography. Characteristics of medications in 
terms of routine dosage and duration have not been well documented. Quality improvement 
initiatives and process of care measures were also not included in many surveys. 
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2.10 Heart failure and heart disease in Sub-Saharan Africa  
Sub-Saharan Africa (SSA) is the geographical term used to describe the region of the African 
continent that lie south of the Sahara desert. It covers a land area of 24.3 million square 
meters. In 2007, the population of the region was estimated to 800 million with a growth rate 
of 2.3% per annum. The United Nation has projected a population of 1.5 billion by 
2050(2006c). SSA is comprised of the following regions:   1. West Africa,  2. Central Africa or 
Middle Africa 3. Eastern Africa 4. Horn of Africa and 5. Southern Africa  (2009)The population 
of SSA is very diverse both physically and culturally and they have differing ethnic background. 
For instance the Negroes inhabit most of West Africa; the Tuaregs Nilohamites occupy the east 
horn of the continent, while the Bantus inhabit the Central and Southern Africa. There are also 
the Hottentots in rural Namibia and the pygmies of the Congo Basin.(2009) 
2.10.1 Historical background 
Cooke(Cooke, 1901) appears to be one of the earliest workers to have reported on the pattern 
of diseases in Africa. In 1901, he analysed 1,500 in-patients he saw at a hospital in Uganda. He 
observed that 3% of all hospital admissions and 6% of all medical admissions were due to heart 
disease. He wrote “Valvular diseases of the heart are common”, “Atheroma and aneurysms are 
very rare, although syphilitic endarteritis obliterans is probably common” and “high tension 
pulses are not often met with”.(Vaughan, 1977a) 
Fifty years after, Sharper and his colleagues analysed 1957 medical admission seen at the 
Mulago hospital in Kampala and noted that cardiovascular disease was responsible for 8-10% 
of medical admissions. The main cardiac conditions reported were hypertension, rheumatic 
heart disease, endomyocardial fibrosis and syphilitic heart disease.(Shaper and Williams, 1960, 
Shaper and Shaper, 1958) 
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Similar work carried out in other countries in the 60s and 70s reported similar percentage that 
cardiovascular diseases are of all medical admissions. For example, 11.2% for Ibadan, 
Nigeria(Lauckner et al., 1961),  8.6%  for Mombasa, Kenya(Turner, 1962a), 8.8% for Dar es 
Salaam, Tanzania(Nhonoli, 1968), 4.3% for Blantyre, Malawi(Brown and Willis, 1975) and 8.6% 
for Sekukhuneland, South Africa(Edginton et al., 1972) (Table 2.8) 
Studies in late 70s, 80s and in the 90s also show the prominence of hypertensive heart disease, 
rheumatic heart disease and dilated cardiomyopathy as the main cause of heart disease in the 
region and decreasing incidence of syphilitic heart disease.  
More recent studies have used echocardiography in the evaluation of heart diseases in the 
region. These have document peculiar characteristics of heart diseases in SSA(Oyoo and Ogola, 
1999, Amoah and Kallen, 2000) (Kingue et al., 2005) (Ojji et al., 2009, Sliwa et al., 2008) 
(Stewart et al., 2008, Ojji et al., 2009, Ogah et al., 2014a, Makubi et al., 2014, Okello et al., 
2014) 
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Table 2.8. Clinical Studies of Heart Failure in Africa 
NO Lead author Country Year No  HHDX (%) 
VHDX 
(%) 
DCM 
(%) 
EMF 
(%) 
CP 
(%) 
PDX 
(%) 
SHDX 
(%) 
IHD 
(%) 
CHD 
(%) 
Misc/Others 
(%) 
Southern Africa 
1 Sliwa(Sliwa et al., 2008, Stewart et al., 2008) 
SA 2008 844 33 8 35 - 27 - - 9 - - 
2 Maharaj(Maharaj, 1991) SA 1991 225 13.8 11.1 48.4 - 16.9 8.0 - - - 1.8 
3 Powell(Powell and Wright, 1965) 
SA 1965 270 14.0 17.0 34.0 - 10.0 6.0 10.0 - - 9.0 
4 Schrire(Schrire, 1964) SA 1964 1952 34 19 5 - 2 12 2 1 5 20 
5 Cosnett(Cosnett, 1962) SA 1962 1000 20.2 20.5 13.8 - 16.2 2.5 8.8 0.6 0.6 17.0 
6 Schwartz(Schwartz et al., SA 1958 275 19.6 23.6 37.5 - 10.9 4.0 1.1 0.4 1.1 - 
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1958) 
7 Baldachin(Baldachin, 1963) ZB 1963 564 22.2 38.3 7.3 - 5.1 2.8 11.3 - 7.1 5.9 
8 Gelfand(Gelfand, 1957) ZB 1957 189 14.8 27.0 15.4 - 3.7 6.9 10.5 - 8.9 12.8 
9 Soliman(Soliman and Juma, 2008) 
MA 2008 3908 24.2 33.6 18.6 0.08 - 14.2 0 0.08 4.4 1.5 
10 Brown(Brown and Willis, 1975) 
MA 1975 114 16 35 5 - 8 7 4.4 - 2.5 22.8 
Western Africa 
1 Ojji(Ojji et al., 2009) NG 2009 340 62.6 11.5* 17.0* 1.2 1.8 2.3 - - 0.29  
2 Onwuchekwa(Onwuchekwa and Asekomeh, 2009) 
NG 2009 423 56.3 4.26 7.3 0.2 2.13 - - 0.24 0.24  
3 Karaye(Karaye and Sani, 2008) NG 2008 79 57 12.7 24 - 2.5 12.7 - 7.6 - - 
4 Ansa(Ansa et al., 2008) NG 2008 558 55.7 6.6 15.1 - - - - - - 22.4 
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5 Familoni(Familoni et al., 2007) NG 2007 82 43.4 9.8 28 2.2 3.7 1.5  8.5 - 3.5 
6 Adewuya(Adewuya et al., 2006) 
NG 2006 100 58 10 11 - 15 - - - 8.0 - 
7 Antony(Antony, 1980) NG 1980 315 11.7 13.7 47 - 6.3 - - - - 21.2 
8 Abengowe(Abengowe, 1979) NG 1979 354 45.5 14.4 20.6 - 2.3 7.9 - 0.8 0.6 7.9 
9 Haddock(Haddock, 1979) NG 1979 41 43.9 24.4 31.3        
10 Ladipo(Ladipo et al., 1977) NG 1978 360 35.8 11.9 35 - 8.1 - 0.6 - 0.3 - 
11 Uzodike(Uzodike, 1975) NG 1977 348 15.5 25.6 25.8 2.5 9.5 4.8 - 1 - - 
12 Ogunmekan(Ogunmekun, 1973) 
NG 1973 131 41.2 2.3 44.3 4.6 2.3 - - - - 7.6 
13 Oviasu(Oviasu, 1973) NG 1973 225 69.8 8.0 9.8 5.3 1.8 - - - 2.7 0.9 
14 Carlisle(Carlisle and Ogunlesi, NG 1972 267 28.5 18.1 13.9 12.1 6.8 6 - 1.5 5.3 8.3 
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1972) 
15 Okuwobi(Okuwobi, 1967) NG 1967 137 26 13 22 14 28 6  7   
16 Ikeme(Ikeme and Parry, 1966) 
NG 1966 225 39.1 8.0 29.3 9.8 1.8    2.2 10.2 
17 Lauckner(Lauckner et al., 1961) 
NG 1961 155 18.7 18.7 30.3 14.2 0.6 0.6 - 1.3 5.2 5.2 
18 Beet(Beet, 1956) NG 1956 358 34 23 8 - 1.7 2.2 16 - 2.2 12.2 
19 Nwokolo(Nwokolo, 1955) NG 1955 40 15 7.5 2.5 10 2.5 12.5 7.5  5 25 
20 Serme(Serme et al., 1991) BF 1991 399 49.1 13.0 18.1 - - - - 6.5 0.8 - 
21 Bertrand(Bertrand E et al., 1991) 
IC 1991 1960 39.3 14.5 7.2 1.9 - - - 6.5 12.4 - 
22 Bertrand(Bertrand et al., 2006) 
** 2006 665 52.3 11.1 20.6 - - - - 6.1 - 9.9 
23 Fofana(Fofana GU 1988 574 37.5 14.0         
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et al., 1988) 
24 Amoah(Amoah and Kallen, 2000) 
GH 2000 572 21.3 20.1 11.4 3.8    9.7 9.8 23.6 
25 Owusu(Owusu, 2007) GH 2007 167 42.5 21.6 17.4  2.4 4.2  3.5 2.4  
26 Ikeme(Ikeme et al., 1978) GH 1977 559 89.3 2.4 7.8      1.6  
27 Payet(Payet et al., 1963) SE 1963 100 25 20 26 5  6  2  16 
28 Harling(Harling et al., 1965 
) 
GB 1965 154 14.3 16.9 33.8  9.7 5.8 5.2   9.7 
29 Rowland(Rowland, 1965) SL 1965 224 32.1 8.9 23.2    11.2  9.4  
30 Sankale(Sankale et al., 1969, Sankale et al., 1958) 
MALI 1958 250 17.2 20.8 29.2   4.4 14 1.6 3.6 9.2 
31 Pole(Pole et al., 1979) GH 1976 241 44.8 16.6 21.2     3.7 2.5 11.6 
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32 Cenac NIGER 1985 162 25.9 37.0 5.5   6.8   4.9 19.8 
Eastern Africa 
1 Oyoo(Oyoo and Ogola, 1999) 
KE 1999 91 17.6 31.9 25.3 - 7.7 13.2 - 2.2 2.2 - 
2 Parker(Parker, 1973) KE 1973 523 6.9 46.1 8.4 0.8 - 1.3 0 1.3 18.2 17.2 
3 Turner(Turner, 1962a) KE 1962 168 39.9 20.2 1.8 11.9 6.0 6.5 4.2 2.4 - 4.8 
4 D’Arbela(D'Arbela et al., 1966) UG 1966 449 19.5 24.7 13.5 11.1 5.0 3.5 6.2 0.7 8.0 11.1 
5 Shaper(Shaper and Williams, 1960) 
UG 1960 712 37.4 14.7 - 13.6 0.28 3.5 13.6 1.3 1.3 14.6 
6 Williams(Williams et al., 1952) UG 1952 352 31.3 11.6 9.1 16.2 0 6.5 20.2 0 1.7 0.9 
7 Vaughan(Vaughan, 1977b) TZ 1977 20,572 22.4 10.6 - - - - - 7.4 - 59.6 
8 Kanti UG 1971 871 29.9 22.8 8.3 7.9 5.1 6.8 4.5 0.2 1.3 18.2 
9 Obineche(Obineche, 1976) ZB 1976 170 33.5 21.8 21.8  5.3 2.9   1.3 13.5 
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10 Nhonoli(Nhonoli, 1968) TZ 1968 225 42.2 9.8 11.1 4.0 4.9 5.3 5.3 2.7 1.3 18.2 
11 Bovet(Bovet, 1995) SY 1995 667 18.8 2.4 9.8 - - - - 21.0 - 42.5*** 
Central Africa 
1 Tambwe(Tambwe et al., 1995) ZA 1995 317 40 4.0 15 - - 4.0 - 3.0 - 0.5 
2 Kingue(Kingue et al., 2005) CAM 2005 167 54.4 24.6 26.3 - - - - - 2.4 - 
3 Kingue(Kingue et al., 2000) CAM 2000 312 38.5 25.6 22.5 0.6 - - - 0.9 - - 
4 Mboulley-Kofo(Mboulley-Koto and Bouelet, 2000) 
CAM 2000 1959 38.6 13.9 17.8 - - - - 1.5 - - 
5 Ikama+(Ikama et al., 2008) CO 2008 225 34.5 9.4 7.6 - 11.2 - - 25.6 - 3.6 
6 Amendezo(Amendezo et al., 2008) 
RW 2008 226 42.9 11.5 11.9 - - 8.0 - 3.1 - 22.5 
7 S’jongers(S'Jongers and RW 1960 5307 22.7 30 - - 4.0 - 10.0 23.3 8.0 2.0 
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Enderle, 1960) 
8 Miller(Miller et al., 1962) GAB 1962 416 19.3 32.7 7.5 12.8 1.5 1.0 8.5 4.7 10.0 2.0 
9 Mets(Mets, 1993) RW 1993 86 25.6        2.3  
Horn of Africa 
1 Maru(Maru, 1993) ET 1993 474 38.1 40.2 4.7 - - 4.5 2.1 6.0 2.1 2.3 
2 Hodes(Hodes, 1988) ET 1988 338 13.9 50.0 10.4 1.2 - - - - - 10.6 
3 Gebrehiwot(Gebrehiwot, 1982) 
ET 1982 NA 15.4 49.3 8.8 - - 2.6 7.9 7.4 3.0 2.2 
4 Lester(Lester and Tsega, 1976) 
ET 1976 NA 32.7 37.6 11.6 -  - - 7.2 2.4 - 
5 Laivonic(Laivonic, 1970) ET 1970 559 30.0 28.5 6.6 - 5.6 3.2 21.5 4.4 - - 
6 Parry(Parry and Gordon, 1968) ET 1968 558 16.3 34.8 13.6 - 1.6 10.8 16.8 - - 6.1 
7 Vukotich(Vukot ET 1968 435 13.6 23.5 22 - 6.5 4.4 22.7 4.4 1.6 0.5 
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ich, 1968) 
8 Molineaux(Molineaux et al., 1965) 
ET 1966 NA 13.3 32.6 - - - 1.7 17.4 ?17.4 1.7 13.2 
9 Halim(Halim and Jacques, 1961) 
SU 1961 958 44.4 25.4 - 3.2 2.0 - 6.0 12.6 3.7 2.7 
HHDX=Hypertensive heart disease, VHDX= valvular heart disease, DCM= Dilated Cardiomyopathy, EMF= Endomyocardial fibrosis, CP= Cor-pulmonale, PDX = Pericardial diseases, SHDX= Syphilitic heart disease, IHD= Ischaemic Heart Disease, CHDX= Congenital heart disease, Misc = MiscellaneousSA=South Africa, NG= Nigeria, GH=Ghana, CAM= Cameroun, KE=Kenya, SE= Senegal, GU= Guinea, GB= Gambia, GAB= Gabon, UG= Uganda, ET= Ethiopia, ZB=Zimbabwe, CO= Congo, SY=Seychelles, ZA= Zaire, TZ= Tanzania , RW= Rwanda** A multicentre study involving 7 Francophone countries., +Study was carried out in elderly subjects (>= 60 years), @ Community based study, ++  Includes 19.6% due to heart failure, 18.2% due to cerebrovascular disease and 9.7% classified as others. ∞Percents obtained from Maru et al 
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2.10.2 Sociodemographic characteristics 
Age of Presentation 
The mean age of presentation of heart disease in the region ranges from 40-55 years. This 
implies that the condition affects the productive age group with the associated longer 
disability adjusted life years. In the recent THESUS-HF study(Damasceno et al.), the median age 
was 55 years. Soliman et al (Soliman and Juma, 2008) reported a mean age of as low as 40 
years in a study in Malawi. Several other studies in SSA have reported a mean age of 50-55 
years (Sliwa et al., 2008, Stewart et al., 2008, Ogah et al., 2008, Laabes et al., 2008, Ojji et al., 
2009, Kingue et al., 2005, Oyoo and Ogola, 1999, Habte et al.).The observation therefore 
suggests that HF affects SSA subjects at the prime of their life. This will definitely result in 
limitation in parenting, employment as well as the ability of individuals to be active in their 
community. Contrary to the situation in SSA, HF is essentially a problem of elderly people in 
high income countries (Nieminen et al., 2006a, Tsuchihashi-Makaya et al., 2009, Tsutsui et al., 
2006a, Adams et al., 2005a, Fonarow et al., 2009)  where the average age at presentation (72 
years) is about two decades later than in SSA. 
Gender distribution 
Heart disease in SSA is generally more frequently reported in men than in women (42.6- 49.1% 
in women).(Ogah et al., 2008) (Ojji et al., 2009) (Onwuchekwa and Asekomeh, 2009) (Kingue et 
al., 2005) (Soliman and Juma, 2008) (Habte et al.) On the other hand, Heart disease rates were 
reported to be higher in women in the Heart of Soweto study (57%)(Stewart et al., 2008) in Jos 
(North central region of Nigeria)-68.6%(Laabes et al., 2008) in Kenya (51.6%)(Oyoo and Ogola, 
1999)and Uganda (66.2%)(Kuule et al., 2009) 
The gender differences reported from different region of SSA may be related to patient 
selection, sex differences in the burden of cardiovascular risk factors such as hypertension, 
diabetes mellitus, obesity and cigarette smoking. The pattern of heart diseases is also 
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important. In areas with predominance of rheumatic heart disease and cardiomyopathy 
(especially peripartum cardiomyopathy), HF rates tends to be commoner in women than in 
men. Healthcare seeking behavior may also play an important role. It is more likely to take the 
breadwinner in the home than the dependent. 
Clinical presentation 
HF subjects in SSA present with severe symptoms (NYHA classes III and IV).  This was reported 
in 96.8% of cases by Kuule et al in Uganda and 93.1% by Laabes et al in Jos Nigeria (93.1%) but 
far less than the report by Stewart et al in the Heart of Soweto (34%) and Damasceno et al 
(34.6%). Oyoo et al (Kenya) also reported a lower figure (37.4%) while Tantchou (Cameroon) 
reported 51%.  In the US ADHERE cohort, 74% of them were in NYHA III and IV (Adams et al., 
2005a) 
Laabes et al documented dyspnoea (100%), orthopnoea (92%), PND (97%), displaced apex beat 
(99%), hepatomegaly (95.1%), elevated JVP (67.6%) and hepatomegaly in 95.1%). In the Heart 
of Soweto study, dyspnoea was present in 89% of Blacks enrolled in the study. Similar 
observation was also made by Oyoo in a study in Nairobi, Kenya. In Indonesia(Siswanto et al., 
2010), dyspnoea, orthopnoea, basal crackles and pedal oedema were present in 97%, 31.5%, 
86.3% and 42%b respectively. In the US, these were documented in 89%, 32%, 60% and 62% 
respectively (Adams et al., 2005a). 
Aetiological risk factor for HF in SSA 
Hypertensive heart disease 
Many years ago Donnison(Donnison, 1929) reported that hypertension was uncommon in 
Africa. This observation was later supported by the post-mortem studies by workers like Jex-
Blake(Jex-Blake, 1934), Vint(Vint, 1937) as well as clinical study by William(Williams, 1941) in 
1941. However, by 1946, workers started reporting on the impact of hypertension on the 
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cardiovascular health of the African. Davies(Davies, 1948) noted that hypertensive heart 
disease was the commonest cause of congestive heart failure in Kampala. Similar report was 
also noted in South Africa(Becker, 1946). Within same period, many other authors from 
different parts of Africa also documented that the disease is common in the continent, 
occasionally with prevalence similar to data from Europe and America.  
It is known that in isolated and primitive areas of the continent the prevalence of hypertension 
is very low and in these populations, blood pressure remain within a narrow range throughout 
adult life(Akinkugbe et al., 1991). Blood pressure rises modestly with age in rural dwellers and 
much more in those who live in the cities. 
More recent data from the continent suggest that hypertension is a major cause of cardiac 
morbidity and mortality (Opie, 2006, Akosa and Armah, 2005). High blood pressure is in fact 
regarded as the foundation of cardiovascular disease in Africa(Cooper et al., 2003). In a recent 
systematic review of hypertension survey in Africa, it was shown that hypertension increased 
from 54.6 million cases in 1990 to 130.2 million in 2010. The prevalence is projected to rise to 
216.8 million cases by 2020, each with an age-adjusted prevalence of 19.1% (13.9, 25.5),  
24.3% (23.3, 31.6) and 25.3% (24.3, 39.7) respectively.(Adeloye, 2014)  
Hypertension is responsible to close to 60% of cases of HF when the clinical studies are pooled 
(Table 2.8). In the Heart of Soweto study, among the 1196 persons with the diagnosis of 
secondary hypertension, 682 or 57% (mean age 60±14 years) had hypertensive HF.(Sliwa et al., 
2008). In the INTERHEART study, hypertension was reported as a strong contributor to the 
hazards of CVD in black Africans, with an odd ratio of 7.0 versus 2.3 to 3.9 in other ethnic 
groups (p <0.0002) (Steyn et al., 2005). 
Hypertension in Africa is associated with body weight, lower intake of potassium and salt 
sensitivity(Seedat, 1990). The peak age group is 40 - 49 yrs. Men are affected more than 
women. The patterns of presentation of hypertensive HF vary. Some present with acute left 
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ventricular failure and severely elevated blood pressure. A sub-group present with HF and 
normal blood pressure which tend to rise as the HF is being treated. And yet a third group 
present with HF and normotension all through. The last group is usually difficult to 
differentiate from dilated cardiomyopathy in the absence of other signs of long standing 
hypertension(Araoye and Olowoyeye, 1984). 
The mortality attributable to high blood pressure in most West African Countries ranges 
between 3 - 7% and cardiovascular mortality is in the range of 20 - 45%(Muna, 1993). Women 
may have added morbidity in Africa if the role of hypertension in pregnancy is factored in. 
Hypertension is largely asymptomatic until end-organ damage ensues and this is partly 
responsible for late diagnosis of the disease.  Inadequate screening and sub-optimal health 
facility utilization are also implicated. Therefore, early diagnosis and appropriate therapy 
would lead to a significant reduction in the prevalence of hypertensive HF in Africa.  
Rheumatic Heart Disease (RHD) 
It is estimated that 12 million people live with the disease and it results in about 400,000 
deaths each year. Two million people will require repeated hospital admission and over a 
million will need surgery to improve their quality of life. It is common in areas with poor 
housing condition and an indicator of their plight. 
Like hypertension, this was initially thought to be uncommon in Africa(Donnison, 1929). But 
Cooke in 1901 reported that valvular diseases are common in the continent(Cooke, 1901). This 
was also supported by reports by other workers(Heinmann, 1929). Post-mortem studies have 
been inconsistent. This may be due to the attitude of Africans towards autopsy. 
SSA has the highest prevalence of RHD which is in the range of 1-14/1000 children.(Marijon et 
al., 2007) (Carapetis et al., 2005) (Kimbally-Kaky et al., 2008)Echocardiographic based 
population studies report higher prevalence of 7.5-51.6 / 1000 children.(Beaton et al., 2012, 
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Kane et al., 2013)  School surveys have given a prevalence of 2.7/103 in Kenya(Anabwani and 
Bonhoeffer, 1996), 4.3/103 in Ethiopia(Oli and Asmera, 2004), and 6.9/103 in South 
Africa(McLaren et al., 1975) (amongst black children). Marijon et al reported a prevalence of 
30/103  from an echocardiography-based school survey.(Marijon et al., 2008)  
RHD accounts for 12 - 32% of cardiovascular admissions in SSA.  Recent reports suggest that 
that 6.6-34% of CV related hospital admissions or echocardiographic data in SSA is due to RHD 
and up to 2.3% of pregnant women have the disease.(Tantchou Tchoumi et al., 2011a, 
Tantchou Tchoumi and Butera, 2009, Soliman and Juma, 2008, Ike, 2008, Sani et al., 2007a).  
There are peculiar features of rheumatic heart disease in Africa (similar to reports from other 
tropical environments). These are the young age at presentation, the severity of the lesions, as 
well as the high mortality associated with it. History of rheumatic fever can be obtained in only 
less than 50% of patients. Pure mitral incompetence and mixed mitral valve disease were the 
commonest valvular lesions that were demonstrated(Onwuchekwa and Ugwu, 1996). This is 
consistent with the findings of other workers in Africa (Jaiyesimi and Antia, 1981a, Jaiyesimi 
and Antia, 1981c, Fadahunsi et al., 1987, Sani et al., 2007a).  A rheumatic carditis has been 
shown to run a more fulminant course in sub-Saharan Africa (like in other tropical countries) 
compared to the developed countries (1981, Essop and Nkomo, 2005, Nkomo, 2007, Nkomo et 
al., 2006). In earlier studies, 33% of 124 mitral valvotomies were in patients under the age of 
16 years in one reported from Kenya.  
The disease appears to be commoner in women. Events in women's life such as pregnancy 
frequently unmask the condition(Cole and Adeleye, 1982). Morbidity and mortality is said to 
be high especially in women and young people (Cole and Adeleye, 1982, Cole, 1976) . Mortality 
at 6-month mortality is estimated as 17.8%.(Gunther et al., 2006) In one report from Ethiopia, 
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the annual mortality from RHD is as high as 12.5% and 70% of such deaths were before the age 
of 26 years.(Oli and Asmera, 2004) 
Sliwa et al (Sliwa et al.)  reported on the characteristics of  344 adult rheumatic heart disease 
cases in the heart of Soweto study. The disease was commoner in black women (68%). The 
most common valvular lesion (n = 204, 59%) was mitral regurgitation (MR), with 48 (14%) and 
43 (13%) cases, respectively, having combination lesions of aortic plus MR and mixed mitral 
VHD. Impaired systolic function was demonstrated in 28/204 cases (14%) of predominant MR 
and in 23/126 cases (18%) with predominant aortic regurgitation.  The finding from the study 
makes a case for the first episode of RHD to be made a notifiable condition in high burden 
countries in order to ensure control of the disease through register-based secondary 
prophylaxis programmes. 
In many countries in SSA, facilities for accurate diagnosis are unavailable. Treatments options 
such as valvotomy, valvuloplasty and prosthetic valve replacement are either unavailable or 
unaffordable to a vast majority of the population. Worse still secondary preventive measures 
are also either unavailable or unaffordable. 
The lack of infrastructure, political, economic and social instability, malnutrition and poverty 
are all factors implicated in the high prevalence of rheumatic fever in Africa which is otherwise, 
largely preventable(Essop and Nkomo, 2005). This culminates in a great burden of rheumatic 
valvular heart disease and infective endocarditis.   
The Cardiomyopathies 
Dilated cardiomyopathy (DCM), endomyocardial fibrosis (EMF) and peripartum 
cardiomyopathy (PPCM) are common and endemic in SSA. Other forms of cardiomyopathy are 
less common. 
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Dilated Cardiomyopathy (DCM)  
DCM is a major cause of heart failure in SSA. It has been plagued with diagnostic and 
therapeutic challenges due to lack of appropriate facilities, definitive diagnosis and 
interventions in resource poor African centres.  
DCM contributes about 18% of cardiac related admissions in West and South African clinical 
studies. It also accounts for 10% of cardiac diseases at autopsy and 12% echo-based studies. It 
typically presents with progressive heart failure and is associated with high mortality. In one 
study, the 4-year mortality was found to be 34%.  
There are marked regional differences in the pathogenesis of dilated cardiomyopathy in Africa. 
The causative factors that have been implicated in several studies across Africa include 
infection(Falase et al., 1982, Falase et al., 1977) and myocarditis(Basile et al., 1973, Falase, 
1979), “burnt out” untreated hypertension(Falase, 1977), genetic factors, alcohol, nutritional 
deficiencies, autoimmune mechanisms ,iron overload and pregnancy(Mayosi, 2007) 
The current concept is that 30% of the disease has genetic basis. Familial DCM is caused by a 
mutation in more than 25 chromosome loci. The genes affected are those encoding 
contractile, cytoskeleton and calcium regulatory proteins.  
In 1975, Owor and Rwomushana reported the first case of familial DCM in Africa(Owor and 
Rwomushana, 1975). They described twin brothers who were affected by the condition in 
Uganda. Subsequently other workers have documented familial DCM in other parts of SSA 
especially from South Africa(Przybojewski et al., 1984). However, there are no systematic 
family studies of the condition in SSA. 
Some gene association studies have however been done especially in South Africa. Some of the 
findings include: 
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1. An association with HLADR1 And DRW10 antigens suggesting possible genetically 
determined immune factors may be responsible for the disease(Maharaj and 
Hammond, 1990, Maharaj et al., 1987) 
2. An association with mutation in troponin T-gene(Arg141Trp)(Mayosi et al., 1999) and 
mitochondrial T16185c polymorphism. 
    On the other hand there is no evidence of association with cardiac (ACTC1) and skeletal 
(ACTA1) alpha-actin gene, alpha-2c adrenoceptor (ADRB2c) gene, beta-1 adrenoceptor 
(ADRB1) gene and tumor necrosis factor-alpha (TNFA) gene. 
Some data suggest the immune modulating agent pentoxifylline may be beneficial in the 
management of DCM in the region. In one trial, patients on this agent had improvement in 
effort tolerance, left ventricular function and trend towards lower mortality than those on 
standard treatment for heart failure(Sliwa et al., 2002). 
In a 14-yer follow up of DCM patients in South Africa, a mortality of 10%/ year was recorded 
for both familial and idiopathic DCM. Heart transplantation was an independent predictor of 
survival while NYHA III and IV and use of digoxin were associated with poor outcome. 
Endomyocardial fibrosis (EMF) 
This is a form of restrictive cardiomyopathy in which there is a deposition of fibrous tissue in 
the mural endocardium resulting in impaired diastolic function as well valvular dysfunction 
resulting from entrapment of papillary muscles of the atrioventricular valve. It occurs mainly in 
the tropical and subtropical areas of Africa. It was first described by William in 1938. It is also 
called Davies disease because of the seminal work done by Davies on this disorder in 
Uganda(Davies and Ball, 1955, Davies, 1956, Davies, 1968). A comprehensive description of the 
clinical features have been documented by Hutt(Hutt et al., 1965) as well as other 
workers(Shaper, 1972, Parry and Abrahams, 1965).Recently Mocumbi et al have suggested a 
diagnostic criteria for diagnosis.(Mocumbi et al., 2008) 
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EMF has been reported in at least seventeen SSA countries: Congo, Cameroon, Egypt, Ethiopia, 
Gabon, Ghana, Kenya, Malawi, Mozambique, Nigeria, Senegal, South Africa, Sudan, Tanzania, 
Uganda, Zambia and Zimbabwe. It has also been reported in India and South America. It is rare 
in Northern and Southern Africa. Right sided EMF appears to be commoner. The peak age 
incidence is 11-15 year in both sexes. In a population based study in Mozambique, a 
prevalence of 8.9% was found. 
EMF is a disease of childhood and early adolescence. It has also been reported in older adults 
and infants. A second peak of incidence has shown during the reproductive age of women. The 
preponderance of one gender over the other is inconsistently reported. In a large database 
from Mozambique, it was reported to be more prevalent in males. 
The pathophysiology postulated is as follows: endocardial thickening of the ventricles lead to 
cardiac constriction or restriction and atrio-ventricular valvular incompetence resulting in 
regurgitation. The right ventricular cavity is usually obliterated from below by the advancing 
fibrosis of layered mural thrombi. In severe and late cases, the papillary muscles are buried in a 
layer of fibrous tissue leading to functionless tricuspid valve and aneurysmal right atrium. 
When the left ventricle is involved dense fibrous tissue are deposited at the apex, spreading 
around the cavity of the LV or may first appear around the papillary muscles of the posterior 
cusp of the mitral valve (leading to anchoring of the muscle and valvular regurgitation)(Davies 
and Ball, 1955, Parry and Abrahams, 1965)  
Chronic pericardial effusion commonly complicates right sided EMF while pleural effusion is 
commoner with left or biventricular disease(Parry and Abrahams, 1965). The clinical features 
depend on the stage of the disease, the anatomical damage done on the affected valve as well 
as the resultant effect on heart function. An initial illness with fever, chills, night sweats, facial 
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swelling, and urticaria can occur and is reported in 30-50% of cases. This can be fatal within 
months but little is known about this phase of the disease(Parry and Abrahams, 1965).  
In left sided EMF, the ventricle is not enlarged and there is almost always mitral incompetence 
and a loud pulmonary component of the second heart sound and progressive pulmonary 
hypertension. There is usually an early third heat sound. When the right ventricle is involved, 
the classical picture is that of a young patient with ‘egg on stick’ or ‘orange on stick’  
appearance  (massive ascites and minimal pedal oedema; often with delayed puberty , some 
exophthalmos and central cyanosis(Parry and Abrahams, 1965). The arterial pulse is usually of 
small volume or feeble. Atrial fibrillation is common. Massive pericardial effusion or a rotated 
heat (because of massive right atrium) could give an impalpable heart. An abrupt third heart 
sound is common but murmur may be absent. 
The pathogenic process is explained by eosinophil and its constituents. The suggested sequelae 
is as follows(Parry and Abrahams, 1965): 
1. A trigger to eosinophilia (helminthic or other infections and liberation of eosinophilic 
major basic proteins and cationic proteins which are toxic to the cardiac cells as well as 
other cells in the body 
2. The damaged endocardium serves as a nidus for thrombus formation 
3. Thrombus formation builds up due to release of platelet activating factors by the 
eosinophils 
4. Further mural thrombi are laid down at the original and adjacent sites leading to the 
formation of fibrotic mass. 
Although this explanation appears plausible, it does not offer reason why the disease is 
rare in some parts of the tropics, the reported ethnic differences(Shaper, 1970) and some 
familial cases of EMF(Adi, 1963). 
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Despite the fact that the aetiology of this condition has not been resolved by scientist since 
the first description, the volume of publication on it has dwindled in the last decade. The 
cause has remained a mystery despite several proposed aetiological factors(Bukhman et 
al., 2008). Some of the factors that have been implicated in the past include: 1. 
Infections/Infestations e.g cardiotropic viruses, mycoplasma pneumonia, malaria, 
schistosomiasis, 2. Autoimmunity, 3. Hypereosinophilia, 4. Genetics, and 5. Traditional 
medications. 
Trend in the incidence and prevalence of EMF has not been well studied in SSA. Ellis et al 
showed that the prevalence has not changed in Uganda. On the other hand, EMF was 
shown to have declined from 10% in the 1960/70s to 0.02% from medical admissions and 
0.04% for cardiac related admissions in the first decade of 21st century. This may not be 
unconnected with improvement in healthcare delivery as well as control of communicable 
diseases in that part of the country. 
The prognosis of EMF is poor. The survival of patients after diagnosis is about 2-years. 
Peripartum Cardiomyopathy (PPCM) 
This is defined as heart muscle disease in which left ventricular systolic dysfunction and 
symptoms of heart failure occur between the last month of pregnancy and the first five 
months postpartum. In many parts of Africa, the prevalence is about 1/1,500 deliveries. 
However, the Northern part of Nigeria appears to be the hot spot for the condition where it 
affects 1/100 women after delivery. Recent  echocardiographic based study from this part of 
Nigeria confirms similar prevalence(Isezuo and Abubakar, 2007). The epidemiology, 
pathophysiology and clinical features of this condition have been reviewed in detail elsewhere 
(Sliwa et al., 2006, Ntusi and Mayosi, 2009a, Abboud et al., 2007, Tibazarwa and Sliwa). Most 
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patients present within the first four months after delivery. Only about 10% present in the last 
month of pregnancy.  
Symptoms and signs are similar to other forms of systolic dysfunction. In addition, they are 
prone to thromboembolic phenomenon(Isezuo et al., 2005). 
Aetiological factors implicated include multiparty, advanced maternal age, multiple gestation, 
preeclampsia, gestational hypertension and Black race. Several plausible aetiological 
mechanisms have been advanced. These include genetic predisposition, myocarditis, 
cardiotropic viral infections, chimerism, apoptosis and inflammation. Others include abnormal 
haemodynamic response, immune complexes, cardiac nitric oxide synthase, immune dendritic 
cells, cardiac dystrophin etc. (Ntusi and Mayosi, 2009a, Ramaraj and Sorrell, 2009). 
A novel molecular mechanism of PPCM has been documented. Such mechanisms include 
elevated pro-inflammatory markers such as sFas /Apo 1, interferon-gamma, interleukin-6 and 
C - reactive protein. These point to the pro-inflammatory mechanism in the initiation, 
progression and prognosis of the disease. 
A pathophysiological circuit that involves unbalanced oxidative stress which leads to enhanced 
cleavage of prolactin into  pro-apoptotic and angiogenic 16KDa sub-fragments has been 
described. This process results in endothelial damage and LV dysfunction. Presence of 
endothelial damage in PPCM is further supported by the presence of endothelial 
microparticles suggesting apoptosis with impaired microcirculation. Furthermore the 
angiogenic imbalance in this condition may also be contributed by soluble fms-like tyrosine 
kinase.(Sliwa et al., 2010b) 
About 23-54% of PPCM patients have normalization of LV function at 6-months. Poor outcome 
is associated with increased LV systolic dimension, lower body mass index and low serum 
cholesterol at the time of presentation. On the other hand older age and smaller LV end-
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systolic diameter is associated with higher chances of recovery of LV function.(Sliwa et al., 
2010b) 
The mortality associated with PPCM is 15% at 6 months, 28% at 2 years and 42% in over 25 
years of follow up. Predictors of mortality include NYHA functional class at presentation, 
cardiothoracic ratio, electrocardiographic QRS duration and higher diastolic pressure 
(Adesanya et al., 1989, Ford et al., 1998) A proof-of-concept pilot study has provided some 
evidence of the benefit of bromocriptine in PPCM patients (Ref 62) 
Other Cardiomyopathies 
Hypertrophic cardiomyopathy 
Earlier reports of this condition were mainly anecdotal and it was generally thought to be 
uncommon in Africa. The earliest report appears to be that of Lewis et al in 1973(Lewis et al., 
1973). Thereafter other reports followed (Colyn and Kleynhans, 1990, Neutel and Myburgh, 
1987, Myburgh et al., 1987, Przybojewski and Blake, 1984, Lewis et al., 1983).  In 1240 
consecutive echocardiography in Ethiopia, the prevalence of HCM was 4.3% (54 subjects) and 
accounted for 34.4% of cardiomyopathies(Abegaz, 1990). In a similar study in Tanzania, it 
accounted for 0.2% of 6680 echocardiograms(Posen et al., 1995). HCM is the third commonest 
cardiomyopathy in Ghana (Amoah and Kallen, 2000). 
The genetic studies done on this condition have emanated only from South Africa where 
facilities are available (van der Merwe et al., 2008b, Heradien et al., 2007, Moolman-Smook et 
al., 2002, Blair et al., 2002, Andersen et al., 2001, Moolman-Smook et al., 2000, Moolman-
Smook et al., 1999, Moolman-Smook et al., 1998, Moolman et al., 1995, Moolman et al., 1993). 
The disease-causing genetic mutation or loci has been documented. These include beta-myosin 
heavy chain (MYH7) gene, myosin binding protein c (MYBPC3) gene, and troponin T (TNNT2) 
gene. Carriers of T (TNNT2) R92W mutation develop cardiac hypertrophy after the age of 35 
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years. They also have abnormal response to exercise which may explain the high mortality 
associated with this mutation. (Revera et al., 2007b) 
The physiological effects of genetic mutations that cause HCM have also been studied in the 
continent. TNNT R92W mutation is associated with a relative increase in LV systolic functional 
parameters. Reduced diastolic function has been demonstrated in MYH7 A797T mutation 
while MYH7 R403W mutation is associated with reduction in both systolic and diastolic 
function.(Revera et al., 2007a, Heradien et al., 2009) 
Furthermore angiotensin II type 2 receptor (AGTR2) gene and angiotensin converting enzyme 2 
(ACE2) gene have been identified as genetic risk factors (i.e. genetic polymorphism with 
evidence of association with HCM).(van der Merwe et al., 2008a, Carstens et al., 2010) 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 
The first report of ARVC from the region was in the year 2000.(Munclinger et al., 2000)  
Kindred that are linked to ARVC type 6 locus have been documented.(Matolweni et al., 2006) 
The first multicentre registry of ARVC was reported from South Africa.(Watkins et al., 2009) 
Data from the registry shows that the disease occurs in all racial and ethnic groups in the 
country. Symptoms starts from the third decade of life and the most common symptoms are 
palpitation, dizziness, syncope and chest pain. Symptoms are more pronounces in males. The 
reported male to female ratio was 2:1. About 28% were professional endurance athletes at 
some point in their lives. About 30% of the participants have family members who are also 
affected and 25% had Plakophilin-2 gene defect.(Watkins et al., 2009, Hendricks et al., 2010) 
Interestingly the rare ‘allele-dose-defect’ was demonstrated in one of the subjects while 
haplotype analysis also demonstrated the uncommon ‘founder effect’ in many of the 
subjects.(Watkins et al., 2009, Hendricks et al., 2010) 
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The annual mortality was 2.8% and 5-year cumulative mortality was 10%.(Watkins et al., 2009, 
Hendricks et al., 2010) 
Isolated Left Ventricular Non-compaction (ILVNC) 
Ker et al(Ker and Van Der Merwe, 2006) reported the first case of ILVNC in SSA in 2006. Since 
then there has been reports other centres in Djibouti(Massoure et al., 2011), South 
Africa(Peters et al., 2012a, Peters et al., 2012b) and Sudan(Ali, 2008). The disorder is a 
common cause of HF, disorders of cardiac rhythm and cardio-embolism and is as a result of 
failure of the myocardium to compact in-utero. 
In a series comprising of 54-ILVNC patients, Peters et al (Peters et al., 2012a) in Johannesburg 
showed that the prevalence is 6.9% and the mean age of presentation is 45.4±13.1 years. 
Occurs commoner in males (55.6%) and majority (63.0%0 present in NYHA class II. HF with 
systolic dysfunction is the common mode of presentation (98.1%) The identified sites of non-
compaction include apical (100%), mid-inferior (74.1%), and mid-lateral walls (64.8%). The 
disorder was also documented to be associated with pulmonary hypertension (83.3%), right 
ventricular (RV) dilation (74.1%), and impaired RV function (59.3%). 
HIV associated cardiomyopathy 
This is another cause of HF in Africa. Globally the prevalence was 2-40% in the pre-highly active 
anti-retroviral treatment (Pre-HAART) era.(Sani et al., 2005, Syed and Sani, 2013) However 
with the introduction of HAART, the prevalence has fallen in many parts of the world. But in 
some parts of SSA, due to poverty, ignorance, weak health system, malnutrition and low utility 
of HAART, the burden of HIV associated cardiomyopathy is prevalent. The effectiveness of 
HAART is also supported by data from Uganda that showed low prevalence of this condition in 
children on this treatment.(Tukei et al., 2012) 
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The true prevalence of HIV associated cardiomyopathy is unknown in the sub-region. 
Prevalence from reported literature ranges from 5% in Nigeria to 57% in Burkina 
faso.(Twagirumukiza et al., 2007, Niakara et al., 2002, Olusegun-Joseph et al., 2012) It is the 
commonest cardiac diagnosis in HIV infected people in the Heart of Soweto study  and more 
common in those with high viral load and lower CD4 count.(Sliwa et al., 2012) 
Pericardial Diseases 
Pericarditis and pericardial effusion are common in SSA and are frequently a cause of heart 
failure in the region. In some areas over 15% of cardiovascular admission may be due to 
primary pericardial diseases. Tuberculosis is the leading cause of pericardial disease in Africa 
and this is often complicated by constrictive pericarditis. The burden of pericardial disease in 
SSA has escalated due to the impact of HIV/AIDS. 
Next to tuberculosis is purulent pericarditis secondary to streptococcal or staphylococcal 
infection. Viruses may be responsible for most cases of benign pericarditis without 
demonstrable aetiology. Other causes include parasitic infections such as trypanosomiasis and 
malaria. 
Congenital Heart Disease  
Few publications have looked at cardiovascular disease in young Africans despite the fact that 
two-thirds of the population of SSA are made up of children and young adults. Congenital 
heart diseases constitute about 0.3% of heart diseases seen in northern Nigeria(Ladipo, 1978) 
to 12% in the series documented by Bertrand in Ivory Coast.(Bertrand E et al., 1991) The high 
value in the later may be because the centre at a time served a large referral centre for cardiac 
surgery in West Africa. 
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A prevalence of 13.1%   was documented in Cameroon (mean age 10±9 years, range-2months 
to 41 years.(Tantchou Tchoumi et al., 2011b) About 35% of children with HF in Uganda have 
congenital heart disease.(Ellis et al., 2007) 
To the best of our knowledge the only population based data on congenital heart disease is 
from Mozambique where the prevalence was reported as 2.3/1000 children.(Marijon et al., 
2006)  
 The pattern of cardiac lesions appears not to be different from reports from other parts of the 
world in terms of the most frequent lesions. In the decreasing order of frequency, ventricular 
septal defect, atrial septal defect, Fallot’s tetralogy and patent ductus arteriosus are the 
common congenital heart diseases that may lead to cardiac failure in Africa(Sani et al., 2007b, 
Marijon et al., 2006, Bassili et al., 2000, Bannerman and Mahalu, 1998, Kokou et al., 1996, 
Jaiyesimi and Antia, 1981b, McLaren et al., 1979, Antia, 1974, Levin and Kanarek, 1973, van der 
Horst, 1985, van der Horst and Wainwright, 1969, Wood et al., 1969, Gupta and Antia, 1967, 
Schrire, 1963, Caddell and Morton, 1967, Caddell and Connor, 1966). Recognition of cyanosis 
in the dark skin may pose a challenge coupled with the fact that anaemia is common in SSA 
population. 
Lack of trained man-power, scarcity of diagnostic tools as well as poverty mitigates the care of 
patients with congenital heart disease in the region. 
Coronary artery disease 
It is generally believed that coronary artery disease is uncommon in SSA. However recent 
reports emanating from the region suggest that the disease is emerging and when it occurs, 
the clinical as well as the pathological features are similar to that seen in Caucasians(Williams, 
1971). In early reports, Edington(Edington, 1954) in 1954 noted only three cases in about 3500 
consecutive autopsies in present day Ghana. Sharper and Williams(Shaper and Williams, 1960) 
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documented 9 cases seen in Uganda over a three year period (1955-1957). Falase et al(Falase 
et al., 1974) reported 26 cases over a period spanning 1961-70 and calculated a prevalence 
rate of 1: 20,500 for Ibadan, Nigeria. In another study by same author, the prevalence has 
increased to 1: 10,000. Okuwobi (Okuwobi, 1968) saw seven cases over a period of three 
years. Bertrand(Bertrand, 1995) reported 75 cases over a 6-year period and this accounted for 
0.83% of total cardiac related admission. 
Recent reports still report low prevalence of this condition but the trend is that it is on the 
increase. In a study of heart failure in elderly subjects (60 years and above), Ikama and his 
colleagues reported a prevalence of 25.6% in this age group(Ikama et al., 2008). 
Studies done in South Africa between 1992 and 2008 show remarkable increase in the 
prevalence of the disease. In 1994, the prevalence was 0.2%(1994) but the recent report from 
the Heart of Soweto study show a prevalence of  about 10%. This is remarkable evidence of 
gradual shift in disease pattern (epidemiologic transition) in this population. The prevalence 
reported in earlier studies ranged from 0.4-1.0 percent (Cosnett, 1962, Schrire, 1971, Schwartz 
et al., 1958) (Table 2.8) 
Pulmonary heart disease (Cor-pulmonale) and pulmonary hypertension 
This is also emerging as a common cause of heart disease in SSA. In the Heart of Soweto study, 
right heart failure or cor-pulmonale was documented in 27% of individuals admitted for heart 
failure. The prevalence in other regions is as follows: 0.8-9.5% in West Africa and 0.3-7.7% in 
Eastern Africa.  
At least four reports have looked at the aetiology of pulmonary heart disease in SSA 
(Sofowora, 1971, Turner, 1962b, Okuwobi, 1967, Toure et al., 2000). The common aetiological 
factors described include chronic obstructive pulmonary disease, bronchiectasis, tuberculosis, 
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bronchial asthma, pulmonary fibrosis of unknown origin, pulmonary embolism (acute cor-
pulmonale) and thrombo-embolic obliterative pulmonary hypertension. 
Tuberculosis and chronic obstructive pulmonary disease is the major culprit. The situation is 
worsened by the emergence of HIV/AIDS. Globally there has been an increase in the incidence 
of tuberculosis by 2.2 million from 1997 to 2005 and 95% of this is occurring in developing 
countries. In a recent autopsy report from South Africa, it was reported that 31% of cases had 
pulmonary hypertension as cause or part of their cardiac lesion. 
HIV(Steenekamp et al., 1992) associated pulmonary hypertension is being increasingly 
reported in SSA. Hakim et al(Hakim et al., 1996) and Niakara et al(Niakara et al., 2002) recently 
reported a prevalence of 5%. Other causes of pulmonary hypertension in SSA include: sickle 
cell anemia(Aliyu et al., 2008), connective tissue disease, congenital heart disease(Diop et al., 
1995), valvular heart disease(Sani et al., 2007a), schistosomiasis(Mpe, 2000, Turner, 1964), 
laryngeal papillomatosis(Grobbelaar et al., 2005), sarcoma(Govender and Pillay, 2001), herbal 
remedies(Heath et al., 1975), hypertensive disorders of pregnancy(Desai et al., 1996),  vaso-
occlusive disorders(McCulloch et al., 2003) and primary pulmonary hypertension(Bouldouyre 
et al., 2006). 
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Chapter 3: Justification
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3.1 Justification 
Most of the published data and current knowledge on HF epidemiology are based on studies in Europe 
and America. The information obtainable from previous studies in sub-Saharan Africa is limited. Many of 
the studies were based on clinical diagnosis alone without the use of such investigations as 
echocardiography. There is also paucity of information on mode of treatment, as well as outcome/ 
prognosis of HF in the sub-region. The cost of HF in Sub-Saharan Africa (SSA) is unknown. 
3.2 Study Hypothesis 
Given the epidemiologic transition occurring in developing countries, it is hypothesized that there will be 
increasing prevalence of heart failure. It is also hypothesized that outcome of contemporary treatment 
of HF will differ from data from advanced countries.  
3.3 Objectives 
The objectives of the study are: 
3.3.1 Primary objective 
The primary objective of this study is to determine the clinical characteristics, six month outcome as well 
as cost of HF in Abeokuta, Nigeria and to compare our findings with that of the Heart of Soweto in South 
Africa. 
3.3.2 Secondary objectives 
1. To describe the relative importance of the different aetiological factors for HF in Abeokuta, Nigeria 
2. To describe the demography and clinical characteristics of patients admitted for HF in Abeokuta 
3. To describe the short and medium term outcomes of HF in Abeokuta and to determine the 
predictors of outcome. 
4. To calculate the cost of heart failure care in Abeokuta based on data generated from the study 
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3.4 End-points 
1. HF related hospitalization and rehospitalisation in Abeokuta Nigeria 
2. HF related and all-cause mortality 
3. Comparison of HF in Abeokuta with data from the Heart of Soweto and other parts of the world. 
4. Description of possible changes in the aetiology of HF in Abeokuta over time (comparison with 
similar study in the early 70s in Nigeria) 
5. Identification of prognostic factors 
6. Estimation of economic cost of Heart failure  
3.5 Study plan 
Figure 3.1 shows the study plan for the project. 
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Figure 3.1.The study plan for the project 
  
 
PART 3: Data to be used 
to estimate economic 
cost of HF 
Acute HF subjects recruited consecutively in year 1 
PART 1 
 All subjects  
Acute HF subjects recruited consecutively in year 2  
Denovo acute HF subject who consented were 
followed up for 180 days 
Decompensated chronic 
HF subjects excluded 
from follow up 
PART 2  Post discharge outcomes  Mortality (30 & 180 days)  Rehospitalization (30 and 180 days) 
Part 1: Data was used to explore the contemporary profile and intrahospital outcome of acute HF in Abeokuta (Manuscript no. 1)   Part 2: Data was used to explore: a. Short term outcome (mortality) of acute HF in Abeokuta (Manuscript no. 2). b. Predictors of rehospitalization after admission for acute HF in Abeokuta (Manuscript no. 3) c. The clinical characteristics of acute hypertensive HF in Abeokuta and outcome (commonest aetiological risk factors for HF in the city) (Manuscript no. 4).  Part 3: Data was used to estimate the economic cost of HF in 2010 in Abeokuta (Manuscript no.5).   
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Chapter 4: Materials and Methods (General)
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4.1 Design and setting  
This was a prospective, observational study conducted at the Federal Medical Centre (FMC), Abeokuta, 
Nigeria. 
Nigeria is located in the West Coast of Africa. It shares land border with Niger Republic in the North, 
Chad and the Cameroon in the East and Republic of Benin in the West. 
The southern border is the Gulf of Guinea in the Atlantic Ocean. The country has a land area of 
923,768km2 (356,667 sq. miles) and an estimated population of 174,507,539 inhabitants (2013 estimate) 
Worldwide the country is the 8th most populous country. It is the most populous black nation globally as 
well as Africa’s most populous country.   
It operates three tiers of Government (local, state and Federal Governments). The country is divided 
into 36 states and a Federal Capital Territory (Abuja). Politically it is structured into six geopolitical zones 
(North-West, North-Central, North-East, South-West, South-East and South-South) 
It is classified as a low - middle income country with a Gini Index of 43.7 and income per capita of $1490. 
About 49% of the population is living in urban areas; the gross national income per capita is $2070.  The 
literacy rate in the country is 69.1% according to the UNDP. In terms of poverty rate, it is estimated that 
64.4% of the population live under 1.25 dollars /day while 83.9% live under 2 dollars /day. 
Life expectancy at birth is 51 years for both sexes (53 for men and 54 for women). The mortality rate for 
under 5s is 138/1000 and the maternal mortality ratio is 840/105 live births. Non-communicable diseases 
contribute about 14% of the number of years of life lost. The number of doctors /10 000 population is 
about 4.  5.1% of men and 9.0% of women aged 20 years and above are obese; 11.9% of men and 1.0% 
of women aged 15 years and above smoke cigarettes. The prevalence of HIV (per 1000 adults aged 15-
49 yrs) is 36 while the prevalence of tuberculosis (per 100 000 population) is 497. 
The total expenditure on health per capita (international dollar) was 161 in 2012 while the total 
expenditure on health as percentage of the GDP was 6.1. 
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 Abeokuta is the capital city of Ogun state, one of the 36 States that make up the Federal Republic of 
Nigeria (Figure  4.1,Figure 4.2). Ogun State has twenty Local Government areas (LGAs) and inhabited 
mainly by the Yoruba ethnic group of South-west Nigeria. The State has a land area of 16, 409, 26 km2 
and it is endowed with favourable climate and good vegetation all year round. According to the national 
census of 2006, Ogun State has a total population of 3,751,140 inhabitants comprising 1,864,907 and 
1,886,233 males and females respectively. It has a population density of 220/km2. It is located within the 
co-ordinates 7o00’N 3o 35’ E. (2006a) 
Abeokuta is the capital and largest city in the State and has two of the twenty LGAs (Abeokuta North 
and Abeokuta South LGAs) It is situated on the East Bank of the Ogun River, “near a group of rocky 
outcrops in a wooded Savanna”. The name “Abeokuta” literally means “underneath of the rock” or 
indirectly “in refuge among rocks.”  It was founded in 1825 as a place of refuge from slave hunters who 
often invade from Ibadan and Dahomey. The city is about 78km (by rail) north of Lagos (the largest, 
former administrative capital and current commercial/economic capital of Nigeria). It is located within 
the geographic co-ordinates of 7o 9’ 39’N 3o 20’ 54’ E and at about 66m above sea level. 
As at the year 2012, the city was estimated to have a population of 888,924 and 1,117,000 for the city 
and metropolis respectively. 
 FMC Abeokuta is a 250 bedded tertiary health centre that was established in 1993 by the Federal 
Government of Nigeria to cater for the health needs of the people of Ogun State and its environs in 
Southwestern Nigeria. The centre is the only tertiary hospital in the city which receives referrals from all 
the health facilities in the city, state and the neighboring states.
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 (Source) 
 
Figure  4.1. A-Map of Africa showing the location of Nigeria, B-Map of Nigeria showing the location of Ogun state, C- Map of Nigeria showing the 
location of Abeokuta, D- Map of Ogun state showing the location of Abeokuta and other towns 
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Figure 4.2. Olumo Rock, one of the tourist centres in the city, B. Aerial view of Abeokuta 
(Source https://www.google.co.uk/#q=OLUMO+rock) 
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4.2 Healthcare delivery in the city 
Like in other parts of the country the state operates three-tier or level of healthcare: primary (health 
posts, health centres), secondary (Cottage, General or State hospitals) and tertiary health care (Federal 
medical centres and University teaching hospitals). Primary health care is constitutionally under the 
jurisdiction of the Local Government. The remaining two are under the State and Federal Governments 
respectively. 
A significant proportion of health care delivery is carried out by private health institutions and mission or 
faith-based hospitals. 
The costs of healthcare in the city and in most parts of the country are generally borne by the patients 
through out of pocket expenses. Social health insurance coverage is low in the city and in most parts of 
the country. On the other hand strong family bonding exist in the city where rich and well-to-do 
individuals assist their poor family members 
A cardiologist covers the cardiac unit assisted by postgraduate resident doctors as well as experienced 
nurses. Facilities for cardiac evaluation that exist in the centre include: chest radiography, 12-lead 
electrocardiography (ECG), exercise ECG, Holter ECG, Ambulatory blood pressure monitoring devices, 
Spirometry and echocardiography (ECHO). All the ECGs and ECHOs were carried out within 72 hours of 
admission as prescribed by the study protocol. 
4.3 Study population 
All cases of AHF, both denovo presentations and recurrent decompensation with a pre-established 
diagnosis of HF were consecutively recruited into the registry between January 1, 2009 and December 
2010. (There were no study refusals) 
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4.4 Enrollment and data collection 
Data from each subject was obtained using a uniform and standardized case report form. Detailed 
clinical documentation on newly diagnosed/ newly presenting cases/ pre-existing cases of HF was 
carried out. The following data were obtained: study identification number, demographic data, date of 
diagnosis of HF and pre-admission history (previous HF-related admissions). Others include NYHA 
functional class, symptoms, signs, self-reported CV risk factors, aetiology of HF, precipitating factor, co-
morbidities, blood investigations, 12-lead ECG, echocardiography, medications and intra-hospital and 6-
month outcomes.  
4.5 Clinical evaluation 
Their blood pressures were measured in the right arm with the subjects seated and rested for 5 minutes 
before the procedure. Measurements were taken using mercury sphygmomanometer (Accosson 
London). Systolic and diastolic blood pressures were measured at Korotkoff sounds phases I and V 
respectively.  The cuff size used was based on the arm circumference of the subject. The cuff was rapidly 
inflated to 30mmHg above the level at which the pulse disappeared and then deflated gradually. Blood 
pressure 140/90 and above was taken as hypertension. Subjects were weighed without shoes and in 
light clothing on a standard beam balance. Height was measured to the nearest centimetre using 
anthropometrical plane with subjects not putting on shoes or headgear. 
Body mass index (BMI) was calculated using the formula: BMI = Weight (kg) / (height in metres)2  A  BMI 
of 24-29.9kg/m2 and >=30kg/m2 defined overweight and obesity respectively.  
Body surface area was calculated using the formula of Dabois(Du Bois and Du Bois, 1916) 
Body Surface Area (BSA) (in m2) =0.0001 x (71.84) x (Weight in kilogram) 0.425 x height in centimetre) 0.725.  
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4.6 Laboratory Investigations 
Urine samples were collected from the subjects with the use of universal bottles for urine analysis using 
Bayers’ uristix test strip. Venous blood samples (5-10ml) was drawn from the antecubital vein of the 
subjects into serially numbered and appropriate sample bottles for full blood count (potassium EDTA 
bottle), and for electrolyte, urea and creatinine (Lithium heparin bottle) 
After an overnight fasting of 8-14 hours , venous blood samples were drawn from the subjects into 
appropriate sample bottles for fasting blood glucose (Fluoride oxalate bottle) and for fasting lipid profile  
(Potassium EDTA bottle) 
For consenting subjects, blood samples were also collected with plain sample bottles for HIV screening. 
All collected samples were immediately sent to the central laboratory of Federal Medical Centre, 
Abeokuta separation and storage.  The blood samples were centrifuged at a rate of 5,000rpm for 10 
minutes. The separated plasma was drawn using a pipette into newly labelled sample bottles with study 
number corresponding to the subjects and CRFs. This was then kept frozen between -2 to 4 degrees 
centigrade before analysis was performed in batches after a week of sample pooling.  
Serum electrolytes were analysed with ISE SFRI 4000 electrolyte analyser (SFRI Medical Diagnostics St.-
Jean-d’lllac, France). Urea and creatinine were analysed with Slim SEAC photometer (dar SEAC –Radim , 
Italy)  while Sysmex 5 parts analyser was used to perform full blood count  wile ELISA washer and reader 
(Tecan Group LTD, Seestrasse 103, CH-8708 Maennedorf, Switzerland) was used for the diagnosis of HIV  
Anaemia was defined as haemoglobin concentration of less than 10g/dl. Glomerular filtration rate was 
estimated using the four variables- Modification of Diet in Renal Disease (MDRD) formula.(Levey et al., 
1999) Renal dysfunction was defined as eGFR of less than 60ml/min/1.73m2 . [(same criteria used by 
Stewart et al.(Stewart et al., 2008)] 
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4.7  Electrocardiography 
A standard 12-lead resting ECG was recorded for each subject using a Schiller ECG machine 
(Schiller AG, Switzerland).  All the 12 lead resting ECG were performed by trained 
nurses/technicians and analyzed by a reviewer who was blinded to the clinical data of the 
patients. The Minnesota code classification(Blackburn, 1969) system was used in sorting out 
the various abnormalities. ECG abnormalities were diagnosed based on standard 
criteria(Rowlands, 1981).(Figure 4.3) 
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Figure 4.3. 12-lead ECG of a subject with hypertensive heart failure. ECG shows left ventricular 
hypertrophy with strain pattern 
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4.8 Echocardiography 
An Aloka SSD-4000 echocardiograph (Aloka Co. Ltd., Tokyo, Japan) was used in evaluating the 
patients. Two dimensional guided M- mode measurements were made according to the 
recommendations of the American Society of Echocardiography (ASE)(Sahn et al., 1978a). LV 
internal dimension, posterior wall thickness and interventricular septal thickness were 
measured at end-diastole and end-systole. Where optimal M-mode imaging could not be 
obtained, 2D linear measurements were obtained according to the ASE criteria(Sahn et al., 
1978a). Left atrial end systolic diameter was obtained from the trailing edge of the posterior 
aortic – anterior left atrial complex. Measurements were obtained in up to 3 cardiac cycles 
according to the ASE convention(Sahn et al., 1978a). 
Because segmental or regional wall motion was not common in our cohort and LV was 
uniformly contracting in most cases, Teichholz method(Teichholz et al., 1976) was used for the 
estimation of LV systolic function. However, where regional or segmental was present, biplane 
Simpson’s method(Schiller et al., 1988) was employed. 
Left ventricular mass was calculated using the formula of Devereux and Reichek.(Devereux and 
Reichek, 1977b) This has been shown to yield LVM closely related to autopsy measurements 
(r=0.90)(Devereux et al., 1986) and has good interobserver reproducibility (ρ=0.93) in one 
study(Palmieri et al., 1999). Relative wall thickness (RWT) was derived from 2 X posterior wall 
thickness/LV internal diameter. Increased RWT was considered to be present when RWT 
exceeded 0.43 This represents the 97.5th percentile in normal subjects(Roman et al., 1995). 
Left ventricular geometric was defined as follows: Normal geometry, when LVMI and RWT 
were normal; Concentric remodeling, when LVMI was normal and RWT increased; Eccentric 
hypertrophy, when LVMI was increased but normal RWT; and Concentric hypertrophy, when 
both LVMI and RWT were increased (Ganau et al., 1992). 
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The left atrial dimension was measured between the leading edge of the posterior aortic wall 
and the leading edge of the posterior wall of the left atrium at end systole. The areas of the 
left atrium was determined by tracing the endocardial border of the left atrium at end systole 
(ventricular) before the opening of the mitral valve in the apical four chamber view(maximal 
LA area or A-max), excluding the LA appendage and pulmonary vein confluences.(Lester et al., 
1999) (Thomas et al., 2002) 
Transmitral flow velocities were obtained with the Doppler sample volume placed just beyond 
the tip of mitral valve leaflets. The parameters measured were early diastolic peak flow 
velocity(E), late diastolic peak flow velocity (A), the deceleration time of early mitral velocity 
and the ratio of E to A (E/A). Isovolumic relaxation time (IVRT) was measured with pulse wave 
Doppler beam intersecting the LV outflow and inflow tracts,(Nishimura and Tajik, 1997). Tissue 
Doppler imaging was only applied to identify true pseudonormalised filling pattern. (Figures 
4.4-4.9)  
One experienced cardiologist (OSO) performed all the echocardiography. In our laboratory, the 
intra-observer concordance correlation coefficient and measurement error have been 
reported.(Ogah et al., 2006a)  
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Figure  4.4. M-Mode Echocardiogram Showing Measurement of Aortic Root and Left Atrial 
Diameter 
RV= Right Ventricle, LA= Left Atrium 
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Figure  4.5.M-Mode Echocardiogram Showing Measurement of  Left Ventricular (LV) 
Dimensions and Indices of LV Systolic Function 
RV =Right Ventricle, SV=Stroke Volume, AMVL= Anterior Mitral Valve leaflet, EF=Ejection 
Fraction, IVSD=Interventricular Septum in Diastole, FS=Fractional Shortening, 
IVSS=Interventricular Septum in Systole, MVCF=Mean velocity of Circumferential  Fibre 
Shortening, LVPWD=Left  Ventricular Posterior Wall in Diastlole, LVPWS=Left Ventricular 
Posterior Wall in Systole, HR=Heart Rate, EDV=End Diastolic Volume, ESV=End Systolic Volume 
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Figure 4.6. Echocardiogram Showing Measurement of Transmitral Flow Velocity Profile ('E' and 
'A'  Waves). RV =Right Ventricle, LV=Left Ventricle, RA=Right Atrium, LA =Left Atrium, 
SV=Sample Volume, AMVL=Anterior Mitral Valve Leaflet, PMVL=Posterior Mitral Valve Leaflet, 
ME=Mitral E wave, MA=Mitral A wave
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Figure 4.7. Echocardiogram Showing Measurement of Deceleration Time (DT) of the Mitral 'E' 
Wave. 
RV =Right Ventricle, LV=Left Ventricle, RA=Right Atrium, LA =Left Atrium, SV=Sample Volume, 
AMVL=Anterior Mitral Valve Leaflet, PMVL=Posterior Mitral Valve Leaflet, ME=Mitral E wave, 
MA=Mitral A wave 
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Figure 4.8. A. Echocardiogram Showing Measurement of Deceleration Time (DT) of the Mitral 
'E' Wave. RV =Right Ventricle, LV=Left Ventricle, RA=Right Atrium, LA =Left Atrium, SV=Sample 
Volume, AMVL=Anterior Mitral Valve Leaflet, PMVL=Posterior Mitral Valve Leaflet, ME=Mitral 
E wave, MA=Mitral A wave. B. Tissue Doppler Imaging (TDI) showing the E’ and A’ wave 
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Figure 4.8 B. Echocardiogram Showing Measurement of Tissue Doppler Imaging (TDI) showing 
the E’ and A’ wave 
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Figure 4.9. Echocardiogram Showing Measurement of maximal left atrial area. 
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4.9 Diagnoses of Heart Failure/ Case definition 
A standardised diagnosis of HF  was made using the Framingham criteria(McKee et al., 1971) as 
well as the according to the guidelines of ESC on the diagnosis and treatment of AHF(Dickstein 
et al., 2008) (Table 4.1) As such, both de novo presentations of AHF as well as recurrent 
presentations of typically decompensated HF (i.e. acute- on –chronic HF) were included in the 
registry. (Figures 4.9-4.11). 
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Table  4.1. Case Definition 
Case definition Diagnostic criteria Hypertensive HF Previous history of hypertension or  sustained BP of  >140/90 mmHg in the presence of symptoms of HF, increased LV mass LV systolic  and/or diastolic dysfunction Valvular HF (mostly rheumatic) HF in addition to any of the following: i. Mitral stenosis: – presence of thickened and calcified mitral valve leaflets, loss of the classic M-shaped pattern of a normal mitral valve, diastolic dooming and restriction of the mitral valve leaflet motions. ii. Mitral Regurgitation: Poor coaptation of the mitral valve leaflets in systole, thickened leaflets, dilated and hyperdynamic left ventricle, iii. Aortic stenosis: Presence of calcified aortic valve, reduction in aortic cusp separation, highly echo reflectant aortic valve leaflets, iv. Aortic regurgitation: Poor coaptation of the aortic cusps in diastole, dilated left ventricles and fine fluttering of the anterior mitral valve in diastole.  Dilated Cardiomyopathy Dilated cardiomyopathy was diagnosed when there are dilated heart chambers with normal or decreased wall chambers as well as impaired LV systolic function.  Endomyocardial Fibrosis Endomyocardial fibrosis (EMF) was documented in the presence of clinical features coupled with dilated atria and thickening of the endocardium especially at the apices of the ventricles   Pericardial Effusion Pericardial effusion was diagnosed when there is echo free space between the visceral and parietal pericardium. Diagnosis of constrictive pericarditis was based on standard criteria. Cor-pulmonale or Right Heart Failure Cor pulmonale was present when there is dilated and hypertrophied right ventricle (RV), evidence of increased RV systolic pressure (D-shaped LV in diastole (diastolic flattening of the LV septum)  Ischaemic Cardiomyopathy HF associated with diagnosis of myocardial infarction. Diagnosis of MI was based on ECG changes, Cardiac enzyme elevation and regional wall motion abnormality at echocardiography   LV systolic dysfunction HF in the presence of LV ejection fraction (EF)<=45% LV diastolic dysfunction HF in the presence of LVEF >=45% and E/a ratio, deceleration time and isovolumic relaxation time (IVRT) within accepted definition( according to the criteria of the European Society of Cardiology (European Heart Journal (1998) 19, 990–1003), European Journal of Heart Failure (2012) 14, 803–869) 
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Figure 4.10. A(1&2). 2D and M-mode echocardiogram of a subject with mitral stenosis; B(1&2). 2D and 
M-mode echocardiogram of a subject with idiopathic dilated cardiomyopathy 
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Figure 4.11. Echocardiogram of a subject with a large atrial septal defect; B. 2D echocardiogram of a 
subject with effusive pericarditis 
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4.10 Follow-Up 
The study cohort was prospectively followed up for six months post index hospitalisation. The 
subjects were contacted through clinic visit or telephone calls at one, three and six months. 
Information obtained during follow-up included their wellbeing, prescribed pharmacotherapy, 
history of re-hospitalization and deaths (from next of kin). In addition to patient or relation’s 
telephone interviews; and where necessary referring physicians were contacted for additional 
information.  
4.11 Health outcomes 
The following health outcomes were documented - 1) length of initial hospital stay (LoS) in 
days, 2) survival status on discharge (dead or alive), 3) short-term case-fatality (30 days), 4) 
medium-term case-fatality (180 days), 5) re-hospitalization status (180 days). 
4.12 Estimation of health care cost of HF 
All available costs associated with in-patient care, out-patient cares (both direct and indirect 
cost) as well as the opportunity costs associated with HF management in the city were 
computed for the year 2010. An annual, prevalence based approach was employed in 
estimating the cost of the resources used for the management of HF.(Stewart et al., 2002, 
Ryden-Bergsten and Andersson, 1999, Czech et al., 2013, Araujo et al., 2005) Healthcare costs 
were then expressed in the local currency-Naira, (and converted to US Dollar [$US] at a rate of 
150 Nigerian Naira to $US1 in 2010)  
4.13 Ethical consideration 
The study was reviewed and approved by the ethics review boards of Federal Medical Centre 
Abeokuta, Nigeria and the University of the Witwatersrand. All the subjects gave informed 
consent and the study was carried out in accordance with the declaration of Helsinki.(Rits, 
1964) 
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4.14 Data management and Statistical Analyses 
Data was entered into EpiData software (The EpiData Association, att. Jens Lauritsen, 
Enghavevej 34, DK5230 Odense M, Denmark) by experienced personnel and analyzed with 
SPSS version 11.0 (SPSS, Inc. Chicago Illinois). Descriptive statistics for baseline data was 
performed on continuous variables using mean, standard deviation, range and median where 
appropriate. Categorical variables are expressed as percentages. MacNemar and chi-square 
tests (for categorical variables) and Student’s t-test or analysis of variance (for continuous 
variables) were used for comparisons as appropriate.  
Survival function estimates was performed using the Kaplan-Meier method and the differences 
were tested using log-rank test. The follow-up was censored at 6 months post admission. 
Subjects who died or were readmitted within the period of six months constituted the event of 
interest for purpose of survival analysis while those still alive/ not readmitted or lost to follow-
up were treated as censored. In the survival analysis, censoring meant that the outcome of 
interest has not been observed. All demographic and clinical profiling variables were 
examined, on a univariate basis, as potential correlates of death during 180 day follow-up in 
those who survived the index hospitalisation. Where appropriate, results are expressed as 
odds ratio (OR) with their 95% Confidence Intervals (95% CI). 
A two-sided p value of <0.05 was considered significant. 
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 Abstract  
Objective 
This study sought to determine the contemporary profile, clinical characteristics and intra-hospital 
outcome of acute heart failure in an African urban community. 
Background 
There is limited data on the current burden and characteristics of acute heart failure (AHF) in 
Nigerian Africans.  
Methods 
We prospectively collected comprehensive and detailed clinical and socio-demographic data from 
452 consecutive patients presenting with AHF to the only tertiary hospital in Abeokuta, Nigeria 
(population 3.2 million) over a two year period.  
Results 
Mean age was 56.6±15.3 years (57.3±13.4 for men, 55.7±17.1 for women) and 204 (45.1%) were 
women. Overall,  415 (91.8%) subjects presented with de novo AHF. The most common risk factor 
for HF was hypertension (pre-existing in 64.3% of cases). Type 2 diabetes mellitus was present in 
41(10.0%). Hypertensive heart failure was the commonest etiological cause of HF being responsible 
for 78.5% of cases. Dilated cardiomyopathy (7.5%), cor-pulmonale (4.4%), pericardial disease (3.3%), 
rheumatic heart disease (2.4%) and ischemic heart disease were less common (0.4%) causes. The 
majority (71.2%) of subjects presented with left ventricular dysfunction (mean left ventricular 
ejection fraction 43.9 ± 9.0%) with valvular dysfunction and abnormal LV geometry frequently 
documented. Mean duration of hospital stay was 11.4± 9.1 days and intra-hospital mortality was 
3.8%. 
Conclusions 
Compared to high income countries, individuals presenting with AHF in Abeokuta, Nigeria are 
relatively younger and still of a working age. It is also commoner in men and associated with severe 
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symptoms because of late presentation. Intra-hospital mortality is similar to other parts of the 
world. 
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5.1 Introduction 
 
Although recognized as a significant health problem in high income countries.(Sidney et al., 2013, 
Mosterd and Hoes, 2007) the syndrome of heart failure (HF), both in its acute(Mosterd and Hoes, 
2007) and chronic(Mosterd and Hoes, 2007)  forms has emerged as an a issue of global public health 
importance.  It has been established that the burden of HF doubles with each passing decade after 
the age of 40 years especially in industrialized countries of the world due to aging population and 
increasing burden of risk factors including  hypertension, diabetes mellitus, ischemic heart disease 
and, more recently obesity .(Cowie et al., 1997). HF is estimated to affect about 15 million people 
worldwide (0.2% of the world population). Whilst there are robust estimates to describe the 
incidence, prevalence and overall burden of HF in Europe (Cowie et al., 1999, Cleland et al., 2003, 
Cleland et al., 2000) and North America, there is a paucity of data to describe the same in other 
major populations around the globe. For example, HF in Africa (including Nigeria) appears to occur at 
a relatively younger age, afflicting individuals at the prime of life and mostly due to non-ischemic 
origin. However, there is limited systematically collected and contemporary data to describe clinical 
characteristics, outcome and cost of HF for the continent.(Damasceno et al., 2007, Ntusi and Mayosi, 
2009b) 
As an extension of this, there is limited data derived from systematically and prospectively 
conducted studies of HF in Nigeria – the most populous region in sub-Saharan Africa. Previous 
studies in the 60s, 70s and 80s were mainly retrospective and the various diagnoses were not 
confirmed by echocardiography.(Antony, 1980, Ladipo, 1978, Parry et al., 1977) Moreover, there is 
even less data to describe acute clinical presentations of HF, to match the clinical registry data 
derived from large cohorts in Europe and North America(Adams et al., 2008). 
Considering the paucity of data on acute HF (AHF) in sub-Saharan Africa, we used the data of the 
Abeokuta Heart Failure Registry to explore and determine the current etiology and characteristics of 
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acute (both de novo and recurrent) presentations of the syndrome in southern Nigeria. The possible 
role of epidemiologic and demographic transition occurring in Nigeria on the profile of HF in the 
country was also assessed(Omran, 1971). 
5.2 Methods  
5.2.1 Design and setting  
This was a prospective, observational study conducted at the Federal Medical Centre (FMC), Idi-Aba, 
and Abeokuta, Nigeria. Abeokuta is the capital city of Ogun state, one of the 36 states that make up 
the Federal Republic of Nigeria. FMC was established in 1993 by the Federal Government of Nigeria 
to cater for the health need of the people of Ogun State and its environs in Southwestern Nigeria. 
The center is the only tertiary hospital in the city which receives referrals from all the health facilities 
in the city, state and the neighboring states. The state has a population of about 3.2 million and a 
land area of about 16,409.26 square kilometers. The city itself has an estimated population of about 
1 million inhabitants.(2006a) The prevalence of  HIV antibodies in individual attending the hospital 
clinics in 2010 was 11.6%(16% in women and 7.3% in men),(Motayo et al., 2012) 
Health care cost in Abeokuta, Nigeria (and in fact in all parts of the country) is generally borne by the 
individual through out of pocket payment. Health insurance in the country is still at a rudimentary 
stage. Only a very small population has access to this. However strong family tie exist in the country 
where poor patients are assisted by their wealthy or well-to do family members. This is in fact a very 
big challenge to health care delivery in the city and the country in general. 
A cardiologist (OSO) covers the cardiac unit assisted by postgraduate resident doctors and well as 
experienced nurses. Facilities for cardiac evaluation that exist in the center include: chest 
radiography, 12-lead electrocardiography (EKG), exercise EKG, Holter EKG, Ambulatory blood 
pressure monitoring devices, Spirometry and echocardiography (ECHO). All the EKGs and ECHOs 
were carried out within 72 hours of admission as prescribed by the study protocol. 
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5.2.2 Study population 
All cases of AHF, both denovo presentations and recurrent decompensation with a pre-established 
diagnosis of HF were consecutively (there were no study refusals) recruited into the registry 
between January 1, 2009 and December 2010. All subjects provided written and/or informed 
consent to participate in the study. Ethical approval was obtained from the ethical committee/ 
ethical review board of the Federal Medical Centre, Abeokuta. The study was carried out in 
accordance with international ethical principles(Rits, 1964).  
5.2.3 Enrollment and data collection 
Data from each subject was obtained using a uniform and standardized case report form. Detailed 
clinical documentation on newly diagnosed/ newly presenting cases/ pre-existing cases of HF was 
carried out. The following data were obtained: study identification number, demographic data, date 
of diagnosis of HF and pre-admission history (previous HF-related admissions). Others include NYHA 
functional class, symptoms, signs, self-reported cardiovascular risk factors, etiology of HF, 
precipitating factor, co-morbidities, blood investigations, 12-lead EKG, echocardiography, 
medications and intra-hospital mortality.  
5.2.4 Clinical evaluation 
Blood pressure measurements were obtained according to standard guidelines with a mercury 
sphygmomanometer (Accousson London). Body mass index (BMI) was calculated using the formula: 
BMI = Weight (kg) / [h)] 2. A BMI of 24-29.9kg/m2 and >=30kg/m2 defined overweight and obesity 
respectively. Anemia was defined as hematocrit of less than 10g/dl. Glomerular filtration rate was 
estimated using the four variables- Modification of Diet in Renal Disease (MDRD) formula.(Levey et 
al., 1999) Renal dysfunction was defined as eGFR  of less than 60ml/min/1.73m2  (same criteria used 
by Stewart et al(Stewart et al., 2008)) 
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5.2.5 Diagnoses of Heart Failure 
A standardised diagnosis of HF  was made using the Framingham criteria(McKee et al., 1971) as well 
as the according to the guidelines of European Society of Cardiology on the diagnosis and treatment 
of AHF(Dickstein et al., 2008) As such, both de novo presentations of AHF as well as recurrent 
presentations of typically decompensated HF (i.e. acute- on -chronic HF) were included in the 
registry. 
5.2.6 Electrocardiography 
A standard 12-lead resting EKG was recorded for each subject using a Schiller EKG machine (Schiller 
AG, Switzerland).  All the 12 lead resting EKG were performed by trained nurses/technicians and 
analyzed by a reviewer who was blinded to the clinical data of the patients. The Minnesota code 
classification(Blackburn, 1969) system was used in sorting out the various abnormalities. EKG 
abnormalities were diagnosed based on standard criteria(Rowlands, 1981). 
5.2.7 Echocardiography 
An Aloka SSD-4000 echocardiograph (Aloka Co. Ltd., Tokyo, Japan).  was used to assess all patients. 
Two dimensional guided M- mode measurements were made according to the recommendations of 
the American Society of Echocardiography (ASE)(Sahn et al., 1978a).  LV internal dimension, 
posterior wall thickness and interventricular septal thickness were measured at end-diastole and 
end-systole. Where optimal M-mode imaging could not be obtained, 2D linear measurements were 
obtained according to the ASE criteria(Sahn et al., 1978a). Left atrial end systolic diameter was 
obtained from the trailing edge of the posterior aortic – anterior left atrial complex.  Measurements 
were obtained in up to 3 cardiac cycles according to the ASE convention(Sahn et al., 1978a). One 
experienced cardiologist (OSO) performed all the echocardiography. In our laboratory, the intra-
observer concordance correlation coefficient and measurement error have been reported.(Ogah et 
al., 2006a) Left ventricular mass was calculated using the formula of Devereux and 
Reichek.(Devereux and Reichek, 1977b) Left ventricular geometric was defined according to 
standard criteria.(Ganau et al., 1992). 
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The left atrial dimension and area  was measured using standard methods (Lester et al., 1999) 
(Thomas et al., 2002) .  
Transmitral flow velocities were obtained with the Doppler sample volume placed just beyond the 
tip of mitral valve leaflets and standard measurements were obtained.(Nishimura and Tajik, 1997) 
Tissue Doppler imaging was only applied to identify true pseudonormalised filling pattern. 
5.2.8 Statistical analyses 
Data was entered into EpiData software (The EpiData Association, att. Jens Lauritsen, Enghavevej 34, 
DK5230 Odense M, Denmark) by experienced personnel and analyzed with SPSS version 11.0 (SPSS, 
Inc. Chicago Illinois). Descriptive statistics for baseline data was performed on continuous variables 
using mean, standard deviation, range and median where appropriate. Categorical variables are 
expressed as percentages. MacNemar and chi-square tests (for categorical variables) and Student’s 
t-test or analysis of variance (for continuous variables) were used for comparisons as appropriate. A 
two-sided p value of <0.05 was considered significant. 
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5.3 Results 
5.3.1 Cohort profile 
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Table 5.1 summarizes the demographic and past history/risk profile of the study cohort. A total of 
452 subjects were recruited into the registry. This constituted 9.4% of the total number of medical 
admissions during the period. There were 248 (54.9%) men and 204 (45.1%) women. The mean age 
of the cohort was 56.4±15.2 years. The majority of subjects were aged > 45 years and married; while 
67.5% of them had at least primary school education. More than two thirds also lived in an urban 
community. Few subjects (3.3%) were current cigarette smokers and was more commonly reported 
in men than women (5.6% and 0.5% respectively) with a similarly low level reporting a positive 
family history of heart disease.  More than half the cohort was being actively treated for 
hypertension. The overall prevalence of diabetes mellitus was 10.0%. Of note, 415 (91.8%) subjects 
were de novo presentations of AHF. About 90% of the subjects were in NYHA class II or III, one 
month prior to evaluation, 27%  were either overweight or obese, 21.7% had moderate-to-severe 
renal dysfunction (eGFR <60ml/min/1.73m2) and 10.5% of the subjects were anemic. Presenting 
symptoms and signs are summarized in Figure 5.1, respectively.  
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 Table 5.1. Socio-demographic and clinical profile of study cohort 
Variable  ALL(n=452) MEN(n=248) WOMEN(n=204) P-value  
 
Mean Age 56.6±15.3 57.3±13.4 55.7±17.1 0.265 
Yoruba Tribe 415(91.8%) 225(90.7) 190(93.1) 0.450 
Others  Tribes 37(8.2%) 23(9.3) 14(6.9) 0.448 
Married  363(80.3) 221(89.1)  <0.001 
No Education  147(32.5) 63(25.4) 84(41.2) 0.006 
Unemployed 13(5.2) 25(12.3) 38(8.4) 0.002 
Urban residence 388(74.8) 185(74.6) 153(75.0) 0.922 
Current smoker 15(3.3) 14(5.6) 1(0.5) 0.006 
Never consumed alcohol 286(63.3) 100(40.3) 186(91.2) <0.001 
Known Hypertension  293(64.3) 174(70.2) 119(58.3) 0.010 
Known Diabetes Mellitus  45(10.0) 20(8.1) 25(12.3) 0.157 
Asthma 9(2.0) 3(1.2) 6(2.9) 0.311 
COPD 16(3.5) 12(4.8) 4(2.0) 0.127 
Arthritis  64(14.2) 10() 35(17.2) 0.105 
Family History of Heart Disease 14(3.1%) 8(3.2) 6(2.9) 0.862 
NYHA Class (n=308)    0.502 
Class II 79(17.5) 47(19.0) 32(15.7) 
Class III 284(62.8) 150(60.5) 134(65.8) 
Class IV 89(19.7) 51(20.4) 38(18.6) 
BMI(kg/sqm) 23.9±5.7 24.0(5.1) 23.7(6.4) 0.470 
% Obese  41(9.1) 21(10.7) 20(12.4) 0.428 
Temperature (0C) (n=299) 36.4±0.8 36.4±0.7 36.4±0.80 0.801 
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Resp. Rate (c/min) (n=395) 27.8±6.3 27.9±6.3 27.7±6.2 0.706 
Pulse Rate (beats/min) (n=418) 96.6±18.3 96.9±17.9 96.3±18.7 0.765 
SBP (mmHg) (n=424) 137.5±31.8 138.7±32.2 136.2±31.4 0.416 
DBP (mmHg) (n=424) 87.3±20.3 88.5±21.0 85.9±19.4 0.186 
     
PCV (%) (n=381) 37.6±7.0 37.9±7.0 37.2±7.1 0.372 
WCC (n=377) 7.13±3.73 7.0±3.8 7.27±3.68 0.519 
% Lymphocytes (n=303)  35.8±12.8 35.3±12.4 36.4±13.2 0.452 
Serum Sodium (mmol/dl) 135.2±10.0 134.9±10.2 135.6±9.8 0.640 
Serum Potassium(mmol/dl) 3.61±0.74 3.63±0.76 3.58±0.72 0.661 
Total cholesterol (mg/dl) 171.0±70.5 164.1±72.2 188.6±64.8 0.228 
Urea (mg/dl) 44.0±39.6 48.3±44.4 38.8±32.1 0.037 
Creatinine (mg/dl) 1.45±2.15 1.67±2.56 1.19±1.46 0.857 
Glucose (mg/dl) 112.8±53.3 112.2±46.6 113.4±61.0 0.028 
Duration in hospital admission (days) 11.4±9.1 10.8±0.78 6.48±0.52 0.608 
Anaemia (n=382) 40(10.5) 18(8.8%) 22(12.4%) 0.169 
Renal Dysfunction(n=366) 174(47.5) 97(48.0) 77(47.0) 0.461 
HIV positive (n=222)(%) 2.7 3.5 1.9 0.474 
*data in bracket are percentages 
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Figure 5.1. Symptoms and signs in the 452 subjects with acute HF 
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5.3.2 Precipitating factors for acute heart failure  
The common precipitating factors for HF in the cohort include infections especially chest infection 
(n=284, 62.8%), uncontrolled hypertension (n=200, 44.2%) and arrhythmias especially atrial 
fibrillation (n=123, 27.3%). Less common precipitants included anemia (n=33, 7.3%), excessive 
physical activity (n=-25, 5.5%) and electrolyte imbalance (e.g. hyponatraemia and hypokalemia n=10, 
2.2%). Of note, there was only one case of acute myocardial infarction (0.2%)  
5.3.3 12 lead electrocardiography 
A majority of subjects presented with an abnormal 12 lead EKG. Axis deviations (most commonly left 
axis deviation) were determined in 76.1% of cases. Atrial enlargement or abnormality was recorded 
in 69.7% of EKGs. EKG-defined LVH was observed in 82.8%, out of which 38.5% had EKG LVH with 
strain pattern, 13.1 % had right ventricular hypertrophy, 28.7% had arrhythmias and atrial fibrillation 
was also present in 52 (11.5%) subjects. 
5.3.4 Echocardiography and etiology of HF 
Figure 5.2 shows the etiological risk factors for HF in the cohort. Hypertensive heart disease, dilated 
cardiomyopathy, cor-pulmonale (right heart disease), pericardial disease and rheumatic heart 
disease were the common risk factors for HF in the cohort and these constituted 78.5%, 7.5%, 4.4%, 
3.3% and 2.4% of cases, respectively. Pericardial diseases and right HF was more common in women, 
while hypertensive HF and DCM was more common in men. Other causes of HF in the cohort 
included peripartum cardiomyopathy (1.3%), endomyocardial fibrosis (EMF) (0.9%), thyroid heart 
disease (0.7%), ischemic heart disease (0.4%) and adult congenital heart disease (0.4%). The 
echocardiographic features of the subjects according to gender are shown in Table 5.2 
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Figure 5.2. Etiology of HF in the 452 subjects 
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Table 5.2 Echocardiographic variables of the cohort in men and women 
Variable ALL(n=452) Men(n=248) Women(n=204) P-Value 
Aortic root (cm) 3.04±0.50 3.22±0.51 2.81±0.39 <0.001 
Left atrium(cm) 4.80±0.66 5.00±1.43 4.54±1.05 0.157 
IVSTd 1.32±0.37 1.38±0.40 1.25±0.36 0.001 
PWTd 1.17±0.35 1.20±0.36 1.12±0.33 0.031 
LVIDd 5.48±1.43 5.79±1.44 5.11±1.33 <0.001 
LVIDs 4.51±1.40 4.82±1.42 4.14±1.29 <0.001 
FS 18.5±9.0 17.6±8.74 19.5±9.12 0.039 
EF 43.9±9.0 42.1±16.8 45.9±17.1 0.037 
LVM 320.7±132.8 360.0±141.8 272.4±102.4 <0.001 
LVMI 86.2±37.0 92.8±40.9 77.9±26.6 <0.001 
RWT 0.44±0.15 0.43±0.15 0.46±0.15 0.189 
E wave(m/sec) 0.82±0.29 0.79±0.28 0.86±0.31 0.031 
A wave(m/sec ) 0.52±0.15 0.49±0.22 0.56±0.28 0.017 
E/A 2.04±0.40 2.10±1.48 1.97±1.28 0.460 
IVRT 145.0±59.7 117.1±35.9 110.6±32.8 0.174 
DT 114.4±34.7 142.6±56.0 148.3±64.4 0.397 
LV Geometry      
CH (%) 38.3 39.6 36.8 0.069 
EH (%) 45.4 47.6 42.8 0.069 
MR (%)  77.9 75.5 80.7 0.256 
TR (%) 69.7 65.5 74.7 0.068 
AR (%) 8.2 8.5 7.8 0.851 
Syst HF (%) 66.4 71.2 60.6 0.028 
Spontaneous Echoes   6.8 8.5 4.8 0.212 
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Intramural Thrombi 0.8 1.0 0.6 0.670 
IVSTd= Interventricular septal wall thickness in diastole, PWTd=  Left ventricular posterior wall 
thickness in diastole, LVIDd= left ventricular internal diameter in diastole,  LVIDs= left ventricular 
internal diameter in systole, FS= fractional shortening, EF= ejection fraction, LVM= left ventricular 
mass, LVMI= left ventricular mass index, RWT= relative wall thickness, E =LV early filling velocity, 
A=Left ventricular late filling velocity,  IVRT= isovolumic relaxation time, DT= deceleration time of E 
velocity, CH= concentric hypertrophy, EH= Eccentric hypertrophy, MR= mitral regurgitation, TR= 
tricuspid regurgitation, AR= aortic regurgitation 
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The aortic root diameter, LV septal wall thickness in diastole, posterior wall thickness, indices of LV 
systolic function and left ventricular mass were significantly higher in men than in women. Men also 
had significantly higher frequency of systolic HF than women (71.2% vs. 60.6%, p=0.028). Table 5.3 
shows the echocardiographic characteristics of the cohort according to the etiological risk factor for 
HF. LV wall thickness was higher in the hypertensive HF group while LV dilatation was found to be 
greatest in the DCM group; which also had the highest frequency of LV systolic dysfunction 
In terms of LV geometry, 93.5% of the cohort had abnormal LV geometry (concentric remodeling – 
9.7%, concentric hypertrophy – 38.3% and eccentric hypertrophy – 45.4%). 
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Table 5.3. Echocardiographic characteristics according to etiological factor 
 ALL(452) HHF(n=355) CMO(n=38) CORPULMALE(n=26) PERICARDIAL(n=15) RHD(n=11) OTHERS(n=7) 
AO* 3.04±0.50 3.10±0.50 2.89±0.48 2.93±0.11 2.76±0.39 2.90±0.42 2.78±0.25 
LA 4.80±2.66 4.90±2.99 4.80±1.18 4.26±1.15 3.87±0.96 4.71±1.06 4.20±0.37 
LA area (cm2) 26.9±8.3 26.6±8.1 26.7±6.1 24.8±4.3 21.5±.4.2 33.5±12.0 27.1±14.6 
IVSTd* 1.32±0.38 1.35±0.37 1.13±0.28 1.18±0.43 1.18±0.23 1.46±0.37 1.25±0.25 
PWTd 1.17±0.38 1.19±0.36 1.05±0.35 1.04±0.16 0.96±0.18 1.21±0.30 1.10±0.34 
LVIDd* 5.48±1.43 5.52±1.49 6.19±0.75 4.59±1.28 4.14±0.70 5.72±0.94 4.69±0.97 
LVIDs* 4.51±1.40 4.57±1.43 5.33±0.87 3.42±1.23 3.05±0.48 4.50±1.01 3.75±1.15 
FS* 18.5±9.0 17.9±8.70 14.3±8.20 26.5±9.0 21.8±9.2 25.9±6.0 21.4±10.5 
EF* 43.8±17.0 42.9±16.5 35.4±16.2 58.6±14.6 50.3±16.5 58.6±10.5 49.0±19.8 
LVM 320.7±132.8 338.4±133.6 297.5±95.1 217.1±134.3 152.4±90.5 338.2±93.1 204.6±57.5 
LVMI 86.2±37.0 90.4±37.7 79.9±31.1 67.1±34.5 38.4±11.0 93.4±24.2 59.2±16.6 
RWT 0.44±0.15 0.45±0.15 0.35±0.14 0.49±0.15 0.48±0.13 0.43±0.15 0.49±0.20 
Systolic HF* 66.4 68.1 80.0 44.4 57.1 11.1 69.2 
ME* 0.82±29 0.82±0.29 0.86±0.21 0.72±0.26 1.03±0.43 0.69±0.22 0.73±0.28 
MA 0.52±0.25 0.53±0.25 0.42±0.26 0.57±0.25 0.64±0.23 0.35±0.15 0.61±0.23 
E/A 2.04±1.40 2.04±1.45 2.50±1.10 1.64±1.10 1.58±0.89 2.49±1.49 1.38±0.81 
DT 145.0±59.7 144.3±57.6 114.6±41.4 183.9±64.6 184.9±91.0 154.0±36.2 146.3±76.8 
IVRT 114.4±34.7 116.4±34.8 109.9±38.4 107.2±29.1 89.0±8.7 92.0±7.0 113.1±26.9 
AO= aortic root diameter, IVSTd= Interventricular septal wall thickness in diastole, PWTd=  Left 
ventricular posterior wall thickness in diastole, LVIDd= left ventricular internal diameter in diastole,  
LVIDs= left ventricular internal diameter in systole, FS= fractional shortening, EF= ejection fraction, 
LVM= left ventricular mass, LVMI= left ventricular mass index, RWT= relative wall thickness, E =LV 
early filling velocity, A=Left ventricular late filling velocity,  IVRT= isovolumic relaxation time, DT= 
deceleration time of E velocity, CH= concentric hypertrophy, EH= Eccentric hypertrophy, MR= mitral 
regurgitation, TR= tricuspid regurgitation, AR= aortic regurgitation. *p<0.05 considered to be 
statistically significant. 
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5.3.5 Intra-hospital medications  
On admission 431(95.4%), 419(92.7%), 383 (84.7%), and 338(74.7%) were placed on diuretics, ACE 
inhibitors, angiotensin receptor blockers and digitalis respectively. Calcium channel blockers, 
centrally acting anti-hypertensives beta-blockers, anticoagulants (heparin) and hypoglycemic agents 
were prescribed for 78(17.3%), 54(12.0%), 42(9.4%), 292(64.7%) and 30(6.7%) subjects respectively. 
At discharge, four hundred and forty eight individuals (99.1%) were prescribed ACE inhibitors, 398 
(88.1%) of the subjects were prescribed a loop diuretic, 327(72.3%) on digoxin, 121(26.8%) on long 
acting calcium channel blockers, 65 (14.4%) on hydrallazine and isosorbide dinitrate combination, 
and 41(9.1%) on beta blockers. Ancillary medication which the patients had during the course of 
admission were aspirin 197(43.6%), centrally acting antihypertensive 79(17.5%), , hypoglycemic 
agents 49(10.8%), thiazide diuretic 32(7.1%), and amiodarone 10(2.2%) 
5.3.6 Intra-hospital outcome  
Seventeen subjects died during the course of admission. Causes of death were pump failure (7 
cases), sudden death possibly due to arrhythmia (5 cases), pulmonary embolism (3 cases) and stroke 
(2 cases).  All the intra-hospital deaths occurred in those with de novo HF and mostly in women. 
Those that died were younger (mean age 48.2 vs. 56.8 years, p=0.025). The majority (9 cases) were 
either hypertensive (52.9%) or had dilated cardiomyopathy (29.4%) and were more likely to present 
with systolic dysfunction (5 cases) and/or in NYHA Class III or  IV (15 cases). 
The mean overall length of hospital stay was 10.8±6.1 days (range 2-61, median 9 days). 
5.3.7 4.3.7. International Comparisons 
Table 17 shows the comparison of our findings with that of other workers in SSA and other parts of 
the world. The age of presentation ranges from 40 years in a study from Malawi to 57 years in 
Cameroon. 
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5.4 Discussion 
This is the first detailed, comprehensive and prospective study of AHF in Abeokuta and in Southern 
Nigeria. Our data shows that acute presentation of HF (predominantly de novo) constitutes just 
fewer than 10% of all medical admissions in the city. In general cardiological related conditions are  
responsible for just under one in five  emergency medical admissions in Abeokuta only second to 
infections/infestations that account for almost one in two cases. (Ogah et al., 2012a) These data 
suggest that AHF in Abeokuta, Nigeria predominantly afflicts young and middle aged in prime of 
their life and most present as de novo AHF. Clinically late presentation is common, with over 80% 
presenting in NYHA class III or IV. Over two-thirds of our cohorts had systolic HF with hypertensive 
heart disease the most common risk factor for HF overall (almost four in five cases).  Alternatively, 
ischemic heart disease is relatively uncommon. Infections and uncontrolled hypertension are the 
commonest precipitating factors with co-morbidities and secondary valvular dysfunction also 
common. We also noted low utilization of disease modifying drugs such as beta blockers and 
hydrallazine – isosorbide combination. Intra-hospital mortality rate was relatively low at just under 
four percent.  
Contrary to the situation in advanced countries of Europe, North America and Japan where HF is 
essentially a problem of the elderly with a mean age at presentation of 72 years this was a relatively 
young cohort. Our finding of lesser rate of HF in women is consistent with many previous reports. 
Alternatively, there have been reports  (notably South Africa and the East African countries of Kenya 
and Uganda)of more women than men presenting with HF. (Stewart et al., 2008, Oyoo and Ogola, 
1999, Kuule et al., 2009) Other aspects of this cohort (including precipitating factors, a 
predominance of de novo cases and late, severe presentations)  are similar to equivalent African  
reports. The etiological pattern in our cohort is also consistent with findings in other parts of Nigeria 
where hypertensive HF contributes to 52.7-62.6% of cases of HF (Ojji et al., 2009, Laabes et al., 2008, 
Onwuchekwa and Asekomeh, 2009, Karaye and Sani, 2008). 
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In a recent systematic review, we have shown that the pooled prevalence of hypertension increased 
from 8.6 % (CI= 13.7-16.3%) from the only study during the period from 1970-1979 to 22.5% 
(CI=21.8-23.2%) from 2000 to 2011. Awareness, treatment and control of hypertension were 
generally low ( 14.2-30%, 18.6-21% and  9% respectively) with attendant high burden of 
hypertension related complications.(Ogah et al., 2012b) 
Hypertension is also the predominant etiological factor for HF in adjacent Cameroon. (Damasceno et 
al.) Alternatively,  in East Africa (Kenya, Uganda) as well as the horn of Africa (Kuule et al., 2009) 
cardiomyopathy is more common.  
Generally two-thirds of HF patient have systolic dysfunction. This is in keeping with the findings of 
our study and other workers (Table 5.4) Consistent with findings of EHFS II and the Heart of Soweto 
Study, valvular dysfunctions was also common. The use of ACEIs and spironolactone is quite 
comparable with findings in advanced countries. This however was not the case with beta blockers 
and hydrallazine-isosorbide combination. This observation presents an opportunity for improvement 
in care of HF patients in Abeokuta in particular and Nigeria in general. Previously reported intra-
hospital mortality rates from SSA are generally higher than our cohort; ranging from 4.3% to 9.2% 
(Damasceno et al., 2012, Oyoo and Ogola, 1999, Kingue et al., 2005, Tantchou Tchoumi et al., 2011a) 
compared to 3.8% to 6.7% (Adams et al., 2005a, Abraham et al., 2008, Nieminen et al., 2006a, 
Tsuchihashi-Makaya et al., 2009) in high income countries. Length of hospital stay (mean 11 days) 
was  longer than that reported in  in the THESUS-HF study (7 days (Damasceno et al.)) but shorter 
than  a Cameroon cohort (13 days (Tantchou Tchoumi et al.)).These are all longer than that  is 
reported in high income countries (4-7 days (Adams et al., 2005a)). 
The younger age of presentation of HF patients in our cohort and in many parts of Africa may be 
related to the etiology of HF. Rheumatic heart disease and cardiomyopathies are essentially 
problems of the young and middle age. Also hypertension is known to occur early in Africans and 
African Americans with greater adverse consequences. The gender differences reported from 
different regions of SSA may be related to patient selection, sex differences in the burden of CV risk 
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factors and regional variations. In areas with a predominance of rheumatic heart disease and 
cardiomyopathy (especially peripartum cardiomyopathy), HF rates tends to be commoner in women 
than in men. Healthcare seeking behaviors may also play an important role. It is more likely that the 
breadwinner is taken to the hospital in Africa especially where there is no health insurance coverage 
for the entire family. Some of the possible reasons of under-utilization of standard medications for 
HF in our cohort may include poor awareness of these therapies in HF in the city, high cost, as well as 
the late presentation and severity of HF in the subjects. Many physicians are still not comfortable 
commencing beta blockers or the hydrallazine-isosorbide combination in severely ill HF patients and 
this presents an opportunity for improved management and outcomes in Abeokuta and wider 
Nigeria. In the EuroHF Registry, “the best survival was seen in hypertensive HF, as almost all the 
patients were discharged alive” (Adams et al., 2005a)The fact that hypertension forms the bulk of 
patients in our cohort may explain, therefore, the lower Intra-hospital mortality rate..  Our data also 
affords us the opportunity of comparing our findings with similar study in the region of the country 
reported 41years ago. It does appear that hypertension now plays an increasingly predominant role 
in driving heart disease in southern Nigeria. Rheumatic heart disease appears to be less prominent. 
Endomyocardial fibrosis is almost disappearing from the scene while pulmonary heart disease is 
emerging as a prominent risk factor (Figure 5.3).  
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Figure 5.3. Comparison of etiology of HF in present study with similar study in southern Nigeria in 
the 70s 
 
5.4.1 Study Limitations 
This was a cross-sectional study with all the inherent limitations of this methodology. As this was a 
tertiary cohort, those with milder forms of HF were likely to be under-represented. To overcome this 
likelihood, all local health facilities were contacted study commencement requesting referral of all 
HF cases to our clinic (the only centre with cardiologic services (including echocardiography). Cases 
of ischemic heart disease may also be under-represented due to an increased likelihood of sudden 
out-of-hospital death and the lack of coronary angiography (all documented cases were investigated 
with coronary angiography elsewhere).  We also did not collect data on the duration of hypertension 
prior to onset of HF. Finally, we did not assess for nutritional deficiencies and malnutrition as a 
possible factor for earlier development of heart failure in this population; although in a related study 
in the country, Olubodun  reported that HF patients were more likely to be thiamine deficient, 
hypoalbuminemic and anemic.(Olubodun, 1992) 
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5.4.2 Conclusions 
In summary, these data suggest that AHF in Abeokuta, Nigeria predominantly affects younger 
individuals of a working age. Overall, HF is more common in men and associated with severe 
symptoms because of late presentation. Severe LV systolic dysfunction and abnormal LV remodeling 
pattern is also common. Intra-hospital mortality was similar to findings in many parts of the world. 
Hypertension has become the most common (and indeed preventable) antecedent in the region. 
Because hypertension has been projected to rise by 89% in countries of SSA(Kearney et al., 2005) 
especially Nigeria which is the most populous country in the region (compared to a projected 24% 
increase in high income countries) between 2000 and 2025, efforts should be made in the area of 
primordial and primary prevention as well as health promotion in order to combat the emerging 
epidemic. 
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 Table 5.4. Comparison of present study with other HF studies in SSA and other parts of the world 
Study No % 
wom
en 
Mea
n 
Age 
Smoki
ng 
Hypertensi
on 
Diabet
es 
0besi
ty 
Choleste
rol 
Anemi
a 
CK
D 
NYHA(
III&IV) 
Mea
n EF 
HH
F 
DC
M 
VHD
X 
RH
F 
IH
D 
LO
S 
M
* 
Present 
Study, 
Nigeria 
452 45.1 56.6 3.3 64.3 10 10.7 164.1 8.8 48 82.5 42 78.
5 
7.5 2.4 4.4 0.4 11 3.8 
Stewart, 
South 
Africa(Stewa
rt et al., 
2008) 
844 57 55 48 55 10 34 162.4* 10 25 34 45 33.
3 
35.
3 
7.9 14.
3 
7.9 NR
** 
NR 
THESUS_HFS(
Damasceno 
et al., 2012) 
1006 50.7 52 9.8 55.5 11.1 16.3 157.6 15.2 7.7 34.6 39.5 45.
4 
18.
8 
14.3 NR 7.7 7 4.2 
Laabes, 
Nigeria(Laab
es et al., 
2008) 
102 68.6 44.8 5.9 44.1 6.9 25.5 NR NR NR 93.1 NR 44.
1 
21.
6 
22.5 NR 1 NR NR 
Ojji, 
Nigeria(Ojji 
et al., 2009) 
315 49.1 50.6 NR NR NR NR NR NR NR NR NR 62.
6 
13.
8 
7.4 1.8 NR NR NR 
Oyoo, 
Kenya(Oyoo 
91 51.6  NR NR NR NR NR NR NR 37.4 NR 13. 25. 32 NR 2.2 NR NR 
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and Ogola, 
1999) 
2 2 
Kingue, 
Cameroon(Ki
ngue et al., 
2005) 
167 40.7 57 NR NR NR NR NR NR NR NR NR 54.
5 
26.
3 
24.6 NR 2.4 NR NR 
Soliman, 
Malawi(Soli
man and 
Juma, 2008) 
3908 39.9 58.9 NR NR NR NR NR NR NR NR NR 24 19 34 NR 0.0
8 
NR NR 
Habte, 
Ethiopia(Hab
te et al., 
2010) 
781 47.6 43.5 NR NR NR NR NR NR NR NR NR 24.
2 
20.
2 
32.8 3.8 12 NR NR 
Amoah,Ghan
a(Amoah and 
Kallen, 2000) 
572 NR 42 NR NR NR NR NR NR NR NR NR 21.
3 
16.
6 
20.1 NR 10 NR NR 
Onwuchekw
a, 
Nigeria(Onw
uchekwa and 
Asekomeh, 
2009) 
423 42.8 54 NR NR NR NR NR NR NR NR NR 56.
3 
12.
3 
4.3 2.1 0.2 NR NR 
Kuule, 
Uganda(Kuul
157 66.2 45 NR NR NR NR NR 64.3 NR 96.8 NR 25. 27. 28.2 NR 1.9 NR NR 
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e et al., 
2009) 
1 3 
Ogah , 
NigeriA(Ogah 
et al., 2008) 
1441 48.4 54 NR NR NR NR NR NR NR NR NR 56.
7 
3 3.7 1.6 0.6 NR NR 
TantChou, 
Cameroon(T
antchou 
Tchoumi et 
al., 2011a) 
462 42.9 42.5 NR NR NR NR NR NR NR 51 NR 15 32 35 8 NR 13 9.2 
Karaye, 
Nigeria(Kara
ye and Sani, 
2008) 
79 44.3 46.9 NR NR NR NR NR NR NR NR NR 57 24 12.7 2.5 7.6 NR NR 
EuroHeart 
failure(Niemi
nen et al., 
2006a) 
3580 38.7 69.9 NR 62.5 32.8 NR NR 14.7 16.
8 
NR 38 11.
4 
19.
3 
 3.2 53.
6 
9 6.7 
ADHERE, 
USA(Adams 
et al., 2005a) 
105,
388 
52 72.4 NR 73 44 NR NR NR 30 76 34.4      4.3 4 
OPTIMIZE, 
USA(Fonaro
w et al., 
4861
2 
52 73 NR NR NR NR NR NR NR NR 39       3.8 
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2007b) 
ADHERE,IND
ONESIA(Sisw
anto et al., 
2010) 
1687 64.5 60 74 54.8 31.2 NR NR NR NR NR 37.9 54.
8 
NR NR NR 23.
3 
7.1 6.7 
JCARE-CARD,  
JAPAN(Tsuch
ihashi-
Makaya et 
al., 2009) 
2675 40.3 71 37.7 52.9 29.9 NR 24.8 20.8 11.
7 
87.5 42.2 24.
6 
21.
9 
15.7 NR 32 NR NR 
*M= mortality, **NR=Not reported, EF= ejection fraction, NYHA= New York Heart Association, CKD= Chronic Kidney Disease, HHF= Hypertensive Heart 
Failure, DCM= Dilated Cardiomyopathy, VHDX= Valvualr Heart Disease, RHF= Right heart failure, IHD= Ischemic Heart Disease, LOS =Length of Stay in 
Hospital, M= Miscellaneous 
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In chapters five and six we sought for the first time to determine the short and medium term outcome 
of acute heart failure in the city. 
The group of subjects who were presenting with acute HF for the first time (Denovo acute HF) was 
followed up for six months. The mean length of hospital stay was 10.5days. There were 23 deaths while 
20 subjects were lost to follow-up. At one month, 4.2% of the subjects had died. This increased to 7.5% 
at the end of six months. 13.9% of the subjects were readmitted at 6months. 
Hypertensive HF patients had the best survival rates while those with pericardial diseases had the 
highest early mortality. Mortality was associated with female gender, being single, lower blood 
pressure, higher heart and respiratory rates and higher body temperature. Anaemia, higher creatinine 
levels, higher while cell count, left atrial diameter, higher NYHA class and valvular dysfunction were also 
associated with higher mortality.  
We also sought to explore the predictors of rehospitalization in patients admitted with denovo acute HF. 
We observed that about 1.53% and 12.2% of this category of HF subjects were readmitted at 30days and 
6-months respectively. Factors associated with rehospitalization, include presence of atrial fibrillation, 
valvular dysfunction, renal dysfunction, age ≥60yrs female gender and body mass index. After adjusting 
for possible confounders, only female sex and BMI <19kg/m2 were the independent predictors of 
rehospitalization during the 6month follow-up period. 
A detailed study of the commonest aetiological risk factor- Hypertensive heart failure was also carried 
out and reported (Chapter 7). 
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Chapter 6: Short- and medium-term outcomes after acute HF in 
Abeokuta, Nigeria. 
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Abstract  
Background  
Compared to other regions of the world, there is paucity of data on the short-term outcome of acute 
heart failure (AHF) in Africa’s most populous country - Nigeria. We examined six-month outcome 
(including case-fatality) in patients admitted with HF to a tertiary hospital in Abeokuta, Nigeria. 
Methods and Results 
A standardized clinical registry captured data on 309 consecutive subjects hospitalized with AHF. These 
were followed up for at least 180 days (mean follow up period was 205 days). There were 285 subjects 
with de novo AHF and 24 individuals with decompensated or acute-on-chronic HF. The former were 
analysed for short-term outcome. Of the 285 individuals with de novo AHF, there were 150 men (52.6%) 
and 135 women. Mean overall body mass index was 24.0±5.3 kg/m2 (24.1±5.0 and 23.7±5.5kg/m2 for 
men and women, respectively). Mean systolic and diastolic blood pressure were 136.6±30.0 and 
87.2±19.1mmHg in men and women, respectively. Women were less likely than men to have formal 
education (26.0 versus 43.7%), and more likely than men to have never smoked (96.3% vs. 68.7%). 
They were also less likely to present with hypertension (77.0% versus 85.3%), diabetes mellitus (12.6 
versus 16.7%) and report a family history of heart disease (9.1 versus 12.5%). Most subjects presented in 
NHYA class III (75.4%).  
Mean LoS was 10.5 ±5.9 days. Intra-hospital mortality was 4.2% overall and 4.0% and 5.2% for men and 
women respectively. Mean follow up was 205 days. Case fatality at 30-days was 4.2% (95%CI, 2.4-7.3%) 
for the whole cohort comprising 3.9% (95%CI, 1.7-8.5%) in men and 4.5% (95%CI 2.1-9.3%) in women. At 
180-days, case-fatality was 7.3% (95%CI, 4.7-11.2%) comprising 7.1% (95%CI, 3.8-12.7%) in men and 
7.5% (95%CI 3.9-14.0%) for women. Patients with pericardial diseases had the highest early mortality 
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which thereafter stabilized. At 180 days, 20.0% of the subjects were re-hospitalised at least once 
(20.7%for women and 19.3% for men).  
Mortality was related to some socio-demographic and clinical characteristics.  
Conclusions 
The characteristic of HF population in Nigeria is different from similar populations in high income 
countries. Our patients were younger and have non-ischemic etiological risk factors for HF especially 
hypertensive heart disease. Mortality is also similar with many of the same clinical correlates of 
outcomes. 
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6.1 Introduction 
Heart failure (HF) , has emerged as a global epidemic in at risk populations, including those living in high 
income countries and, as recently described, in low-to-middle income regions of the world such as sub-
Saharan Africa.(Damasceno et al., 2012, Al Suwaidi et al., 2012, Santhanakrishnan et al., 2013) Whilst 
there are well-established HF registries to capture both the characteristics and health outcomes among 
those hospitalized with acute heart failure (AHF) in Europe(Oliva et al., 2012, Nieminen et al., 2006a), 
North America(Adams et al., 2005a, Fonarow et al., 2007b) and the Asia-Pacific Region(Sato et al., 2013, 
Tsutsui et al., 2006b, Santhanakrishnan et al., 2013) there are few reports from sub-Saharan Africa. This 
includes Nigeria (the most populous country in the region), where HF has emerged as a potentially large 
public health problem.(Damasceno et al., 2012) Although there have been many therapeutic gains in the 
management of  chronic HF(Scott and Jackson, 2013) leading to improved overall survival rates(Scalvini 
and Giordano, 2013), there has been very little parallel success (pending further evaluation of the 
recently reported RELAX Trial(Teerlink et al., 2013)) in respect to AHF. This is particularly important 
when one considers the high proportion of patients who still require hospitalization for acute HF and 
associated high levels of in-patient case-fatality and poor short-to-medium term health outcomes. 
6.1.1 Study aims 
Given the paucity of data describing health outcomes in unselected patients hospitalized with AHF in 
Nigeria (and indeed wider Sub-Saharan Africa), we examined short (30 day) to medium-term outcomes 
(180 days) in consecutive patients recruited into the Abeokuta HF registry over a period of 6 months. 
Standardized data collected via the registry were used to both describe the baseline characteristics of 
the cohort and identify correlates of mortality during 6 month follow-up. 
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6.2 Materials and methods 
The Abeokuta HF registry is a prospective observational study which consecutively recruited all patients 
admitted for HF from January 1, 2009 to December 31, 2010.  Subjects were enrolled if they were 
admitted for new onset HF (de novo HF) or worsening of chronic HF (decompensated HF). The main 
objective of the registry was to characterize the current profile of HF in the community. It was also 
aimed at determining the mode of care as well as intra-hospital and six months outcomes. Clinical 
information relating to the socio-demography, medical history, signs and symptoms, medications, 
results of laboratory investigations including 12 lead ECG and echocardiography were collected. A 
uniform and standardized case report form was used for data collection. Home addresses and telephone 
contacts of the subjects as well as their next of next of kin were also collected for study follow-up. 
6.2.1 Clinical assessment 
Subjects were weighed without shoes and in light clothing using a standard beam balance. 
Anthropometric plane was used for height measurement to the nearest centre. Body mass index (BMI) 
was calculated using standard formula. Blood pressure (BP) measurements were done according to 
international guideline(1999b) with the use of mercury sphygmomanometer (Accousson, London). We 
defined anaemia as haemoglobin concentration of less than 10g/dl. The modification of diet in renal 
disease (MDRD) formula (Levey et al., 1999) was used for the estimation of glomerular filtration rate 
(eGFR); an eGFR value of < 60ml/min/1.73m2 was the criteria used for defining moderate to severe renal 
dysfunction.(Stewart et al., 2008) 
6.2.2 Diagnosis of HF 
A clinical diagnosis of HF was  made by the attending Cardiologist based on the Framingham 
criteria.(McKee et al., 1971) Using recently updated guidelines of the European Society of Cardiology 
(Dickstein et al., 2008), subjects were categorized into de novo presentation as well as recurrent 
presentation of typically decompensated HF (i.e. acute-on-chronic HF). 
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6.2.3 12 lead ECG and Echocardiography 
Standard 12-lead resting ECG were recorded for each patient using a Schiller ECG machine (Schiller AG, 
Switzerland). All ECGs were performed at rest by trained nurses/technicians and analysed by a reviewer 
who was blinded to the clinical data of the patients. Echocardiography was performed on the subjects 
with the use of an Aloka SSD – 4000 echocardiography (Aloka Co. Ltd, Tokyo, Japan). Standard views and 
2D-guided M-mode measurements were obtained according to international guidelines. Aortic root and 
left atrial diameter, LV internal dimensions and wall thicknesses were obtained according to ASE criteria. 
Measurements were obtained in up to three cycles and averaged. One experienced Cardiologist (OSO) 
performed all the procedures. The intra-observer concordance correlation coefficient and measurement 
errors from our laboratory have been reported previously.(Ogah et al., 2006a) The formula of Devereux 
and Recheck was used for LV mass calculation.(Devereux and Reichek, 1977a) Increased relation wall 
thickness (RWT) was defined as RWT >0.43.(Roman et al., 1995) The different patterns of LV remodelling 
were defined according to international guideline.(Ganau et al., 1992) Impaired LV systolic function was 
defined as left ventricular ejection fraction (LVEF) of <50%. Transmitral flow velocities, deceleration time 
and isovolumic relation time were obtained using standard methods.(Nishimura and Tajik, 1997) Tissue 
Doppler Imaging (TDI) was applied only to identify true pseudo normalized filling pattern.               
6.2.4 Follow-Up 
The study cohort was prospectively followed up for 6 months post index hospitalisation. The subjects 
were contacted through clinic visit or telephone calls at one, three and six months. Information obtained 
during follow-up included their wellbeing, prescribed pharmacotherapy, history of re-hospitalization and 
deaths (from next of kin). In addition to patient or relation’s telephone interviews, where necessary 
referring physicians were contacted for additional information.  
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6.2.5 Health outcomes 
The following health outcomes were documented - 1) length of initial hospital stay (LoS) in days, 2) 
survival status on discharge (dead or alive), 3) short-term case-fatality (30 days), 4) medium-term case-
fatality (180 days), 5) re-hospitalization status (180 days) and 6) event-free survival from readmission or 
death.  
6.2.6 Ethical consideration 
The study was reviewed and approved by the institution’s ethics review board. All the subjects gave 
informed consent and the study was carried out in accordance with the declaration of Helsinki.(Rits, 
1964) 
6.2.7 Statistical Methods 
Continuous variable are presented as mean and standard deviations (SDs) or medians with their 25th and 
75th percentiles when the distribution of the data does not follow Gaussian distribution. Categorical 
variables are displayed as frequencies and proportions. Group comparison was done with the student’s 
t-test and Chi square statistics was used for comparison of categorical variables. Survival function 
estimates was performed using the Kaplan-Meier method and the difference were tested using log-rank 
test. The follow up was censored at 6 months post admission. Subjects who died within the period of six 
months constituted the event of interest for purpose of survival analysis while those still alive or lost to 
follow up were treated as censored. In the survival analysis, censoring meant that the outcome of 
interest has not been observed. All demographic and clinical profiling variables (see Tables 1 and 2) were 
examined, on a univariate basis, as potential correlates of death during 180 day follow-up in those who 
survived the index hospitalisation. Given the small number of fatalities overall, multivariate analyses 
were not performed. Where appropriate, results are expressed as odds ratio (OR) with their 95% 
Confidence Intervals (95% CI). Data was entered into EpiData software (The EpiData Association, att. 
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Jens Lauritsen, Enghavevej 34, DK5230 Odense M, Denmark)  was used for data entry while SPSS version 
15 ( and Stata version 11.1 ) was used for data cleaning and  analysis. 
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6.3 Results 
Three hundred and nine (309) subjects were followed up for 6-months after discharge from the index 
hospital admission.Figure  6.1 is a flow chart showing the recruitment and main outcome of the 
subjects. The cohort comprised 285 (92%) de novo cases of AHF and 24 cases of decompensated HF 
(acute-on chronic HF). The later were excluded in the final analysis. 
Two hundred and forty two patients with de novo AHF were known to be alive after 6-months, 23 were 
known to have died while the remaining twenty were lost to follow-up. Those lost to follow up did not 
come for follow up after the first admission, they or their relations did not have telephone contacts or 
they gave addresses that were difficult to assess. 
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Figure  6.1. Flow chart showing the recruitment of the subjects 
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6.3.1 Clinical and demographic profile of the subjects 
Table  6.1 summarises the clinical and demographic profile of the study cohort. Overall, there were 150 
men (52.6%) and 135 (47.4%) were women. The mean age for the cohort was 56.3±15.6 years 
(57.0±13.6 and 55.4±17.6 years for men and women respectively.) Just fewer than 50% of subjects were 
aged ≥60 years, one third did not have any form of formal education while two thirds were married. A 
small minority were unemployed and three quarters were urban residents. Mean overall BMI was 
24.0±5.3 kg/m2 (24.1± 5.0 and 23.7± 5.5kg/m2 for men and women respectively) and mean systolic and 
diastolic BPs were 136.6±30.0 and 87.2±19.1 mmHg, respectively. 
Women were less likely than men to have formal education (26.0 versus 43.7%), and have a 
current/past history of smoking (68.7 versus 96.3%). They were also less likely to present with 
hypertension (77.0% versus 85.3%), diabetes mellitus (12.6 versus 16.7%) and report a family history of 
heart disease (9.1 versus 12.5%). 
On the other hand, men were more likely to present with hypertension (85.3 versus 77.0%) and chronic 
obstructive pulmonary disease (7.3 versus 6.7%) but less likely to be suffering from chronic 
osteoarthritis (21.3 versus 32.6%). Most subjects were in NHYA class III (75.4%) on presentation; the 
majority being in either NYHA class III or IV (91.5%).  
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Table  6.1. Demographic and clinical profile Characteristics of the cohort 
Variable All(n=285) Men(n=150) Women(n=135) Sociodemographic variables    Age (years) 60.0±13.2 57.0(13.6) 55.6(17.3) Age >60yrs 46.3% 48.7% 43.7% No education 98(34.4) 39(26.0) 59(43.7) % Married                                                                 156(67.8) 92(73.0) 64(61.0) Unemployed  7(2.5) 1(6.7) 6(4.4) Urban residence  216(75.8) 113(75.3) 103(76.5) Risk factors and co-morbidities    Never smoked cigarette 233(81.8) 103(68.7) 103(96.3) Current alcohol use  17(6.0) 14(9.3) 3(2.2) Diabetes mellitus 37(13.0) 19(12.7) 18(13.3) Hypertension 232(81.4) 128(85.3) 134(77) COPD 20(7.0) 11(7.3) 9(6.7) Arthritis 76(26.7) 32(21.3) 44(32.6) Family history of Heart Disease 25(8.8) 9(6.0) 16(11.9) Clinical/Laboratory  parameters    NYHA Class    Class II 24(8.4) 16(10.7) 8(5.9) Class III 215(75.4) 107(71.3) 108(80.0) Class IV 46(16.1) 27(18.0) 19(14.1) Cough  254(89.1) 129(86.0) 125(92.6) Dyspnoea  275(96.5) 145(96.7) 130(96.3) Orthopnoea  234(82.1) 123(82.0) 111(82.2) PND 244(85.6) 129(86.0) 115(85.2) Leg oedema  228(80.0) 121(80.7) 107(79.3) Palpitation  148(52.1) 77(51.7) 71(52.6) Basal crepitation  239(83.9) 129(86.0) 110(81.5) Elevated JVP 229(80.4) 124(82.7) 105(77.8) Third heart sound  207(72.6) 111(74.0) 96(71.1) Tender hepatomegaly  204(71.6) 99(66.0) 105(77.8) Body weight (kg) 66.9±15.4 66.9(13.9) 61.1(14.5) Height (cm) 162.8±8.1 166.7(7.5) 160.3(6.1) BMI(kg/m2) 25.2±5.7 24.1(5.0) 23.7(5.5) Systolic BP(mmHg) 131.9±25.1 137.9(30.0) 133.3(27.9) Diastolic BP(mmHg) 85.4±15.9 89.0(19.6) 85.3(17.1) Pulse pressure(mmHg) 46.5±15.7 49.0(19.0) 47.7(16.6) Temperature (oC) 36.3±0.6 36.4±0.8 36.4±0.8 Respiratory rate (c/min) 30.2±6.5 28.5±6.4 27.9±6.7 Pulse rate (bpm) 95.9±16.7 96.2±18.2 96.3± Packed cell volume (%) 35.9±7.8 37.5±7.2 36.8±7.7 Total white cell count () 6.4±2.9 7.3±3.7 7.4±3.8 % Lymphocytes 37.9±11.1 36.7±12.7 36.1±12.9 
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Serum Sodium (mmol/l) 136.5±6.4 135.9±6.7 136.3±6.1 Serum potassium(mmol/l) 3.7±0.8 3.7±0.8 3.6±0.8 Total Cholesterol(mg/dl) 162.5±53.3 157.7±84.0 181.2±64.6 Serum Glucose(mg/dl) 111.7±53.2 115.6±50.6 114.0±58.5 Serum Urea(mg/dl)* 38.5±30.0 50.5±51.4 36.1±29.7 Serum Creatinine(mg/dl)* 1.8±0.4 1.7±2.5 1.2±1.4  
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Table 6.2 shows the laboratory profile, aetiological risk factors and discharge medications. 
Serum urea and creatinine were significantly higher in men compared to women. Except for peripartum 
cardiomyopathy (PPCM), the aetiological risk factors were similar in men and women. Hypertensive 
heart disease was responsible for the majority (75.8%) of cases of HF. Other causes (all <10% of cases) 
included dilated cardiomyopathy, cor-pulmonale, pericardial disease and rheumatic heart disease; with 
PPCMO, thyroid heart disease, coronary artery disease and endomyocardial fibrosis being responsible 
for a minority of cases.  Discharge medications were similar in men and women except for beta blockers 
which were more commonly prescribed more in men. 
Table  6.3 depicts the 12-lead ECG and echocardiographic parameters according to gender. 
Men had higher mean absolute QT intervals, left atrial area, left ventricular internal dimensions as well 
as absolute and indexed LV mass. 
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 Table 6.2. Aetiology of HF and discharge medications in the 285 subjects 
Variable All Men Women Aetiology of HF (n/%)    Hypertension 216(75.8) 119(79.3) 97(71.9) Dilated Cardiomyopathy 24(8.4) 16(10.7) 8(5.9) Cor pulmonale 16(5.6) 9(6.0) 7(5.2) Pericardial Diseases 9(3.2) 1.(0.7) 8(5.9) Rheumatic Heart Disease 7(2.5) 4(2.7) 3(2.2) Peripartum Cardiomyopathy 6(2.1) 0(0.0) 6(4.4) Thyroid Heart Disease 3(1.1) 0(0.6) 3(2.2) Ischemic Heart Disease 1(0.4) 1(0.7) 0(0.0) Adult Congenital Heart Disease 1(0.4) 0(0.0) 1(0.7) Endomyocardial Fibrosis 2(6.7) 0(0.0) 2(0.7) Type of Heart Failure    Systolic Heart Failure (%) 66.4 71.4 60.9 Heart Failure with normal EF (%) 33.6 28.6 39.1 Medications (n/%)    Loop diuretics 249(87.4) 132(88.0) 117(86.7) Digoxin 219(76.8) 114(76.0) 105(77.8) ACEI/ARBs 281(98.6) 148(98.7) 133(98.5) Beta-blockers 56(19.6) 35(23.3) 21(15.6) Spironolactone 247(86.7) 133(87.3) 116(85.9) Hydrallazine/Isosorbide 33(11.7) 19(12.9) 14(10.4) Amiodarone 5(1.8) 4(2.7) 1(0.7) 
 
 156  
 
 Table  6.3. 12-lead ECG and echocardiographic profile according to gender 
Variable All(n=285) Men(n=150) Women (n=135) Ventricular rate (beats/min) 96.3±22.5 94.3±17.3 101.3±21.8 QRS duration (ms) 116.0±26.2 117.1±24.5 107.8±41.1 QT Interval (ms) 350.7±30.6 374.3±35.0 348.8±45.5 Corrected QT(ms) 442.0±20.9 462.2±38.2 447.6±36.2 Atrial fibrillation (%) 13.3 16.7 9.6 Aortic root diameter(cm) 3.2±0.6 3.26±0.58 2.84±0.38 Left atrial diameter(cm) 5.9±0.8 4.75±0.89 4.50±0.85 Left atrial area (cm2) 30.15± 9.91 28.8±9.0 24.7±6.3 IVERSUSD(cm) 1.18±0.28 1.33±0.39 1.23±0.32 LVPWd(cm) 1.38±0.35 1.19±0.39 1.10±0.35 LVIDd(cm) 5.52±0.97 5.81±1.61 5.16±1.45 LVISs(cm) 4.51±1.57 4.80±1.63 4.16±1.43 Fractional shortening (%) 14.5±2.97 17.77±13.10 19.80±12.21 Ejection fraction (%) 36.8±6.53 40.57±23.61 45.12±20.11 E-wave (m/s) 0.70±0.24 0.82±0.28 0.84±0.32 A-wave (%) 0.41±0.17 0.49±0.23 0.56±0.28 E/A ratio 2.11±1.55 2.14±1.47 1.90±1.25 DT(ms) 145.8±59.2 144.2±58.3 147.9±60.5 IVRT(ms) 111.0±34.3 114.9±35.8 106.1±32.1 LV Mass (absolute) 449.0±217.5 561.7±106.6 233.0±54.24 LV Mass (indexed) 274.1±117.5 336.4±46.6 160.9±16.1 Mitral Regurgitation (%) 19.6 18.7 20.7 Tricuspid regurgitation (%) 15.1 12.7 17.8  
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6.3.2 Intra-hospital and follow up outcomes 
Mean LoS was 10.5 ±5.9 days, with women having slightly longer hospitalisations than men (10.0±6.3 
and 11.0±5.4 days). Intra-hospital mortality was 4.2% overall and 4.0% and 5.2% for men and women 
respectively. Mean follow up was 205 days. Case fatality at 30-days was 4.2% (95%CI, 2.4-7.3%) for the 
whole cohort comprising 3.9% (95%CI, 1.7-8.5%) in men and 4.5% (95%CI 2.1-9.3%) in women. At 180-
days, case-fatality was 7.3% (95%CI, 4.7-11.2%) comprising 7.1% (95%CI, 3.8-12.7%) in men and 7.5% 
(95%CI 3.9-14.0%) for women. Patients with pericardial diseases had the highest early mortality which 
thereafter stabilized. Those diagnosed with hypertensive HF subjects had the best survival profiles 
(Figure  6.2, Figure 6.3). At 180 days, 20.0% of the subjects were re-hospitalised at least once (20.7% for 
women and 19.3% for men).  
Characteristics of subjects that died 
Table 6.4 shows the univariate correlates of survival in the cohort. Increased likelihood of case fatality 
was associated with NYHA classes III and IV, higher total white cell count, renal impairment, higher E/A 
ratio, larger LA diameter or area and presence of tricuspid regurgitation. 
Higher systolic blood pressure was associated with better prognosis. 
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Figure  6.2. Kaplan-Meier survival curve for males and females 
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Figure 6.3. Kaplan-Meier survival curve for the different etiological risk facto
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Table 6.4. Clinical and demographic predictors of outcome on univariate analysis (6 months survival) 
Variable All (n=285) Alive(258) Dead(23) OR 95% CI P-VALUE Age (years) 57.3±15.4 57.4±14.0 57.2±19.1 0.99 0.96-1.01 0.324 Female gender(%) 52.6% 54.5% 50% 1.14 0.48-2.70 0.764 No education(%) 33.3% 32.8% 30.0% 0.77 0.26-2.28 0.635 Not married (single)(%) 67.8% 69.6% 52.9% 1.51 0.56-4.07 0.417 Body mass index 24.0±5.4 23.7±4.9 23.4±3.6 0.97 0.87-1.08 0.580 Non-smoker(%) 81.8 82.3% 85.0% 1.51 0.43-5.34 0.521 Alcohol use(%) 6.0% 5.6% 5.0% 0.79 0.32-1.95 0.609 Presence of Diabetes(%) 13.0% 13.1% 10.0% 0.65 0.14-2.92 0.574 Temperature(oC) 36.4±0.8 36.4±0.9 36.4±0.7 1.31 0.65-2.62 0.449 Respiratory rate(cpm) 28.3±6.2 28.0±6.6 29.2±5.3 1.02 0.96-1.08 0.639 Heart rate (bpm) 95.5±17.1 95.0±17.4 100.5±15.9 1.00 0.97-1.03 0.846 Systolic blood pressure(mmHg) 136.1±29.4 137.3±27.7 122.5±20.0 0.98 0.96-6.99 0.017 Diastolic blood pressure(mmHg) 87.1±29.4 88.6±18.7 80.0±13.4 0.98 0.95-1.00 0.085 Pulse pressure>30mmHg 3.3% 2.1% 5.0% 0.42 0.16-1.10 0.078 NYHA (III & IV)(%) 91.5 90.4 95.0 4.03 1.53-10.65 0.005 Serum Sodium (mmol/l) 136.9±4.6 136.0±6.4 137.2±7.4 1.03 0.96-1.11 0.428 Serum Potassium(mmol/l) 3.7±0.5 3.6±0.7 4.0±1.0 1.64 0.72-3.75 0.243 Blood glucose (mg/dl) 112.3±56.0 117.0±58.5 111.8±58.5 1.00 0.99-1.01 0.501 Packed cell volume (%) 41.0±7.6 37.6±7.0 32.2±8.4 0.92 0.86-0.97 0.004 Total white cell count 6.8±3.1 6.9±3.4 9.2±5.1 1.13 1.02-1.25 0.024 % Lymphocytes 42.9±4.1 36.7±12.3 37.5±16.7 1.02 0.98-1.06 0.432 Serum Creatinine(mg/dl) 0.8±0.3 1.2±1.0 2.1±2.5 1.38 1.04-1.83 0.024 QRS duration  (ms) 107.1±9.4 110.3±29.5 110.9±32.2 1.01 0.99 – 1.03 0.171 Corrected QT (ms) 439.4±40.9 449.3±34.4 457.3±34.6 1.01 0.99-1.04 0.173 Atrial fibrillation(%) 13.3% 14.6% 20.0% 1.14 0.36-3.55 0.827 E/A ratio 2.2±1.0 2.1±1.3 2.7±1.6 1.40 0.99-1.97 0.060 Left atrial area(cm2) 26.2±6.7 26.8±7.5 34.2±12.1 1.11 1.01-1.21 0.025 Left atrial diameter (cm) 4.8±0.9 4.6±0.9 5.0±1.1 1.56 0.94-2.60 0.084 LVID(cm) 5.47±1.55 5.6±1.5 5.7±1.2 1.11 0.74-1.67 0.614 HF with systolic dysfunction 66.4% 67.5% 70.6% 0.66 0.27-1.59 0.356 MR(Yes)(%) 19.6% 20.2% 25.0% 1.34 0.50-3.60 0.562 TR(Yes)(%) 15.1% 13.1% 35.0% 2.64 1.00-6.95 0.050 
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6.4 Discussion 
Our data is the first detailed study of clinical profile and short-term outcome of HF in southern 
Nigeria. The key findings from the study are that HF in our community is a problem of young and 
middle aged individuals who are in the prime of their lives. Majority presented with de novo AHF 
and hypertensive heart disease and other non-ischaemic aetiology contributing over 90% of the 
cases. The use of some disease modifying agents such as beta blockers and nitrate therapy is low 
although ACE inhibitors or ARBs and aldosterone antagonists are used very frequently. The mortality 
rates in the short to medium term are relatively low and higher in women than in men but this was 
not statistically significant. We also noted that socio-demographic and clinical variables are related 
to mortality. 
 
Our finding of the relative young age at presentation of AHF is similar to reports from many parts of 
Africa. AHF patients in the continent are about 20 years younger than similar patients in high income 
countries with a mean age ranging from 40 to 57 years.(Soliman and Juma, 2008, Dzudie et al., 2008) 
The high frequency of de novo cases is higher than the values in registries in Europe and America 
which ranges from 24% in the ADHERE registry(Adams et al., 2005a) to 44% in the Italian HF 
registry.(Tavazzi et al., 2006) A high frequency of de novo HF has been reported from Japan in the 
ATTEND registry (63%)(Sato et al., 2010) and (64.7%) in the Acute Heart Failure Database (AHEAD) 
registry. Randomized controlled trails have shown that ACEIs(1987), ARB(McMurray et al., 2003), 
and beta-blocker(1999a) can improve survival in patients with HF. Furthermore, the African-
American Heart Failure trial has shown the efficacy of hydrallazine-isosorbide combination in the 
treatment of HF in blacks.(Taylor et al., 2004) 
 The high rate of use of diuretics, ACEI/ARBs and aldosterone antagonists is similar to findings in 
many parts of the world. On the other hand the rate of use of beta-blockers falls short of the 
findings from Europe and America.(Fonarow et al., 2007b) (Cowie et al., 1999, Okin et al., 1996, 
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Adams et al., 2005a) One of the important findings is the comparable or even lower short-term 
mortality rate of HF in our cohort compared to findings in the advanced countries.  Mortality rates 
were 4.2% (95%CI, and 7.3(95%CI; I4.7-11.2%) at 30 days and 180 days respectively. In our study 
demographic and clinical variables were also noted to affect short term out-come although many of 
the variables did not reach statistical significance probably because of the short term follow-up and 
few fatalities recorded. Unlike finding in advanced countries (Adams et al., 2008, Okin et al., 1996), 
we noted that age was not associated with poorer outcome in our cohorts. Our finding of better 
prognosis in obese individuals is similar to the findings of other workers (Cowie et al., 1999, Okin et 
al., 1996). In the Framingham study, high BMI was associated with better prognosis (HR for mortality 
per 1SD: 0.88, 95CI =0.75-1.04 for men and 0.86, 95%CI= 0.72-1.03 for women)  This is also 
consistent with the “obesity paradox” in HF.(Arena and Lavie, 2010, Ballo et al., 2013, Komukai et al., 
2012) Underweight in HF patients may be indicative of cardiac cachexia and progression of HF and 
poor prognosis. Lower BP or pulse pressure was associated with poorer outcome. This may reflect 
advanced HF and decreased stroke volume. This has been noted by previous workers (Senni et al., 
2013, Adams et al., 2008). It is now well known that impaired renal function is an independent risk 
factor for all-cause mortality in HF (Damman et al., 2009, Ghali et al., 2009, Hillege et al., 2006). This 
is also same in this study. Patients with renal impairment often develop cardio-renal syndrome 
which is caused by low cardiac output. These patients often develop multiple alterations at the 
vascular level leading to endothelial dysfunction, coagulation abnormalities, insulin resistance, 
hyperhomocystinemia and activation of the sympathetic nervous system as well as the renin-
angiotensin and aldosterone system. They are prone to unstable HF and susceptible to high 
catecholamine levels. Furthermore HF patients with renal dysfunction are also less likely to receive 
proven medications for HF. Lower serum sodium or potassium was associated with better prognosis 
in this study. This is contrary to most reports from the Western world, although in a Polish study, 
Biegus   et al (Fonarow et al., 2007b) had showed that lower serum potassium was associated with 
better outcome. This may be related to better response to diuretics in the survivors leading to the 
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electrolyte derangement. It may also be speculated that sodium may play a lesser role in the 
pathophysiology of HF in our setting. Hypertension may be associated with relatively less neuro-
hormonal activation than ischemic heart disease which is the commonest risk factor for HF in the 
developed counties of Europe and North America. We observed also that left atrial size, left atrial 
volume , left  ventricular size, higher e/a ratio  and presence of mitral and tricuspid regurgitation 
were associated with poorer outcome. This has been well recognized by earlier workers. Left atrial 
or ventricular size reflects left atrial or ventricular pressure and volume overload and the severity 
and duration of increases LV filling in response to cardiac function abnormality associated with 
HF(Benjamin et al., 1995). 
The plausible reasons for the younger age of presentation of HF in our study and many parts of 
Africa may be related to the aetiology of the condition which are conditions that present in young 
and middle age. In additions hypertension and related target organ damage present at younger age 
in Africans and people of African descent. The dominance of de novo presentations in our cohort 
may be related to poorer long-term outcome of HF in our setting such that few people are living with 
chronic HF. Another reason is because of poor or inadequate health education; most often patients 
do not keep to one health facility when they have chronic illnesses such as HF. They often move 
from one facility to another (including alternative healthcare facilities) seeking for cure. Low 
mortality in our cohort may be related to the fact that the study was conducted in a cardiology unit 
and may not reflect what happens in a general medical ward or in private practice in the country. 
The clinical characteristics of our patients may also be explanatory. Our subjects are younger 
compared to the typical patients with HF in the Western world who are generally elderly. The 
average length of hospital stay is longer in our setting ( 9 days) compared to 6.1 days in the 
US(Cowie et al., 1999) and  nine days in Europe(Adams et al., 2005a). However it is shorter than 21 
days reported from Japan (Redfield et al., 2012). It is possible that longer stay in hospital affords 
patients the opportunity to recover well and get used to medications for HF. Mortality from HF is 
generally better in Japanese patients compared to other advanced countries. Furthermore it is also 
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possible that etiology of HF in our cohort could have affected the outcome. Hypertension is 
predominantly the major risk factor for HF in our cohort. Ischemic heart disease is relatively 
uncommon. It is well known that mortality rates from CAD are generally worse than those with non-
ischemic heart disease. Mitchell et al(Mitchell et al., 2008) reported a total mortality rate of 30% at 3 
years in the placebo group of ischemic HF compared to a rate of 15% in the non-ischemic HF group.   
The poorer outcome of women in our study may be because the women were less educated and 
more likely to be unemployed and dependent than the men and may not be able to pay for HF 
medications. Clinic follow up may also be poorer in the women. The main etiological factors for HF in 
our cohort are non-ischemic in origin with hypertensive heart disease responsible for over 75% of 
cases.  It may be reasonable to suggest that applying guidelines derived from clinical trials in the 
Western world where the majority of HF are ischemic in origin may be in-appropriate in our 
population. 
6.4.1 Limitations 
Our study is a single centre hospital based study and conducted in a cardiology unit and, therefore, 
may not have captured all the patients with HF in the city during the study period although many 
referrals were received from surrounding hospitals and clinics during the period due to the 
awareness that was created for the study. The findings of the study may not be extrapolated to the 
general population or the practice in other Nigerian hospitals. A national HF registry is needed as has 
been done in many countries. The use of the Framingham criteria as a screening tool may have 
missed some patients especially the elderly with HF as the criteria is not sensitive in this population. 
Due to cost consideration, our subjects did not have NT-proBNP levels done as this has not become a 
routine practice in the country. NT-proBNP has been shown to be a strong predictor of prognosis in 
HF.(Adlam et al., 2005) Other prognostic variables such as exercise capacity (Vo2 and 6-minute walk) 
were not assessed in our patient. Some of our patients were lost to follow up and may have affected 
the survival information in this study. However the rate of attrition is similar to other follow up 
studies. This is complicated by the fact that there is no effective national death registry in the 
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country. We also could not ascertain the exact cause of death for patients who died outside the 
hospital environment. 
6.4.2 Conclusions 
The characteristic HF population in Nigeria is different from similar populations in high income 
countries. Our patients are about 20-years younger and have non-ischemic etiological risk factors for 
HF especially hypertensive heart disease. Mortality is similar to findings in many countries and has 
some similar clinical and laboratory prognostic factors.  
Because hypertension is a major risk factor for HF in Abeokuta and in many parts of Nigeria, effort 
should be made at all levels on regular BP surveillance, treatment and control. Proactive application 
of agents that have been shown to be particularly effective in African populations or hypertensive 
subjects should be advocated. There is also need for the development of HF management 
programmes which at moment is not existent in the city. 
Finally, there is need for a national HF registry in the Nigeria to better understand the 
characteristics, management and outcome of HF in the different regions of the country. 
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 Abstract  
Objective 
We sought, for the first time, to examine the rate and predictors of hospital readmission in patients 
discharged after an episode of HF in Nigeria. 
Methods  
This was a hospital-based, prospective, observational study that used the data from the Abeokuta HF 
Registry.  
Findings 
Overall, 1.53% (95% CI, 0.58-4.02) and 12.2% (95%CI, 8.88-16.8) of patients, respectively, were re-
hospitalized at least once within 30 days and 6 months (5.3% had multiple readmissions); the latter 
comprising  21/138 men (15.2%) and 11/124 (8.9%) women. A total of 11 (4.2%) also died (all of 
whom had been re-hospitalized). Worsening HF (24 cases, 75%) was the commonest reason for 
readmission. Among others, factors associated with rehospitalization include presence of mitral 
regurgitation (OR, 2.37; 95%CI, 1.26-4.46), age ≥ 60 years (OR, 2.04; 95%CI, 0.96-3.29), presence of 
tricuspid regurgitation (OR, 1.77; 95% CI, 0.86-3.61), and presence of atrial fibrillation (OR, 1.34; 
95%CI, 0.59-3.03). However, on an adjusted basis, only female gender (adjusted OR 0.33, 95% CI 
0.14-0.79; p=0.014 versus men) and body mass index <19kg/m2 (adjusted OR 3.74, 95% CI 1.15-
12.16; p=0.028 versus rest) were independent correlates of readmission during 6-months follow-up. 
Conclusions     
HF rehospitalization within 6-months follow-up occurs in about 12% of our cohort living in an 
environment where HF etiology is predominately non-ischemic and the HF population is relatively 
younger. Higher rates of readmission were noted in those of older age, lower BMI, low literacy, 
lower serum sodium level, presence of atrial fibrillation, renal dysfunction and valvular dysfunction. 
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7.1 Introduction 
Heart failure (HF) affects over 23 million people worldwide.(Bui et al., 2011) In the United States of 
America (USA) alone, about 5.8 million people are affected and up to 2.4 million hospital admissions 
can be attributed to HF as primary or secondary diagnoses.(Roger et al., 2011)  In Europe, over 60% 
of economic cost of HF is related to hospital admissions.(Stewart et al., 2001a) This is because HF is 
associated with high rates of recurrent hospitalizations and frequent clinic visits. HF in Nigeria and in 
most parts of Sub-Saharan Africa commonly afflicts people in the prime of their life, mostly due to 
non-ischemic origin especially hypertensive heart disease and patients often present late with 
severe symptoms.(Ogah et al., 2014a, Stewart et al., 2008, Damasceno et al., 2012, Ojji et al., 2009, 
Laabes et al., 2008, Ojji et al., 2013) 
Data from developed countries show that half of HF patients are rehospitalised within 6-months of 
discharge(Butler and Kalogeropoulos, 2008) and 70% of these are due to  worsening of previously 
diagnosed HF.(Gheorghiade et al., 2005)  In a recent report, Jencks et al(Jencks et al., 2009) showed 
that HF is the number one reason for readmission in the USA. Predictably, HF readmission is 
associated with higher mortality compared to the index admission. Whether similar patterns of 
readmission occur in patients affected by HF in Sub-Saharan Africa and specifically West Africa is 
unknown. 
We have previously re-confirmed via the Abeokuta HF Registry(Ogah et al., 2014a)  that the  risk 
factors and etiology of HF are not entirely same in sub-Saharan, compared to other parts of the 
world.(Stewart et al., 2008) The aim of this study was for the first-time, therefore, to identify 
predictors of rehospitalisation in a Nigerian HF population using the data from the Abeokuta HF 
Registry. 
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7.2 Methods 
7.2.1 Study design and clinical setting 
As described previously (Ogah et al., 2014a), this is a hospital-based, prospective, observational 
study in which all patients with clinical diagnosis of HF were recruited from January 1, 2009 to 
December 31, 2010. Patients were enrolled if they met the Framingham(McKee et al., 1971) as well 
as the European Society of Cardiology(Dickstein et al., 2008) criteria for the diagnoses of HF.  
The study was primarily conducted at the Federal Medical Centre (FMC), Abeokuta. The institution is 
the only tertiary health facility in the city. 
Abeokuta is the capital city of Ogun state in Southwestern, Nigeria (one of the 36 states that make 
up the Federal Republic of Nigeria)  
The entire state has an estimated population of 3.2 million inhabitants based on the 2006 national 
population census, out of which a million are living in Abeokuta alone.(2006b) 
Like in other parts of the country the state operates three-tier or level of healthcare: primary (health 
posts, health centers), secondary (Cottage, General or State hospitals) and tertiary health care 
(Federal medical centers and University of teaching hospitals) Primary health cares is constitutionally 
under the jurisdiction of the Local Government. The remaining two are under the State and Federal 
Governments respectively. 
A significant proportion of health care delivery is carried out by private health institutions and 
mission hospitals. 
The costs of healthcare in the city and in most parts of the country are generally borne by the 
patients through out of pocket expenses. Social health insurance coverage is low in the city and in 
most parts of the country. On the other hand strong family bonding exist in the city where rich and 
well-to-do individuals assist their poor family members 
 Referrals were received from private as well as public primary and secondary health care facilities 
within the city of Abeokuta who were informed of the existence and importance of the registry. 
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Patients aged 18-years and above were enrolled and all gave written informed consent and the 
institution’s ethics review board approved the study. The study was carried out according to 
international laid out guidelines as enshrined in the Declaration of Helsinki.(Rickham, 1964) 
7.2.2 Clinical evaluation  
A standard case report form was used in data collection. Baseline clinical and demographic variables 
such as age, gender, contact addresses, telephone number of patients and their relations, marital 
status, occupation, educational background, history of cardiovascular risk factors such as 
hypertension, family history, cigarette smoking etc. were collected. 
Also collected were the signs and symptoms, clinical diagnoses, co-morbidities, medications, result 
of investigation, date of discharge and intra-hospital outcome. 
Blood pressure was recorded according to standard guideline(1992b) with the use of Mercury 
Sphygmomanometer (Accosson, London). Systolic and diastolic blood pressures were measured at 
Korotkoff sound phases I and V respectively. An average of three readings was taken after 5 minutes 
of rest. Patients were weighed without shoes and in light clothing on a standard beam balance. An 
anthropometric plane was used for height measurement with patients not putting on shoes or 
headgear. 
Body mass index (BMI) was calculated using the formula: BMI = Weight (kg) / [height (m)] 2. A  BMI of 
24-29.9kg/m2 and >=30kg/m2 defined overweight and obesity respectively.  Anemia was defined as 
hematocrit of less than 10g/dl. Glomerular filtration rate was estimated using the four variables- 
Modification of Diet in Renal Disease (MDRD) formula(Levey et al., 1999) Renal dysfunction was 
defined as eGFR  of less than 60ml/min/1.73m2  (same criteria used by Stewart et al(Stewart et al., 
2008) 
12 lead ECG tracing was obtained with Schiller ECG electrocardiograph (Schiller AG, Switzerland) and 
the reports were analyzed by the authors blinded to the clinical history of the patients. M-mode, 2D 
 171  
and Doppler echocardiography were performed using an ALOKA 4000 SSD machine (ALOKA co. Ltd, 
Tokyo, Japan) according to standard criteria.(Henry et al., 1980)  
The criteria employed for diagnoses of the different etiologies have been previously reported.(Ogah 
et al., 2014a)  
7.2.3 Follow up 
The patients were followed up for a period of six months. Information on readmission was assessed 
through: hospital case record, telephone contact of patients or their relatives (Cell phone coverage 
in Nigeria is quite extensive and remarkable), telephone calls to their private doctors (where 
necessary) and occasional home visits by research assistants. 
 Follow up was done at 1- and 6-months after the index admission. Information collected during 
follow up among other things included patients’ wellbeing (subject’s feeling about his or her general 
health which was graded from markedly improved to markedly worse), medications as well as 
information on rehospitalization. At the end of 6 months, 233 out of the 262 patients were known to 
be alive, 18 were lost to follow up and 11 patients were known to have died (all during hospital 
readmission). Thirty two patients were readmitted at least once, 13 patients twice and one was 
readmitted thrice within 6 months. 
7.2.4 Data management and statistical analysis 
Data management was with the use of EpiData data management software (The EpiData 
Association, att. Jens Lauritsen, Enghavevej 34, DK5230 Odense M, Denmark). Data analysis was with 
IBM SPSS version 20 (SPSS, Inc. Chicago Illinois) and STATA version 11 (Stata Corp LP 4905 Lakeway 
Drive College Station, Texas 77845-4512 USA) statistical softwares. 
Continuous data are expressed as mean ± SD, (or median ± IQR where necessary) and 95% 
confidence interval. Categorical variables are expressed as proportions. The patients were grouped 
into two (group 1, those not rehospitalised; and group 2, those rehospitalised). They were compared 
accordingly. Univariate regression analysis was used to identify factors associated with 
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rehospitalization. Forest plot was constructed for the result of the univariate analysis. Multiple 
logistic regression analysis was used to determine the independent predictors of readmission. The 
criteria for inclusion in the multiple logistic regression analysis was a p-value <0.15 in the univariate 
analysis.P<0.05 was adjudged statistically significant. 
7.3 Results 
7.3.1 Sociodemographic characteristics   
Two hundred and sixty two patients, comprising 138 men (53%) and 124 (47%) women, who 
survived admission for de novo HF were followed up for six months. Table  7.1 compares the socio-
demographic and clinical profile of the cohort according to 6-month readmission status. The group 
readmitted were significantly older (mean age 61.7±14.0 vs.56.1±15.4, p=0.026). Except for body 
mass index and serum sodium, which were significantly higher in the readmitted group (p=0.029 and 
0.039 respectively), all the other parameters were similar between the two groups. ( Table  7.1) 
The overall mean length of hospital stay was 10.5 +- 6.1 days (range 2-61 days; median 9 days). 
Eleven (12.2%) of the 90 patients who were on admission for 7 days or less (short stay) compared to 
21 (12.2%) of the 172 patients who had length of hospital admission (>7days) were rehospitalised. 
7.3.2 Readmission rates 
The readmission rates at 30- and 180-days were 1.53% (95% CI, 0.58-4.02) and 12.2% (95%CI, 8.88-
16.8) respectively. Figure 7.1 is a Kaplan-Meier survival curve for re-admission in our cohort. 
7.3.3 Reasons for 6 month readmission 
Twenty four (75%) of the 32 patients were admitted on account of worsening HF. Three were due to 
arrhythmias (atrial fibrillation) while one each was due to pneumonia, lower gastrointestinal 
bleeding, renal failure, angioedema and severe hypertension.  
7.3.4 Clinical correlates of readmission 
Those readmitted were older, more likely to be men and non-smokers, took less alcohol (59.4% vs. 
61.7%), and had lower frequency of diabetes mellitus (DM) (9.4% vs.13.5%). They also tended to 
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have more severe symptoms and signs of HF such as orthopnea (87.5 vs. 81.2%), paroxysmal, 
nocturnal dyspnoea (93.8 vs. 84.2%). virtually all the readmitted cases were in NYHA Class III or IV 
(100 vs. 91.4%). They also had lower body mass index (22.0 vs.24.3kg/sqm) – see Table  7.1. Total 
white cell count, lymphocyte count, serum sodium, total cholesterol, blood sugar were also higher in 
the readmitted group. Alternatively, serum potassium, creatinine, and packed cell volume levels 
were lower in rehospitalised patients. The frequency of atrial fibrillation was also higher in the 
readmitted group (18.8% vs. 11.7%) 
7.3.5 Echocardiography  
Accordingly to echocardiography, the left atrial diameter and left atrial area left ventricular diameter 
in systole were significantly higher in the readmitted group compared to the rest. Alternatively, LVEF 
was lower with 76.7% in those rehospitalised with those recording a LVEF <50% compared to 62.6% 
for the rest. Significantly the rehospitalised group also had higher rates of valvular dysfunction 
(Table 7.2) In terms of prescribed pharmacotherapy the two groups were similar; with the notable 
exception of more digoxin prescribed in those rehospitalised (84.4% vs. 67%, p=0.046).  
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Table  7.1 . Baseline socio-demographic and clinical profile of the subject 
Variable  All (n= 262) Rehospitalised  (n=32) Rest (n=230) p-value Socio-demography     Gender (n/%) Men  
 138(52.7)  
 21(65.6)  
 117(50.9)  
 0.133 
Age (years) 56.1(15.4) 61.7(14.0) 55.3±15.5 0.026 Single marital status (n/%) 45(21.5) 5(17.9) 40(22.1) 0.735 Urban residence (n/%) 201(76.7) 21(65.6) 180(78.3) 0.122 CV risk factors/co-morbidities (n/%)     Never Smoked  214(81.7) 26(81.2) 188(81.7) 0.800 Current alcohol user 161(61.5) 19(59.4) 142(61.7) 0.305 Diabetes mellitus (Yes) 34(13.0) 3(9.4) 31(13.5) 0.779 Hypertension (Yes) 213(81.3) 27(84.4) 181(80.9) 0.810 Atrial fibrillation (%) 33(12.6) 6(18.8) 27(11.7) 0.263 COPD (Yes) 19(7.3) 4(12.5) 15(6.5) 0.265 Arthritis (Yes)  67(25.6) 12(37.5) 55(23.9) 0.128 Family history of heart disease  23(8.8) 4(12.5) 19(8.3) 0.500 Symptoms and signs (n/%)     Cough  232(88.5) 27(84.4) 205(89.1) 0.385 Dyspnoea  253(97.3) 30(93.8) 223(97.8) 0.388 Orthopnoea  214(82.0) 28(87.5) 186(81.2) 0.470 Paroxysmal nocturnal dyspnoea 222(85.4) 30(93.8) 192(84.2) 0.189 Leg oedema  209(80.1) 26(81.2) 183(79.9) 0.859 Basal crepitation 218(83.2) 29(90.6) 189(82.2) 0.315 Elevated Jugular venous pressure 209(79.8) 28(87.5) 181(78.7) 0.348 Third heart sound  189(72.1) 24(75.0) 165(71.7) 0.834 Systolic murmur  123(46.9) 15(46.9) 108(47.0) 0.993 Hepatomegaly  186(71.0) 23(71.9) 163(70.9) 0.907 Ascites  59(22.5) 8(25.0) 51(22.2) 0.821 NYHA III or IV on admission  242(92.4) 32(100) 210(91.4) 0.325 Body mass index (kg/m2) 24.0(5.2) 22.0±4.2 24.3±5.3 0.029 Temperature  36.4(0.8) 36.2±0.5 36.4±0.9 0.186 Respiratory rate  28.7(6.6) 29.7±8.8 28.5±6.3 0.335 Pulse rate  96.3(18.0) 96.1±18.1 96.4±18.0 0.942 Systolic blood pressure (mmHg) 136.2(29.7) 87.8±21.8 134.0±18.3 0.678 Diastolic blood pressure (mmHg)  87.6(18.8) 87.8±21.8 87.5±18.3 0.935 Pulse pressure  48.7(18.3) 50.5±16.0 48.5±18.6 0.568 Packed cell volume (%) 37,1(7.3) 37.6(6.8) 37.1(7.3) 0.719 White cell count  7.5(3.7) 7.6(3.9) 7.6(3.9) 0.194 Lymphocytes (%)  35.6(12.8) 35.1(11.4) 35.6(13.0) 0.833 Serum Sodium (mmol/L)* 136.0(6.5) 133.4(6.2) 136.5(6.5) 0.039 Serum Potassium (mmol/L) 3.65(0.8) 4.0(0.9) 3.6(0.7) 0.102 Total Cholesterol (mg/dl) 166.0(80.4) 139.4(49.7) 169.5(83.4) 0.437 Blood Glucose (mg/dl)   115.9(55.9) 116.8(65.2) 116.0(54.5) 0.990 Blood Urea(mg/dl)+ 43.7(4.1) 56.2(8.4) 42.0(3.1) 0.105 Blood creatinine(mg/dl)+ 1.50(0.11) 1.36(0.15) 1.53(0.16) 0.683 QRS duration (msec) 109.7(29.5) 100.3(21.0) 112.2(31.1) 0.220 
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QT Interval (msec) 358.9(37.6) 355.3(37.1) 359.8(38.1) 0.716 QTc (msec) 453.3(35.8) 449.9(30.4) 454.1(37.3) 0.720 Etiology of Heart failure (n/%)     Hypertensive heart disease 199(76.0) 24(75.0) 175(76.1)    0.866 
Dilated Cardiomyopathy 22(8.4) 2(6.2) 20(8.7) Right heart failure 15(5.7) 3(9.4) 12(5.2) Pericardial diseases 8(3.1) 2(6.2) 6(2.6) Rheumatic heart disease 7(2.7) 0(0.0) 7(3.0) Others 11(4.2) 1(3.1) 10(4.3) 
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  Table 7.2. Echocardiographic profile of the subjects 
Variable  All subjects  (n= 262) Readmitted (n=32) Rest  (n= 230) p-value Left atrial diameter (cm) 4.62(1.0) 4.8(0.7) 4.60(1.0) <0.001 Left atrial area (sq.cm) 26.9(8.4) 27.1(8.0) 26.8(8.5) 0.006 Septal wall thickness in diastole(cm) 1.31(0.69) 1.72(0.67) 1.26(0.37) 0.050 Posterior wall thickness in diastole(cm) 1.20(0.82) 1.21(0.21) 1.20(0.87) 0.803 LV internal diameter in diastole (cm) 5.63(3.01) 5.68(0.88) 5.63(0.61) 0.490 LV internal diameter in systole (cm) 4.45(1.57) 4.74(0.93) 4.41(0.64) 0.004 Fractional shortening (%) 19.2(11.0) 17.3(10.4) 19.6(11.2) 0.099 Ejection fraction (%) 39.7(18.5) 36.8(18.1) 40.1(18.6) 0.020 Mitral ‘E’ wave velocity (m/sec) 0.81(0.29) 0.87(0.32) 0.80(0.30) 0.880 Mitral ‘A’ wave velocity 0.53(0.26) 0.53(0.25) 0.53(0.26) 0.905 E/A ratio 1.94(1.35) 1.96(1.20) 1.93(1.37) 0.088 Systolic dysfunction (%) (n=236) 152(64.4) 23(76.7) 129(62.6) 0.156 Mitral regurgitation (n=219) 165(75.8) 25(92.6) 140(72.9) 0.056 Tricuspid regurgitation (n=219) 152(69.4) 23(85.2) 129(67.2) 0.232  
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Figure 7.1 Kaplan-Meier survival curve for re-admission
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7.3.6 Predictors of rehospitalisation 
According to univariate analysis (Table7.3,Figure7.2) Low BMI (OR, 2.95; 95%CI, 1.16-7.47; p=0.018), 
low literacy (none or less than 6-years of formal education), serum sodium <130mmol/L (OR, 4.11; 
95%CI, 1.58-10.75; p=0.002), and presence of mitral regurgitation (OR, 4.64; 95%CI, 0.1.06-20.29; 
p=0.026)   were significantly associated with higher risk of rehospitalization. Factors associated with 
lower risk of rehospitalisation include: female gender, history of smoking, presence of DM, higher 
random blood sugar, and higher packed cell volume. On an adjusted basis (see figure 7.2), only 
female gender (adjusted OR 0.33, 95% CI 0.14-0.79; p=0.014 versus men) and body mass index 
<19kg/m2 (adjusted OR 3.74, 95% CI 1.15-12.16; p=0.028 versus rest) were independent correlates 
of readmission during 6-months follow-up. 
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 Table7.3.  Univariate correlates of readmission in the 262 denovo HF subjects 
Variable OR 95% CI P-value 
Age >60years 2.04 0.96 – 4.29 0.058 
Female gender 0.54 0.25 – 1.18 0.117 
Body mass index <19 2.95 1.16 – 7.47 0.018 
No education 1.47 0.62 – 3.46 0.376 
Not married 0.73 0.30 – 1.75 0.481 
History of smoking  1.06 0.41 – 2.74 0.907 
Alcohol use 1.10 0.52 – 2.35 0.796 
History of diabetes mellitus 0.66 0.19 – 2.31 0.518 
Serum Sodium (<130mmol/l) 4.11 1.58 – 10.75 0.002 
Random blood glucose (>140mmHg) 0.67 0.22  - 2.02 0.459 
Packed cell volume (<=30%) 0.53 0.15 – 1.85 0.313 
Serum Cr (> 2mg/dl) 1.20 0.43 – 3.39 0.729 
Presence of atrial fibrillation 1.74 0.65 – 4.59 0.263 
Ejection fraction<35% 1.36 0.61 – 3.04 0.459 
Presence of mitral regurgitation 4.64 1.06 – 20.29 0.026 
Presence of tricuspid regurgitation 2.81 0.93 – 8.45 0.057 
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Figure7.2. Shows univariate variables associated with readmission represented with forest plot. 
(Adjusted OR for women= 0.33 (95%CI, 0.14-0.79), Adjusted OR for BMI=3.74(95%CI, 1.15-12.16) 
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7.4 Discussion 
This represents one of the first-ever reports from the city of Abeokuta, Nigeria to prospectively 
determine medium-term outcomes in adults who survive a de novo hospitalization for HF.  Our 
sample represents a unique population of HF patients from the south-western zone of Nigeria.  
As in other parts of Africa (Stewart et al., 2008, Damasceno et al., 2012) and in contrast to reports 
from high income countries (Adams et al., 2005b, Nieminen et al., 2006a) this was a relatively young 
cohort with HF of predominantly non-ischemic causes.  With full follow-up in the majority of case, 
we found a low-rate of 6 month mortality (4.2%), as well as relatively low-rates of rehospitalisation 
(predominantly recurrent HF) at 30 days (1.53%) and 6 months (12.2%). In this Nigerian population 
and HF cohort, there were a number of characteristics that appeared to modulate the risk of 
rehospitalisation. Higher rates of rehospitalisation were observed in those of older age, lower BMI, 
low literacy , lower serum sodium level, presence of atrial fibrillation, renal dysfunction and valvular 
dysfunction were associated with higher likelihood of readmission. Conversely, women, being single, 
history of DM and lower packed cell volume were associated with lower rates of rehospitalisation. 
Given the size of the cohort and relatively low number of rehospitalised patients, it was difficult to 
determine independent predictors of such an event. However, further analyses did show that on an 
adjusted basis, women were two-thirds less likely to be readmitted compared to men, while those 
with a low BMI were almost four times more likely to be readmitted to their heavier, potentially 
more nourished counterparts. 
The readmission rate of 12% in the present study is generally lower than the rates reported from 
North America and Europe.  In a study by Krumholz et al(Krumholz et al., 1997), it was reported that 
about 50% of HF patients were readmitted within 6-months after the initial admission. Ross et 
al(Ross et al., 2010) showed from Medicare data, that all cause readmission ranges from 22.9% to 
23.3% between 2004 and 2006 in the United States. However, consistent with other data from sub-
Saharan Africa (Damasceno et al., 2012, Stewart et al., 2008) this was a relatively young cohort with 
 182  
HF caused by predominantly non-ischaemic causes. In other parts of the world hospital readmission 
risk increases with age. Patients aged ≥65 years are far more likely to experience recurrent 
hospitalization.  A 4-fold increase in 30-day readmission rate was reported for elderly populations 
who were 80-years or older. Blackledge et al(Blackledge et al., 2003a) and Koitabachi et al(Koitabashi 
et al., 2005) observed a 24% increase per 10-year age increment in the annual readmission rate. The 
reported impact of gender on readmission rates in those with HF is inconsistent. While some authors 
reported higher rates in women (Howie-Esquivel and Dracup, 2007), others reported higher rates in 
men similar to our finding.(Alla et al., 2007, Nieminen et al., 2008)  
Arrhythmias especially atrial fibrillation (AF) is common in HF and adversely affects hemodynamics in 
patients. Several studies have shown that this rhythm disorder is associated with higher risk of 
readmission in individuals with HF irrespective of ejection fraction or rhythm control.(Middlekauff et 
al., 1991, Rivero-Ayerza et al., 2008) Recent findings from Africa suggest that AF occurs in 4.6% of 
cardiac cases(estimated 5.6 cases/100,000/year)(Sliwa et al., 2010a) The mean age of occurrence is 
57.2 ±18.8 years in Africa compared to70.1±13.4 years in North America.(Oldgren et al., 2014) 
Common risk factors include hypertension, heart failure and valvular heart disease.(Sliwa et al., 
2010a, Shavadia et al., 2013, Ntep-Gweth et al., 2010, Oldgren et al., 2014) Our finding of higher risk 
of readmission in patients with poor LV function is similar to the findings of many workers.(Babayan 
et al., 2003, Harjai et al., 1999) However some recent reports indicate similar risk in HF with 
preserved ejection fraction.(Agoston et al., 2004, Malki et al., 2002) Our study also confirmed 
previous reports that presence of valvular dysfunction is associated with 4-fold higher risk of HF 
related readmission.(Berry et al., 2005)  
 
Some plausible reasons for lower rate of readmission in our cohort compared with data from 
developed countries may be related to the younger age of our patients as well as the fact that 
majority of the patients had hypertensive heart failure related HF and other forms of non-ischemic 
related HF. Several studies have documented higher readmission rates with ischemic etiology. 
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(Blackledge et al., 2003a)  Our patients also stayed longer on the ward (mean length of hospital stay 
was 9 days compared to 4 days in the USA) before discharge. This could have afforded them the 
opportunity of better stabilization. The fact that the study was carried out in a cardiology 
unit/tertiary institution may account for our finding and may not reflect the situation in the general 
Nigerian population. The higher rate of readmission in lean patients may be related to cardiac 
cachexia and severe HF. It may also support the concept of obesity paradox in HF. Hyponatremia has 
been linked to frequent ventricular ectopics and sudden death. Hyponatremia in HF is due to 
activation of the renin-angiotensin-aldosterone axis, decreased sodium and water delivery to the 
collecting ducts of the nephron, coupled with resistance to the action of natriuretic peptides. 
Hyponatremia in HF is also linked to increased vasopressin levels in HF as a result of increase in 
number of aquaporin water channels in the collecting duct of the kidney(Mielniczuk et al., 2008). We 
also observed that the group rehospitalised had higher frequency of osteoarthritis. This may be 
related to age. It may also be due to concurrent use of non-steroidal anti-inflammatory drugs 
(NSAIDs) which can worsen their HF.  
The impact of current smoking status on HF readmission is inconsistent. Similar to our finding, the 
“smoker’s paradox” has been demonstrated by other workers where a 23% lower risk of 90-day 
rehospitalization risk was reported in current cigarette smokers.(Fonarow et al., 2008)  It has been 
postulated that current smoking has a preconditioning-like effect on HF patients, allowing a better 
outcome during acute decompensation. Furthermore sudden or recent cessation of smoking during 
hospitalization allow for more rapid stabilization and compensation among patients who were 
smoking up until the time of HF hospitalization. The paradox could also be explained by the 
beneficial or lower dimethyl arginine (ADMA- a potential nitric oxide synthase inhibitor) profile 
which has been documented in smokers by some authors.(Onat and Hergenc, 2008, Eid et al., 2004) 
ADMA is increased in HF patients and it is associated with the severity of HF and also predicts 
adverse outcomes.(Duckelmann et al., 2008) 
 184  
Presence of DM or high blood glucose is an established predictor of readmission in HF patient. 
(Montero Perez-Barquero et al., 2007, Krumholz et al., 2000, Greenberg et al., 2007, Dungan et al., 
2010)  This is due to the role of hyperglycemia and insulin resistance in the development of diabetic 
heart disease partly as a result of in-efficient myocardial fuel metabolism.(Aneja et al., 2008) 
Hyperglycemia   could also induce shifts in the fluid and electrolytes that may affect the outcome of 
HF patients.  
In the present study we observed that DM patients were less likely to be readmitted. This could be a 
statistical chance finding. It could also be due to the higher prevalence of HF with preserved EF in 
DM patients. These are generally less likely to be readmitted compared to those with reduced EF. 
The implication of our finding is that simple socio-demographic and laboratory variables especially 
BMI, age , serum sodium ,presence of atrial fibrillation and valvular dysfunction could be used to 
predict patients who are at risk of rehospitalisation in our environment. It may be worthwhile to 
look at the impact of nutritional rehabilitation in our HF patients.  
The process of care, access to health care, low literacy, poverty and cultural practices may also affect 
the timing of presentation of patients to health care facilities as well as adherence to clinic 
attendance and drug therapy. 
Because of ignorance coupled with poverty or lack of access to healthcare, patients in developing 
countries such as in Africa often present late to the hospital and when they do, catastrophic 
spending for care of chronic conditions such as HF is often a major challenge. This consequently 
affects adherence. 
Cultural practices as well as superstitious beliefs also affect health seeking behavior in Africa. 
Patients often visit hospitals as a last option (after trying other alternatives including native or 
traditional medicine). For chronic conditions such as HF, they often move from one center to the 
other seeking for permanent cure. This also affects compliance. 
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It will be worthwhile to explore the impact of these factors in future outcome studies on HF or other 
chronic non-communicable diseases in our environment. 
7.4.1 Limitations  
As noted in a previous report (Stewart and Sliwa, 2009), research is often problematic and 
challenging in a resource-poor environment and there are a number of limitations that require 
comment. The first of these is the sample size and fewer events which did not allow for the 
development of models of risk prediction for the population. A larger and multicentre study is 
therefore advocated to provide this information.  
Heart rate variability and newer echocardiographic parameters such as tissue Doppler imaging were 
also not assessed. We also did not assess the impact of quality of life and psychosocial factors. 
Finally, because our sample is limited to Abeokuta (south-western part of the country), our findings 
cannot be generalized to other parts of Nigeria. 
7.4.2 Conclusions  
HF rehospitalization within 6-months follow-up occurs in about 12% of patients in our cohort living 
in an environment where HF etiology is predominately non-ischemic. Higher rates of readmission 
were noted in those of older age; lower BMI, low literacy, lower serum sodium level, presence of 
atrial fibrillation, renal dysfunction and valvular dysfunction. 
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Abstract 
 Data from the Abeokuta Heart Failure Registry were used to determine the clinical characteristics, 
mode of treatment as well as intra-hospital outcome of hypertensive heart failure (HT-HF).  
Three hundred and twenty subjects were consecutively studied; comprising 184 (57.5%) men and 
136 (42.5%) women aged 58.4±12.4 and 60.6±14.5 years, respectively. Most (80%) presented in 
NYHA Class III or IV and around one third (35%) had preserved systolic function. Median hospital stay 
was 9 (IQR 5 to 21) days whilst intra-hospital mortality was 3.4% .  The 30-day, 90-day and 180-day 
mortality rates were 0.9% (95%CI-0.2-3.5), 3.5% (95%CI-1.7-7.3) and 11.7% (95%CI-7.8-17.5) 
respectively. In a multiple logistic regression analysis, only serum creatinine was the independent 
predictor of mortality at 180-days (adjusted OR=1.76, 95%CI-1.17-2.64) 
Hypertension is the commonest etiological risk factor for heart failure in Nigeria. Most present in 
their prime of life with severe heart failure and secondary valvular dysfunction and significant in-
hospital mortality. 
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8.1 Introduction 
High blood pressure is the leading risk factor for cardiovascular diseases (CVDs) and CV related 
morbidity and mortality globally. It is responsible for about 7.5 million deaths every year worldwide. 
(Danaei et al., Kearney et al., 2005, Mancia et al., 2013) Over 80% of these deaths occur in young and 
middle aged men and women in developing/ low income countries.(Kearney et al., 2005, Modesti et 
al., 2014)  It has been projected that hypertension will increase by 89% in countries in sub-Saharan 
Africa compared to a rate of 24% in advanced countries(Kearney et al., 2005)  
In a recent report on the national, regional and global trends in systolic BP (SBP) since 1980, Danaei 
et al(Danaei et al.) showed that while SBP fell in many developed countries, it actually rose in many 
developing countries including countries in East and West Africa. 
In Nigeria for example, the pooled prevalence of high blood pressure in the country increased from 
8.6% during the period from 1970-1979 to 22.5% (2000-2011). Awareness, treatment and control of 
hypertension are generally low with attendant high burden of hypertension related complications. 
Hypertension is the commonest risk factor for heart and kidney disease in Nigeria.(Ogah et al., Ogah, 
2006, Ojji et al., 2009, Ojji et al., 2013, Damasceno et al., 2012, Ogah et al., 2014a) 
Recently hypertension and other non-communicable diseases (NCDs) have been included as a point 
of emphasis for global initiative. It has been added to the agenda of the World Health Organisation 
(WHO) and the United States’ Center for Diseases Control  and Prevention (CDC) especially the new 
global standardized treatment initiative for hypertension.(2014b) 
The aim of this study is to describe the socio-demographic characteristics, clinical features and 
echocardiographic characteristics and clinical outcome of individuals with hypertensive HF in 
Abeokuta, South western, Nigeria. 
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8.2 Material and methods 
This was a hospital-based, prospective and observational study which was conducted at the 
Cardiology Unit, Department of Medicine, Federal Medical Centre Abeokuta, Nigeria as part of the 
Abeokuta Heart Failure Registry. The baseline characteristics and clinical profile has been 
published.(Ogah et al., 2014a) The center is a tertiary institution located in the Capital of Ogun State 
in the South Western Region of Nigeria, which is one of the 36 States that make up the Federal 
Republic of Nigeria. 
The center receives referrals from primary and secondary health facilities within and outside the 
state. The city has a population of about a million people .(2006a) 
During a 2-year period (January 2009- December 2010), a total of 452 patients who were admitted 
for HF (constituting 9% of total medical admissions for the period) at the centre were recruited into 
the registry.(Ogah et al., 2014a)  Three hundred and fifty five cases (78.5%) were due to 
hypertensive heart disease. 320 (90.1%) of these were included in the current sub-analysis.  Thirty 
five subjects were excluded because of insufficient BP data. 
A standardised diagnosis of HF  was made using the Framingham criteria(McKee et al., 1971) as well 
as the according to the guidelines of European Society of Cardiology on the diagnosis and treatment 
of AHF.(Dickstein et al., 2008)  As such, both denovo presentations of AHF as well as recurrent 
presentations of typically decompensated HF (i.e. acute- on -chronic HF) were recruited.  
All the subjects gave consent before they were enrolled into the study. Ethical clearance was 
obtained from the institution’s ethics review board and the study conformed to international ethics 
standards(Rickham, 1964)  
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8.2.1 Clinical Evaluation  
A standard case report form was used in data collection. Baseline clinical and demographic variables 
such as age, gender, contact addresses, telephone number of subjects and their relations, marital 
status, occupation, educational background, history of cardiovascular risk factors such as 
hypertension, family history, cigarette smoking etc. were collected. 
Also collected were the signs and symptoms, clinical diagnoses, co-morbidities, medications, result 
of investigation, data on discharge and intra-hospital outcome. 
Blood pressure was recorded according to standard guideline(1992b) with the use of Mercury 
sphygmomanometer (Accousson, London). Systolic and diastolic blood pressures were measured at 
Korotkoff sounds  phases I and V respectively. 
Blood pressure was measured at the right arm in the sitting position and cuff size was based on the 
size of the subjects arm. An average of three readings taken after 5 minutes rest was recorded. 
Diagnosis of hypertensive heart failure was made if the following criteria were met: clinical and 
echocardiographic confirmed diagnosis of HF in a known hypertensive or a persistent blood pressure 
of ≥140/90 in those who were not previously known hypertensive. Denovo hypertensive heart 
failure (HHF) were those presenting for the first time with HF while decompensated HHF were those 
who have had previous history of HF due to hypertensive heart disease.(2003, Nieminen et al., 
2006b)   
Patients with clinically overt renal failure or on dialysis therapy were excluded from the study. 
Others excluded were those with HF due primarily to ischaemic heart disease and right heart failure 
due to COPD. The criteria for the diagnosis or exclusion of other causes of HF in our environment 
have been reported previously.(Ogah et al., 2014a) 
Body mass index was calculated using standard formula. 
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A  BMI of 25-29.9kg/m2 and >=30kg/m2 defined overweight and obesity respectively. Anemia was 
defined as hematocrit of less than 10g/dl. Glomerular filtration rate was estimated using the four 
variables- Modification of Diet in Renal Disease (MDRD) formula. (Levey et al., 1999) Renal 
dysfunction was defined as eGFR of less than 60ml/min/1.73m2.   
12-lead ECG tracing was obtained with Schiller ECG electrocardiograph. (Schiller AG, Switzerland)  
The ECG paper speed was adjusted to 25mm/sec All the ECGs were recorded in the supine position. 
For each recording, the styli control was set at 10mm/mV (except in very high voltages when it was 
set at 5mm/mV). ECG reports were analyzed by one of the authors blinded to the clinical history of 
the subjects. 
Electrocardiographic LVH by voltage was based on Sokolow-Lyon (SV1+RV5 or V6)(Sokolow and 
Lyon, 1949),  and/or Cornell (SV3+RaVL with 0.6mV added in women)(Casale et al., 1987) 
Repolarization abnormalities in the lateral leads (V5-V6, 1, and aVL) indicated typical strain when 
there is a down-sloping convex ST segments depression (≥0.1mV) with an inverted asymmetrical T-
wave opposite to the QRS axis.(Okin et al., 2001, Ogah et al., 2006b)   
Voltages in individual leads were calculated as the mean of three complexes wherever possible. 
M-mode, 2D and Doppler echocardiography were performed using an ALOKA 4000 SSD machine 
(ALOKA co. Ltd, Tokyo, Japan). Two dimensionally guided M-mode measurements were made 
according to standard guidelines.  The left atrial dimensions and area were measured according to 
standard guidelines(Lester et al., 1999) (Thomas et al., 2002) .  
Measurements of the left ventricular (LV)  dimensions were made from M-mode readings, according 
to the recommendations of the American Society of Echocardiography.(Sahn et al., 1978b)   
Measurements were averaged over 3 cardiac cycles.  Where optimal M-mode imaging could not be 
obtained, 2D linear measurements were obtained according to ASE guidelines. LV fractional 
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shortening fraction was calculated accordingly. Where there is regional wall motion abnormality, the 
Simpsons method of disc was used for LV function assessment. 
Left ventricular mass (LVM) was calculated by the equation(Reichek, 1994):  
LV mass = 0.8[1.05 (IVSTd+LVIDd+PWTd) 3 - (LVIDd) 3] +0.6g.  This formula  has good interobserver 
reproducibility (ρ=0.93) in one study(Palmieri et al., 1999).  
Left ventricular mass index (LVMI) was calculated by dividing the value of LV mass by height to its 
allometric growth rate of 2.7 (LVMHt2.7)(de Simone et al., 1992, de Simone et al., 1995) The 
partition value of 51g/ht2.7 was used since this was the only criterion that demonstrated as the 
optimal threshold value for left ventricular hypertrophy in blacks irrespective of gender in two 
previous studies(Nunez et al., 2005, Adebiyi et al., 2006) 
Relative wall thickness (RWT) was derived from 2 X posterior wall thickness/LV internal diameter. 
Increased RWT was considered to be present when RWT exceeded 0.43. This represents the 97.5th 
percentile in normal subjects (Roman et al., 1995). Left ventricular geometric was defined 
accordingly(Ganau et al., 1992). 
 Doppler flow mapping was used in the assessment or absence of presence of valvular regurgitation.  
Left ventricular diastolic function was evaluated by studying the filling dynamics of the left ventricle. 
This was quantified by measuring the transmitral ‘E’ wave velocity (peak early mitral inflow velocity) 
and the ‘A’ wave velocity (peak atrial inflow velocity), the E/A ratio and the deceleration time (DT): 
time interval of peak E wave velocity to its extrapolation to the baseline.  The E/A ratio were not 
evaluated in individuals with atrial fibrillation or marked tachycardia. 
8.2.2 Follow-Up 
The cohort was prospectively followed up for 180 days. The subjects were contacted through clinic 
visit, telephone calls or home visits at 30-days, 90-days and 180-days. Information obtained during 
follow-up included their wellbeing, medications, history of re-hospitalization and deaths (from next 
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of kin).  In addition to patient or relation’s telephone interviews, where necessary referring 
physicians were contacted for additional information.  
8.2.3 Outcomes measures 
 These included:  1) length of hospital stay (LoS), 2) Intrahospital outcome, 3) rehospitalisation at 180 
days, and 4) survival within 180 days.  
8.2.4 Quality Control 
One of the authors (OSO) performed all the echocardiography. In our laboratory, the intra-observer 
concordance correlation coefficient and measurement error have been reported.(Ogah et al., 2006a) 
8.2.5 Data analysis and statistics 
All data collected were entered into Epi-data data management software. Analysis was done with 
SPSS statistical package. Categorical variables are expressed as percentages. Continuous variables 
are presented as mean and SDs or median and inter-quartile ranges where applicable. Comparison 
of continuous variables was with the use of student’s t-test while categorical variables were done 
with chi square statistics. Non-parametric tests were used where necessary. 
Survival function estimates was assessed by the Kaplan-Meier method and the difference were 
tested using log-rank test. The follow up was censored at 180-days post admission. Subjects who 
died within the period of 180-days constitued the event of interest for purpose of survival analysis 
while those still alive or lost to follow up were treated as censored.  
Predictors of survival were determined using univariate Cox-proportional regression analyses. 
Thereafter multiple logistic regression analysis was performed to identify independent predictors of 
survivals (p<0.1 used for selection of variables). Results were expressed as odds ratio (OR) with their 
95% Confidence Intervals (95% CI).  
 A 2- tailed p value of <0.5 was assumed as statistically significant. 
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8.3 Results 
A data of three hundred and twenty subjects were analysed. There were 184 (57.5%) men and 136 
(42.5%) women who were aged 58.4±12.4 and 60.6±14.5 years respectively. The mean age for all the 
subjects was 59.3±13.4 years. Figure 18 shows histogram of the age distribution of all the subjects 
and in men and women. Table 8.1 shows the socio-demographic characteristics of the patients. Over 
90% of them were of the Yoruba tribe (the dominant tribe in the South Western region of Nigeria). 
Majority were married (72.8%); had at least primary education (63.5%); employed (95%) and resided 
in the urban area (73.4%) 
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Figure 8.1. Histogram showing the age distribution of the 320 hypertensive subjects. 
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Men significantly attained higher levels of education than their female counterpart and were more 
in the skilled and professional occupation category. In terms of CVD risk factors, women had higher 
body mass index than the men. On the other hand cigarette smoking and alcohol consumption were 
significantly higher in men. Only about 15% had acute on chronic hypertensive HF.  Two hundred 
and ninety (90.6%) of the subjects were known hypertensives, 70(92.4% of the men and 120(88.2%) 
of the women. There was history of diabetes mellitus (DM) in 12.2% of the subjects 
The commonest co-morbidity was osteoarthritis (67, 20.9%) which was significantly commoner in 
women than men [29(15.8%) vs. 38(27.9%), p=0.006]. Chronic obstructive pulmonary disease 
(COPD), asthma, and stroke were present in 8(2.5%), 7(2.2%), and 1(0.3%), respectively. One patient 
each had stroke, migraine, inguino-scrotal hernia and psychosis. Dyspnoea on exertion was the 
commonest symptoms and was present in 94.4% while basal crepitation /crackles were seen in 
84.4%). Over 80% were in NYHA classes III or IV.  
Figure 19 shows the identified precipitating factors for decompensation. 
The mean heart rate on admission was 96.2 beats /min while the mean systolic and diastolic blood 
pressures were 143.5 and 90.5mmHg respectively. The mean packed cell volume, total white cell 
count, serum sodium, serum potassium and blood glucose were similar between men and women. 
Total cholesterol was higher in women but not statistically significant.  Blood urea and creatinine 
were higher in men (49.9 versus 38.2mg/dl) and 1.8 versus 1.3mg/dl respectively.  2.7% of those 
who had HIV screening tested positive. (Table 8.1) 
QRS duration and QT intervals were higher in men but this was not statistically significant. 12.8% of 
the cohort was in atrial fibrillation. 
Almost all the echocardiographic measures of chamber size and wall thickness were statistically 
higher in men compared to women (Table 8.2) 
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Table 8.1.  Baseline socio-demographic and clinical profile of the 320 hypertensive subjects 
Variable  All (n=320) Men (n=184) Women (n=136) 
Demographic characteristics    
Age (years) 59.3±13.4 58.4±12.4 60.6±14.5 
Married (n/%)**  233(72.8) 149(81.0) 84(61.8) 
No education (n/%)*  85(37.3) 36(27.1) 49(51.6) 
Unemployed (n/%) 16(5.0) 6(3.3) 10(7.4) 
Rural dweller (n/%) 85(26.6) 48(26.1) 37(27.2) 
CV Risk factors & Comorbidities    
Never smoked (n/%)** 260(81.3) 131(71.2) 129(94.9) 
Ever consumed alcohol** 156(48.7) 118(64.2) 38(28.0) 
Current alcohol consumption (n/%) 42(13.1) 34(18.5) 8(5.9) 
Diabetes mellitus (n/%) 39(12.2) 22(12.0) 17(12.5) 
Bronchial asthma (n/%) 7(2.2) 3(1.6) 4(2.9) 
COPD (n/%) 8(2.5) 6(3.3) 2(1.5) 
Arthritis (n/%)*  67(20.9) 29(15.8) 38(27.9) 
Family history of heart disease (n/%) 20(6.3) 13(7.1) 7(5.1) 
Clinical & laboratory features    
NYHA  Class 
II (n/%) 
III (n/%) 
IV (n/%) 
 
57(17.8) 
201(62.8) 
62(19.4) 
 
36(19.6) 
109(59.2) 
39(21.2) 
 
 
21(15.4) 
92(67.6) 
23(16.9) 
Symptoms and signs    
Nocturnal cough(n/%) 292(91.3) 166(90.2) 126(92.6) 
Dyspnea on exertion (n/%) 302(94.4) 172(93.5) 130(95.6) 
Leg edema (n/%) 242(75.6) 140(76.1) 102(75.0) 
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Paroxysmal nocturnal dyspnea(n/%) 262(81.9) 157(82.1) 111(81.6) 
Raised JVP(n/%) 210(65.6) 128(69.6) 82(60.3) 
Basal crepitation(n/%) 270(84.4) 160(87.0) 110(80.9) 
Hepatomegaly (n/%) 210(62.8) 116(63.0) 85(62.5) 
Third heart Sound(n/%) 207(64.7) 115(62.5) 92(67.6) 
Temperature ( oC). 36.4±0.82 36.4±0.77 36.3±0.88 
Respiratory rate (c/min) 28.7±8.9 29.2±10.3 28.0±6.6 
Pulse (beats/min) 96.2±18.9 97.4±19.1 94.7±18.7 
Systolic BP(mmHg) 143.5±32.1 143.8±32.9 143.0±19.4 
Diastolic BP 90.5±20.6 91.1±21.5 89.6±19.4 
Body mass index(kg/m2 24.2±5.3 24.0±5.0 24.5±5.7 
Overweight(n/%) 43(23.3) 41(30.3) 84(26.1) 
Obese(n/%) 19(10.1) 19(13.8) 38(11.6) 
Denovo HF(n/%) 274(85.6) 115(84.2) 119(87.5) 
Length of admission in days 10.4±5.2 10.1±4.8  10.8±5.5 
Laboratory findings    
Packed cell volume(%) 37.4±6.9 37.3±6.7 37.5±3.3 
White cell count 6.9±3.6 7.1±3.8 6.9±3.3 
Serum sodium (mmol) 135.8±6.9 135.3±7.1 136.4±6.7 
Serum potassium (mmol/l) 3.66±0.79 3.71±0.81 3.60±0.78 
Total cholesterol (mg/dl) 166.2±74.1 162.9±76.7 174.7±68.6 
Blood glucose (mg/dl) 113.3±51.2 113.4±47.6 113.3±56.2 
Urine protein(164 tested) 58(35.4%) 26(25%) 32(42.1%) 
Blood Urea (mg/dl)+ 44.5± 42.8++  
32.8(27.5)+++ 
49.9±49.7 
37.0(29.7) 
38.2±32.0  
28.0(22.0) 
Blood Creatinine (mg/dl)+ 1.5±2.0++ 
0.9(0.8)+++ 
1.8±2.4  
1.0(0.8) 
1.3±1.5 
0.8(0.5) 
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Estimated glomerular filtration rate+ 94.6±51.7++ 
(90.2)& 
95.2±52.6 
(89.1) 
93.8±50.7 
(91.2) 
HIV positive(150 tested) 4(2.7%) 3(3.4%) 1(1.5%) 
Abbreviation: *=p<0.05, **p<0.001, NYHA= New York Heart Association, COPD=Chronic Obstructive 
Pulmonary Disease, BP= Blood Pressure, HF= Heart Failure + Data  is skewed. ++ reflect mean (SD), +++ reflect 
Median(IQR), &= median value 
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Figure 8.2. Pie chart showing the precipitating factors identified in the 320 hypertensive subjects 
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Table 8.2. 12-Lead ECG and Echocardiographic abnormalities in the 320 hypertensive subjects 
 
Variable  All (n=320) Men (n=184) Women (n=136) 
Ventricular Rate (beats/min) 96.8±20.4 95.8±17.1 98.4±25.2 
QRS Duration (msec) 109.8±24.7 113.1±23.9 104.4±25.5 
QT Interval (msec) 364.8±44.3 368.5±36.6 358.8±54.6 
Corrected QT(msec 454.8±35.4 457.5±35.5 450.3±35.5 
Atrial Fibrillation /Flutter 41(12.8) 23(12.5) 18(13.2) 
ECG LVH++   309(96.5) 173(94.3) 136(100) 
ECG LVH with Strain 138(43.0) 87(47.2) 49(36.4) 
Aortic root diameter (cm) 3.10±0.50 3.24±0.50 2.90±0.39 
Left atrial diameter (cm)  4.68±0.85 4.77±0.86 4.55±0.81 
Left atrial Area*  26.6±8.1 27.7±8.3 24.8±7.36 
IVSTd (cm)* 1.35±0.37 1.40±0.41 1.28±0.29 
IVSTs (cm)* 1.60±0.85 1.67± 0.55 1.48±034 
LVIDd (cm)* 5.52±1.49 5.84±1.47 5.08±1.40 
LVIDs (cm)* 4.57±1.49 4.86±1.43 4.15±1.31 
PWTd (cm)* 1.19±0.36 1.22±0.30 1.15±0.35 
PWTs (cm)* 1.65±0.37 1.66±0.38 1.65±0.37 
Fractional shortening (%) 17.9±8.7 17.4±8.7 18.7±8.6 
Ejection fraction (%) 42.9±16.5 41.8±16.6 44.5±16.3 
LV Mass (g)*  338.4±133.6 376.4±140.8 283.9±100.4 
Indexed LV Mass (g/ht2.7)* 90.4±37.7 96.7±41.8 81.1±28.0 
Relative wall thickness 0.45±0.15 0.44±0.15 0.47±0.15 
LV geometry (n=263)    
Normal geometry (%) 4.2 4.5 3.7 
Concentric remodeling (%) 7.2 3.9 12.0 
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Concentric hypertrophy (%) 42.6 43.2 41.7 
Eccentric hypertrophy (%) 46.0 48.4 42.6 
Mitral ‘E’ Wave  0.82±0.29 0.80±0.28 0.85±0.32 
Mitral ‘A’ Wave  0.53±0.25 0.50±0.23 0.57±0.28 
E/A ratio  2.05±1.45 2.11±1.52 1.95±1.35 
Deceleration Time (msec) 144.3±57.6 141.5±55.1 148.6±61.4 
IVRT(msec) 116.4±34.8 118.5±36.5 113.0±31.9 
LV filling pattern (n=262)    
Impaired relaxation(%) 26.7 26.4 27.2 
Pseudonormalised filling(%) 45.5 45.3 45.6 
Restrictive filling(%) 27.9 28.3 27.2 
Mitral regurgitation (%)** 79.1 78 80.3 
Tricuspid regurgitation(%)** 60.8 58.2 63.9 
Aortic regurgitation(%)** 47.7 43 46.7 
Systolic HF(n/%) 182(65.5) 114(69.9) 68(59.1) 
Diastolic HF(n/%) 96(34.5) 49(30.1) 47(40.9) 
Abbreviation: *=p<0.05.++ LVH diagnosed by Sokolow-Lyon  and or Cornel Criteria. IVSTd= Interventricular 
septal wall thickness in diastole, PWTd=  Left ventricular posterior wall thickness in diastole, LVIDd= left 
ventricular internal diameter in diastole,  LVIDs= left ventricular internal diameter in systole, FS= fractional 
shortening, EF= ejection fraction, LV= left ventricular, E =LV early filling velocity, A=Left ventricular late filling 
velocity,  IVRT= isovolumic relaxation time, HF= Heart Failure. **Moderate/severe AR, MR and TR were 
present in 3.6, 31.6 and 21.1% respectively 
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 In terms of drug administration 278(86.9%) were on loop diuretics, 25(7.8) on thiazide diuretics, 
319(99.1%) were on ACEI/ARBs while 98(30.6%) were placed on long acting calcium channel blockers 
(CCBs). 81.3%, 73.1%, 15.3% and 2.7% were on spironolactone, digoxin, hydrallazine – isosorbide 
combination and beta blockers respectively.  (Figure 8.3) 
 
Figure 8.3. Bar chart showing the pattern of drug prescription in the 320 hypertensive subjects. 
 204  
 
7.3.1. Outcome 
The median length of hospital stay was 9-days and this was same in both men and women. There 
were eleven intrahospital deaths (5 men and 6 women) giving in-hospital mortality of 3.6% (3.4 and 
3.8% for men and women respectively) 
The rehospitalisation rates at 30-day, 90-day and 180-day were 4.2% (95%CI-2.3-7.6), 5.6% (95%CI-
3.3-9.5), 7.3% (95%CI-4.5-11.7) respectively (Figure 8.4A)  
Similarly, the 30-day, 90-day and 180-day mortality rates were 0.9% (95%CI-0.2-3.5), 3.5% (95%CI-
1.7-7.3) and 11.7% (95%CI-7.8-17.5) respectively (Figure 8.4B) 
Compared to those that survived at 180-days, subjects who died were in worse NYHA class –III & IV 
(86.7% vs. 38.7%, p<0.001). They also had significantly lower systolic blood pressure (130.7± 20.9 vs. 
144.1 ± 32.4mmHg, p=0.030), lower diastolic BP (80.0 ±13.7 vs. 89.3 ± 18.9, p=0.044),and pulse 
pressure (42.7±13.3 vs. 53.5 ± 12.1 mmHg, 0.009), lower packed cell volume (31.7 ±8.8 vs. 37.7 ± 6.6, 
0.011), higher serum creatinine 2.2 ±  2.6 vs. 1.2 ± 1.0, p=0.005) and higher total white cell count (9.4 
±5.2 vs. 7.0 ± 3.5, p=0.019).  
Subjects that died also had significantly larger left atrial size, lower mitral A-wave and higher E/A 
ratio. 
In a multiple logistic regression analysis, only serum creatinine was the independent predictor of 
mortality at 180-days (adjusted OR=1.76, 95%CI-1.17-2.64) 
The only significant difference in the rehospitalisation status of the cohort was the serum potassium 
level. This was significantly higher in the rehospitalised group (4.3 ± 0.9 vs. 3.6 ± 0.7, p=0.011) 
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Figure 8.4. A. Kaplan Meier curve showing the rate of mortality of the cohort in 180-days. B. Kaplan  Meier 
curve showing the rate of rehospitalisation of the cohort in 180-days. 
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8.4 Discussion  
There has been limited study on the characteristics and outcome of HT-HF in Nigeria and this is the 
first comprehensive study of this disorder in the country.  
Our findings from this study indicate that HT-HF is a problem of middle aged Nigerians.  Only 46% 
were above the age of 60-years. Majority of the patients present with severe symptoms and are in 
worse NYHA functional class (82% were in NYHA III or IV). We also noted that severe LV remodeling 
patterns and frequent functional valvular dysfunction were common in a predominantly denovo HF 
(Moderate/severe AR, MR and TR were present in 3.6, 31.6 and 21.1% respectively). Co-morbid 
conditions were common. While the use of disease modifying drugs such as ACEI/ARB and 
spironolactone was high, the rate of use of beta-blockers and hydrallazine – isosorbide was 
abysmally low. Finally intra-hospital mortality of 3.4% (95% CI 1.5-6.6%) was recorded. 
Table 8.3 depicts the comparison of our data with previous studies in other parts of Africa and high 
income countries. While our subjects were slightly older than a Cameroonian study (59.3 vs. 54.9 
years) (Dzudie et al., 2008), they were younger than hypertensive subjects in South Africa (61years) 
(Stewart et al., 2008), Europe (69.8years) (Nieminen et al., 2006b)    or North America (74.8 years) 
(Sato et al., 2010) 
The male preponderance in our cohort is similar to the report from Europe.(Nieminen et al., 2006a, 
Nieminen et al., 2008). Higher frequency in women has been reported elsewhere.(Stewart et al., 
2008, Sato et al., 2010) The rate of co-morbidities (diabetes mellitus, CAD, COPD, stroke, atrial 
fibrillation) is lower in our cohort compared with similar data in Europe and America (Table III). This 
not unconnected with higher rate of CVD risk factors in Europe and America such as cigarette 
smoking, obesity, dyslipidemia etc. The frequency of anemia is similar. The mean blood pressure  
compares well with the report from South Africa(Stewart et al., 2008)  but lower than the mean 
blood pressure in the ATTEND registry.(Sato et al., 2010)  Our subjects had more severe LV systolic 
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dysfunction and larger LA size (surrogate of LV diastolic dysfunction) compared to previous reports 
elsewhere.(Stewart et al., 2008, Nieminen et al., 2006a, Sato et al., 2010) 
The use of disease modifying drug such as ACE inhibitors is comparable to previous reports however 
beta-blocker utilization is very low in our report. 
The intrahospital outcome is better than the report from a Polish report but worse than that of 
EuroHF survey and that ATTEND registry. 
Several factors could explain the severity of the disease in our cohort. Late presentation is one 
reason. Most often the patients are unaware that they have high blood pressure. In a recent review 
it was found that only 14.2-30% of Nigerian are aware that they are hypertensive, 18-21% are on 
treatment and only 9% are controlled.(Ogah et al., 2012b) Other factors may include ignorance, lack 
of health education, weak healthcare system and poor social support.   
Some reasons may account for lower history of stroke in our study compared to data from high 
income countries. It is possible that most of our stroke patients die and do not live long enough to 
develop HF.  Better facilities available for care of stroke patients may have accounted for higher 
number of subjects with previous history of stroke in advanced countries. In a 10-year review of 
stroke, Ogun et al(Ogun et al., 2005)  documented that that the case fatality at 24-hours , 7-days, 30-
days and 6-months were 9%, 28%, 40% and 46%, respectively[154]. In 2007, mortality from stroke in 
the country was put at 126/100, 000 population.(Strong et al., 2007) 
An important feature of our study is the assessment of LV geometry and filling pattern in 
hypertensive HF patients which has been scarcely studied in Africa. Severe forms of LV geometry 
(concentric or eccentric hypertrophy) were frequent which is indicative of severe myocardial 
remodeling in our HF patients. 
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Presence of high frequency of pseudo-normalized and restrictive LV filling pattern indicates severe 
degrees of LV diastolic dysfunction. This may also explain the high frequency of valvular 
abnormalities in our cohort. 
Some of the potential reasons for the high prevalence of severe diastolic dysfunction in our study 
population may include severity of the hypertension and LVH.  Race as well as salt sensitivity may 
also be responsible. 
The commons reasons for the low utilization of beta-blockers in our cohort could include severity of 
disease and oedema at presentation, low blood pressure on admission, poverty (since patients pay 
out of their pocket and sometimes ignorance on the side of the care givers.  The high rate of use of 
digitalis could be related to the high burden of systolic HF as well as ignorance on the part of health 
professionals 
These finding s provide an opportunity for intervention (education and training of health care 
providers) The finding that presence of renal impairment is an independent predictor of outcome in 
our cohort supports the known abysmal outcome of patients with chronic kidney disease (CKD) in 
Nigeria and in most African countries.(Seck et al., 2013, Ulasi and Ijoma, 2010) In most cases renal 
replacement is out of the reach of patients because of high cost or non-availability.  
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Table 8.3. Comparison of our findings with similar studies in other parts of the world 
 
Characteristics  
Present study  
(n=320) 
HOS(Stewart et al., 2008) 
(n=281) 
EHFS II(Nieminen et al., 2006b) 
(n=200) 
AHEAD(Sato et al., 2010) 
(n=149) 
Venskutonyte et al(Venskutonyte et al., 2009)  
(n=65) 
Female (%) 42.5 61 39.6 65.4 33.3 
Mean age (yrs.) 59.3 61 69.8 74.8 65.5 
Denovo HF (%) 85.6 NA 37.3 74.3 66.7 
NYHA III+IV (%) 82.2 29 NA 34.0 NA 
Previous history of hypertension (%) 90.6 100 94.6 94.3 100 
Diabetes mellitus (%)  12.2 14 34.5 43.1 33.3 
Previous MI or CAD (%) 0.3 1.0 53.8 26.4 46.7 
COPD (%) 2.5 NA 18.0 17.8 26.7 
Stroke or TIA in History (%)   0.3 12 16.0 26.4 20 
Atrial Fibrillation (%) 12.8 9 37.7 19.0 46.7 
Mean systolic BP(mmHg) 144 140 NA 198 NA 
Mean diastolic BP(mmHg) 91 80 NA 100 NA 
Heart Rate (beats/min) 96 NA NA 93 NA 
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Body Mass Index (kg/m2) 24.2 NA NA 28.0 33.9 
Hospitalization for HF within last 12 months 
(%) 
82.2 NA NA 45.1 46.6 
Renal Failure (%) 14.4 27 
 
18.7 NA NA 
Anaemia (%) 11.5 10 11.3 NA NA 
Infection (%) 63.4 NA 15.6 NA 13.3 
Non-Compliance with Therapy (%) 74.1 NA 21.9 NA 66.7 
ACE Inhibitors (%) 99.1 NA NA 71.3 NA 
Beta-blockers (%) 2.7 NA NA 77.0 NA 
Calcium antagonists (%) 30.6 NA NA 51.1 NA 
Diuretics (%) 86.9 NA NA 88.5 NA 
Spironolactone (%) 81.3 NA NA 36.2 NA 
Digoxin (%) 73.1 NA NS 13.8 NA 
LVEDD (mm) 55 46 56 NA 50* 
Mean ejection fraction 42.7 53 44 55 50.5 
LA (mm) 47 NA 45 NA 42* 
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Mitral regurgitation (%) 79.1 7 77.6 NA 100 
Tricuspid regurgitation (%) 60.8 6 53.7 NA 93.3 
LOS days, median  9 NA 8 NA 13 
Intra-hospital mortality (%) 3.4 NA 1.5 2.2 6.6 
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8.4.1 Perspectives 
The study has some important clinical and public health implications. In view of the rising burden 
CVD risk factors especially hypertension in Nigeria, our finding may indicate possible increase in the 
burden of heart failure and other hypertensive target organ damage. This is against the background 
of high burden of HIV/AIDs and other communicable disease that has place a lot of strain on the 
weak health system of the country. 
There is therefore need for regular and systematic national and regional data necessary for policy. It 
is important to set up chronic disease clinics at the community level to cater for diseases such as 
hypertension and the twin sister- diabetes mellitus. This will reduce the burden on general 
physicians as well as reduce the waiting time encountered by hypertensive patients in most general 
clinics. Government can also subsidize the cost of drugs as the burden of out-of-pocket purchasing of 
medications often lead to non-compliance. 
Basic equipment for measuring BP should be made available at all levels of care in the country 
especially at the PHC. Capacity building in the form of training and retraining of health workers as 
well as education of the general population on the significance of causes and control of hypertension 
is important. 
At the individual level, the use of nurse led PHC for the diagnosis and follow-up has been shown to 
be effective.(Sindhu et al., 2010) Integration of blood pressure control into other control 
programmes such as HIV/AIDS control programmes have been demonstrated to be useful and 
effective in some countries such as Cambodia and South Africa.(Levitt et al., 2011) The national 
policy on non-communicable disease must be put into use especially at the primary health care 
(PHC) level.  The national guideline on the management of hypertension has to be tailored to the 
needs and peculiarities of the Nigerian environment. The guideline should also be available and 
accessible to healthcare providers at all levels of care.  The process of procurement and distribution 
of anti-hypertensive medications has to be standardized in order to prevent “out of stock” 
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syndrome. There must also be quality control in order to stop the flow of counterfeit medications in 
the country. 
Reduction of salt intake is one of the most cost effective approaches to BP control. In this regard 
Nigeria can learn from South Africa that recently passed a law that will regulate the amount of salt in 
processed foods in the country.(2012b)  
The global risk management approach must remain the key message in Nigeria. This has been shown 
to be economically beneficial in many third world countries.(Gaziano et al., 2008) 
Finally community participation is an important approach in public health control programmes in 
SSA. The use of traditional and religious rulers has produced good results in many primary 
healthcare programmes and this can be applied to BP control.  
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8.4.2 Limitations 
This study has some limitations. Because the study was hospital based, it may not have captured all 
cases of heart failure in the community especially those with mild disease as well as chronic stable 
HF cases. However, effort was made by the group to inform healthcare providers (both in public and 
private health institutions) in the community about the registry. More so our institution was the only 
one that had the services of a cardiologist and that has cardiac evaluation tools in the city. We may 
not have captured some of the heart failure cases that presented to the out-patient department. A 
community based data is better in order to estimate the true burden of the disease in the state. 
We could not assess biomarkers in this study due to cost constraint. 
LV systolic function evaluation did mid include mid-wall function assessment which has been 
repeatedly shown to be prognostically valuable and to respond to treatment in hypertensive heart 
disease.(Verdecchia et al., 2001, Wachtell et al., 2010) Finally some of the newer parameters for 
accessing diastolic function were not used in this study. 
8.4.3 Conclusion 
In conclusion, HT-HF afflicts Nigerians in their productive age group with attendant economic loss 
high disability adjusted life years. The disease is often severe due to late presentation. Efforts should 
be made at the community level to ensure primordial prevention, early detection, treatment and 
control of hypertension in the country. 
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In the previous chapters, we explored the contemporary profile of Nigerian patient presenting with 
acute HF including their antecedents, clinical presentation and indeed health outcomes following 
their initial admission with acute HF. In order to respond to increasing burden of acute and chronic 
forms of HF in the region, it is imperative to understand the economic burden of acute HF. 
In this chapter we describe the economic cost of HF (both direct and indirect cost) in Abeokuta for 
the year 2010. The annual cost per person was calculated. 
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Chapter 9: The economic cost of acute HF in Abeokuta, Nigeria 
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Abstract  
Background: Heart failure (HF) is a deadly, disabling and often costly syndrome world-wide. 
Unfortunately, there is a paucity of data describing its economic impact in sub Saharan Africa; a 
region in which the number of relatively younger cases will inevitably rise.  
Methods: Heath economic data were extracted from a prospective HF registry in a tertiary hospital 
situated in Abeokuta, southwest Nigeria. Outpatient and inpatient costs were computed from a 
representative cohort of 239 HF cases including personnel, diagnostic and treatment resources used 
for their management over a 12-month period. Indirect costs were also calculated. The annual cost 
per person was then calculated. 
 Results: Mean age of the cohort was 58.0 ±15.1 years and 53.1% were men. The total computed 
cost of care of HF in Abeokuta was 76, 288,845 Nigerian Naira (US$508, 595) translating to 319,200 
Naira (US$2,128 US Dollars) per patient per year. The total cost of in-patient care (46% of total 
health care expenditure) was estimated as 34,996,477 Naira (about 301,230 US dollars). This 
comprised of 17,899,977 Naira- 50.9% ($US114, 600) and 17,806,500 naira 49.1%($US118,710) for 
direct and in-direct costs respectively. Out-patient cost was estimated as 41,292,368 Naira ($US 
275,282). The relatively high cost of outpatient care was largely due to cost of transportation for 
monthly follow up visits. Payments were mostly made through out-of-pocket spending. 
Conclusion: The economic burden of HF in Nigeria is particularly high considering, the relatively 
young age of affected cases, a minimum wage of 18,000 Naira ($US120) per month and considerable 
component of out-of-pocket spending for those affected. Health reforms designed to mitigate the 
individual to societal burden imposed by the syndrome are required. 
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9.1 Introduction 
Heart failure (HF) has recently emerged as a global health problem.(Cook et al., 2014) It is a highly 
symptomatic syndrome that affects 2-3% of the population in high income countries especially in 
people above the age of 65 years.(Redfield et al., 2003, Mosterd et al., 1999) Approximately 15 
million (out of 900 million) Europeans and 5.8 million (out of 300 million) Americans are affected by 
HF.(Wijeysundera et al., 2010, McMurray et al., 2012)  The burden of HF has increased due to 
increasing elderly population as well as improved survival of patients with risks of HF such as acute 
myocardial infarction, hypertension and diabetes mellitus.(Nagamine et al., 2006, Hines et al., 2006) 
In response, strategies for the effective management of the disease in the outpatient setting have 
been developed and applied.(McMurray et al., 2012)  This has led to improved survival in some 
countries.(Wijeysundera et al., 2010, MacIntyre et al., 2000, Schaufelberger et al., 2004) In high-
income countries, the economic burden of HF is high because it is associated with frequent hospital 
admissions.(Stewart et al., 2002, Ryden-Bergsten and Andersson, 1999) Moreover, management of 
HF places significant financial burden on patients, their families/ care-givers and, as indicated, 
society as a whole.(Araujo et al., 2005, Stewart et al., 2002, Stewart, 2005)  
Until recently, little was known about the emerging problem of non-communicable forms of HF 
supplementing traditional pathways to the syndrome in sub-Saharan Africa. Contemporary studies 
from South Africa(Stewart et al., 2008, Sliwa et al., 2008) and Nigeria(Ojji et al., 2013, Ojji et al., 
2009, Laabes et al., 2008, Ogah et al., 2014a) have built on historical reports to demonstrate that the 
aetiology, natural history and indeed case profile of HF (i.e. more women and younger individuals 
affected in the prime of their life) is different from high-income countries. As such, HF is now 
responsible for 7-10% of medical admissions in the region.(Ojji et al., 2013, Oyoo and Ogola, 1999, 
Ogah et al., 2014a) Significantly, given its potential enormous cost implications (both related to 
direct health care costs and economic burden on affected individuals and their families) there is 
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virtually no data on the economic burden of HF in sub-Saharan African countries and major 
populaces such as Nigeria.  
9.1.1 Study Aims & Objectives 
The aim of this study, therefore, was to determine the consumption of health care resources for the 
treatment of HF in Abeokuta, Nigeria and to estimate overall healthcare costs associated with its 
management in a large and representative cohort of affected cases. Data were used to estimate the 
annual cost of HF in the region to inform health care policy towards efficient use of resources to 
mitigate the individual to societal impact of the syndrome.  
9.2 Material and Methods 
9.2.1 Ethics Statement 
This study was approved by the Federal Medical Center Abeokuta and University of Witwatersrand 
Health Research Ethics Review Committees and all the participants provided informed consent in 
writing, in accordance with the Declaration of Helsinki. (Rits, 1964)  
9.2.2 Study site 
The study was undertaken at the Federal Medical Centre, Abeokuta, Ogun state, southwest Nigeria. 
The state has a population of about 3,751,140 inhabitants.(2014c) Abeokuta is the state capital and 
has a population of about a million people.(2014a)  As described previously (Ogah et al., 2014a), 
Federal medical center Abeokuta is a tertiary institution that receives referrals from primary and 
secondary health facilities within and outside the state. All the patients that were discharged alive 
were given monthly appointments for clinical review as well as for refill of their medications. 
Patients pay out of pocket and many may not be able to buy medication that will last for longer 
period. Home based nursing care is not in existence in the city and in many parts of the country. 
Patients are often taken care of by their relations. Healthcare cost in the city of Abeokuta and in 
most parts of Nigeria is generally borne by the patient through out of pocket payment payments. 
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Only a small proportion of the Nigerian population has access to social health insurance.(Soyibo et 
al., Lawanson et al., 2012, 2012a) However, there exist very strong family bonding and extended 
family systems where poor patients are assisted by their wealthy or well-to-do family members. The 
limited coverage of social health insurance in Nigeria is a very big challenge to the achievement of 
universal health coverage and health care delivery in the country.  
9.2.3 Study design and sample 
As described previously(Ogah et al., 2014a), the Abeokuta HF registry was a  hospital based, 
prospective, observational registry that ran from January 2009 to December 2010 which was  
established to determine the current clinical profile of HF in the city as well as to assess typical  
clinical outcomes and healthcare costs (the focus of this report) associated with  HF. A more detailed 
description of the registry has been documented.(Ogah et al., 2014a) Briefly, all cases of HF 
presenting to the hospital were captured into the database. Private health facilities, primary health 
centres as well as health workers were sensitized on the existence of the registry with good 
response. To a large extent, the sample was fully representative of the population. During the 
period, HF was responsible for 9% of total medical admission (Ogah et al., 2014a) a figure that is 
consistent with equivalent reports from other parts of Africa.(Oyoo and Ogola, 1999, Laabes et al., 
2008, Stewart et al., 2008)  
9.2.4 Data collection 
A specific data extraction proforma was developed and used to obtain data on resource 
consumption in those cases enrolled in the Abeokuta HF registry. The clinical diagnostic criteria 
employed in the diagnosis of HF have been described elsewhere.(Ogah et al., 2014a) Clinical 
diagnoses were coded using the International Classification of Diseases (ICD-10) coding 
system.(2010) The proforma was used to extract the following direct outpatient and inpatient cost 
categories as shown in the textbox below. 
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9.2.5 Health Care Expenditure 
i. Direct Health Care Costs 
The inpatient costs include the cost of medical and nursing care, cost of investigations and drugs. It 
also includes the cost of surgery and procedures as well transportation to and from the hospital. 
Personnel costs include the opportunity cost of medical care, nursing as well as ancillary support by 
other health workers. The wages of these health workers were derived from the Federal 
Government of Nigeria salary scales. This included their basic salary; call duty allowance, hazard 
allowance and housing allowance. We did not capture cost associated with purchase of medications 
over the counter, cost of alternative medical care which is common in Africa, aids, home 
modifications etc. We assume that these categories are likely to represent a very small percentage 
of the total costs identified from this study. We also did not capture capital costs. 
ii. Indirect Health Care Costs 
For indirect costs, the days of lost work (productivity loss) were calculated and the minimum wage 
used to monetize them. 
 
 
 
 
 
 
 
 
Text box showing summary of the cost components. 
Cost Component 
A. In-patient care 
i. Direct cost  Hospital care (Medical consultation, Nursing care, utility fees, accommodation and feeding and ward consumables including oxygen) 
 Laboratory investigations 
 Medications 
 Surgery and procedures 
 Transportation ii. Indirect cost(the days of lost work (productivity loss) 
B. Out-patient care 
i. Direct cost 
 Clinic visits 
 Laboratory investigations 
 Medications 
Transportation ii. Indirect cost: the days of lost work (productivity loss)  
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In-patient cost 
The standard costing table (unit costs) of the Federal Medical Center, Abeokuta for the year 2010 
was used for computing the cost of consultations, hospital admissions, medical consumables, 
medical investigations, and drug therapy (see Text box above). It was assumed that the cost of 
single hospital admission covers the cost of treatment in the emergency room as well as in the 
medical ward. The cost of medications was taken as a whole. We assumed that the cost of 
medications had remained unchanged throughout the year. 
Out-patient costs 
This was also grouped into direct and indirect costs. All the patients that were discharged alive were 
given monthly appointments for clinical review as well as for refill of their medications (see Text 
box). 
Specific costs 
i. Cost of drugs  
The costs of drugs were based on the hospital’s price list (which includes the tender prices plus a 
10% mark up or dispensing fee). The frequency of use of the various categories of drugs was based 
on the findings from the HF registry. The most frequent dosage was used for cost calculation. We did 
not account for increase or reduction in dose of the drugs during the course of treatment. We 
assumed that substitution of one class or brand of medication occurred without additional costs. 
ii. Cost of Laboratory and diagnostic tests 
The cost of all laboratory and diagnostic tests (haematological, biochemical, microbiological, chest 
radiography, electrocardiography and echocardiography) were based on the price list of the hospital 
in 2010.  The rate of consumption of these items was also garnered from the HF registry. 
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iii. Cost of Surgery and Procedures 
The cost of surgeries and procedures were obtained from the Lagos State University Teaching 
Hospital (LASUTH), as well the Reddington multi-specialist hospital, Lagos where majority of the 
surgeries and procedures were performed.(Falase et al., 2013, Johnson et al., 2014) The surgeries 
and procedures include valve surgeries, coronary angioplasty/stenting, pericardiectomies etc. Total 
cost was multiplied by the frequency of the surgeries and procedures.  
9.3 Estimation of indirect costs 
The human capital approach was used to estimate the indirect cost.  The average annual earning of 
the patients was estimated based on their occupational group. These were used to calculate their 
average daily earnings. The product of the working days lost and average daily earnings provided the 
productivity losses associated with HF in the study and these were assigned monetary values.  
Cost analyses 
All available costs (as detailed above) associated with in-patient care, out-patient care as well as the 
opportunity costs associated with HF management in the city were computed for the year 2010. An 
annual, prevalence based approach was employed in estimating the cost of the resources used for 
the management HF.(Stewart et al., 2002, Ryden-Bergsten and Andersson, 1999, Czech et al., 2013, 
Araujo et al., 2005)  Healthcare costs were then expressed in the local currency-Naira, (and 
converted to US Dollar [$US] at a rate of 150 Nigerian Naira to $US1 in 2010).  
9.4 Results 
Outpatient and inpatient costs were computed from a representative cohort of 239 HF cases over a 
12-month period for the year 2010. Table 9.1 provides a summary of the study cohort used to derive 
all HF-related health care activities. Mean age was 58.0±15.1 years, 46.9% were female and around 
one third were aged ≤ 55 years and in the prime of their potential working life. 
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9.4.1  Cost of components of in-patient care 
i. Cost of hospital care 
The following were computed for the subjects: medical consultation (N300/day), nursing care 
(N200/day), utility fees(N400/day), accommodation and feeding (N900/day) and average cost of 
ward consumables/patient/ admission (N3500/patient)The estimated cost of hospital care for the 
year was   about 5.5 million naira (about $U36,500) 
ii. Cost of laboratory investigations 
The laboratory investigations considered in the costing is as shown in Table 9.2.The estimated cost 
was approximately 3.8 million naira (about $US28,000). 
iii. Cost of medications  
This includes cost of standard drugs for the management of HF, as well as other drugs such as 
antituberculous drugs used for the management of T.B pericarditis. The estimated cost of drugs was 
N6,565,527 (about $US43770) (Table 9.3). 
iv. Cost of Surgery/Procedures 
As stated earlier, we estimated the cost of surgery/ procedures for the few patients who were able 
to afford them. This was estimated to cost N1, 092, 000 (about $US72800) – see Table 9.4. 
v. Cost of transportation 
This was calculated to cost N216, 600 (about $US1, 444) (see Table 9.5) 
vi. Indirect in-patient care  cost 
This was estimated to cost N17, 806,500 Naira ($US118, 710) – (Table 9.6) 
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Table 9.1. Sociodemographic profile of the HF subjects seen in 2010 
Variable Value Gender  Male (n/%) 127(53.1) Female (n/%) 112(46.9) Mean age (years) 58.0(15.1) Median age(years) 60  Age range (years)  <24 8(3.3) 25-34 15(6.3) 35-44 21(8.8) 45-54 40(16.7) 55-64 59(24.7) 65-74 63(26.4) >=75 33(13.8) Marital status  Single 32(13.4) Married 168(70.3) Widow/widower 5(2.1) Separated/ Divorced 34(14.2) Educational level  No formal education 88(36.8) Primary (<=6 years) 60(25.1) Secondary (6-12 years) 44(18.4) Post-Secondary/University/Postgraduate (>12years) 47(19.7) Occupation  Unemployed 20(8.4) Unskilled labour 146(61.1) Skilled labour 18(7.5) Professional 24(10.0) Pensioner/Retiree 31(13.0) Place of residence  Within Abeokuta city 138(57.7) Outside Abeokuta but within Ogun State 53(22.2) Outside Abeokuta and outside Ogun State 48(20.1) Monthly Income of subjects in Naira(Median value)  Unemployed* 18000(120USD) Unskilled labour 90,000(600USD) Skilled labour 240,000(1600USD) Professional 480,000(3200USD) Pensioner/Retiree 330,000(2200USD) Aetiology of HF  Hypertensive HF 195(81.6) Dilated Cardiomyopathy 14(5.9) Pericardial Diseases 8(3.3) Rheumatic Heart Disease 4(1.7) Others 4(1.7) Co-morbidities  Hypertension 185(77.4) 
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Osteoarthritis 49(20.9) Atrial fibrillation 37(15.5) Diabetes Mellitus 24(10.0) Chronic Obstructive pulmonary disease 7(2.9) Others 6(2.4) *Allocated minimum wage in the country 
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Table 9.2. Cost of investigations (In-patient) 
A. In-patient Investigations 
Investigation Cost per test Percent* Number  Cost (Naira) Cost (US Dollars) Urinalysis 200 88 225 45000 300.0 
Full blood count 1350 96 229 309150 2061.0 
Blood sugar 400 96 229 91600 610.7 
Electrolyte and Urea 2500 96 229 572500 3816.7 
Lipid profile 3500 65 155 542500 3616.7 
Electrocardiography 2500 96 229 572500 3816.7 
Echocardiography 5000 92 220 1100000 7333.3 
Chest X-Ray 2000 96 229 458000 3053.3 
Cardiac enzyme 5000 0.8 2 10000 66.7 
INR 3500 10 24 84000 560.0 
HIV screening 500 46 111 55500 370.0 
Liver function tests 3000 50 120 360000 2400.0 
Total Cost    3840750 28005.0 
Note: Cost based on the hospital costing list for 2009 
B. Out-patient investigations 
Investigation Cost per test Percent* Number  Cost (Naira) Cost (US Dollars) Electrocardiography 2500 96 197 492500 3283.3 
Electrolyte and Urea 2500 96 197 492500 3283.3 
Total 5000 96 394 985000 6566.7 
Note: Calculation based on those that survived, it is assumed that same proportion on admission  performed  these investigations during follow up   
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Table 9.3. In-patient cost of medications 
Drug Route Dose Dosing Unit cost (Naira) Cost per  daily dose(Naira) 
Total Cost(Naira) Number of subjects 
Total cost in US Dollars 
Frusemide IV 40mg 3 20 60 13620 227 90.8 
Frusemide Oral 40mg 3 5 15 3405 227 22.7 
Amlodipine Oral 5mg 1 15 15 615 41 4.1 
Lisinopril Oral 10mg 1 15 15 3330 222 22.2 
Spironolactone Oral 25mg 1 10 10 2030 203 13.5 
Digoxin Oral 0.125mg 1 5 5 1015 203 6.8 
Carvedilol Oral 6.25mg 1 25 25 550 22 3.7 
Hydrallazine Oral 25mg 1 5 5 90 18 0.6 
Isosorbide dinitrate Oral 10mg 1 220 220 3960 18 26.4 
Heparin (LMW) SC 40mg 1 1350 1350 209250 155 1395.0 
Warfarin Oral 2.5mg 1 40 40 1120 28 7.5 
Atorvastatin Oral 10mg 1 180 180 7380 41 49.2 
Amiodarone Oral 200mg 2 20 40 200 5 1.3 
Antibiotics (Augmentin) IV 600mg 3 600 1800 399600 222 2664.0 
Antibiotics (Augmentin) Oral 625mg 2 170 340 75480 222 503.2 
Prednisolone Oral 30mg 1 30 30 7170 239 47.8 
Anti-tuberculous therapy Oral Multiple drugs 1 60 60 480 8 3.2 Aspirin Oral 75mg 1 2 2 208 104 1.4 
Total      729503  4863.4 
Grand Total      6565527  43770.2 
Source: Federal Medical Centre, Abeokuta costing list, Median length of hospital stay= 9 days, 1 US 
Dollar = 150 naira (2010) 
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Table 9.4. Cost of procedures (In-patient) 
Procedure Number  Cost per procedure Total cost(Naira) Cost (US Dollar) 
Pericardiocentesis 11 20,000 220000 1466.7 
Pericardiectomy* 2 150,000 300,000 2000.0 
Coronary angioplasty/Stenting* 2 700,000 1,400,000 9333.3 
Valve surgery* 5 1,800,000 9000000 60000.0 
Total   10,920,000 72800.0 
*Source= Lagos State University Teaching Hospital and Reddington Hospital Lagos (Ref),  
1 US Dollar = 150 Nigerian Naira,  
 
 
 
Table 9.5. Cost of transport   (In-patients) 
Residence Number  Mean Cost* Total(Naira) Total Cost (Dollars) 
Within Abeokuta 138 250 34500 230 
Outside Abeokuta but within Ogun 
State* 
53 900 47700 318 
Outside Ogun State* 48 2800 134400 896 
Total   216600 1444 
*Mean Cost= Cost per visit = (to and fro), Source= Transport fair at the city motor park,  
1 US Dollar= 150 Nigerian Naira 
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 Table 9.6. Indirect cost (In-patient/ outpatient) 
A. Indirect in-patient care  cost 
Occupation Monthly Income Daily income  Daily income(Dollars) No of Subjects Total Income lost/day(Naira) Income lost (Naira)** Income lost (Dollar)** Unemployed* 18000 900 6 20 18000 162000 1080 
Unskilled 90000 4500 30 146 657000 5913000 39420 
Skilled 240000 12000 80 18 216000 1944000 12960 
Professional 480000 24000 160 24 576000 5184000 34560 
Pensioners 330000 16500 110 31 511500 4603500 30690 
Total 1158000 57900 386 239 1978500 17806500 118710 
Note: Income loss was based on 5 working days in a week, **Income loss was based on median Los of 9 days  B. Indirect out-patient care  cost 
Occupation Monthly Income Daily income  Daily income(Dollars) No of Subjects Total Income lost/day(Naira) Income lost (Naira)** Income lost (Dollar)** Unemployed* 18000 900 6 14 12600 151200 1008 
Unskilled 90000 4500 30 130 585000 7020000 46800 
Skilled 240000 12000 80 15 180000 2160000 14400 
Professional 480000 24000 160 21 504000 6048000 40320 
Pensioners 330000 16500 110 25 412500 4950000 33000 
Total 1158000 57900 386 205 1694100 20329200 135528 
Note: *Assigned the minimum wage in Nigeria, Income loss was based on 5 working days in a week ,  Because most mortality occurred early, it was assumed that 205 subjects completed follow up, 1dollar =150Nigerian Naira  
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9.4.2 Cost of components of out-patient care 
i. Out-patient clinic visit 
This was based on the cost of medical consultations (N250/visit) and nursing/ ancillary services 
(N200/visit).The calculated total cost was N29, 700 ($US198 US dollar) – see Table 9.7. 
ii. Cost of out-patient investigations 
This was calculated for subjects who survived initial hospital admission. It was assumed that the 
proportion of subjects who had these tests during admission were also able to have them done 
during the follow up period. It was estimated to cost N985, 000 ($US 6567 – see Table 29B. 
iii. Cost of outpatient medications 
This is shown in Table 9.8. It was estimated to cost N9, 154,168 ($US61, 028) 
iv. Cost of outpatient transportation 
This constituted a greater proportion of the out-patient care cost. It was calculated as N9, 717, 000 
($US 64,780) – see  
v. Indirect out-patient care  cost 
This was estimated to cost about   20,329,200 Naira ($US135, 528) – Table 9.6. 
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Table 9.7. Cost of clinic visits (Out-patient) 
Month 
(Year_2010) 
No of 
admissions 
Mortality No followed up No of months 
followed up 
Cost (Naira) Cost 
(Dollars) 
January 34 0 34 11 4950 33 
February 20 0 20 10 4500 30 
March 16 1 15 9 4050 27 
April 25 5 20 8 3600 24 
May 29 1 28 7 3150 21 
June 20 2 18 6 2700 18 
July 21 1 20 5 2250 15 
August 18 0 18 4 1800 12 
September 12 1 11 3 1350 9 
October 21 2 19 2 900 6 
November 9 1 8 1 450 3 
December 14 0 14 0 0 0 
Total 239 14 225 66 29700 198 
Assumption= All the mortalities occurred early in the process of follow up,  
Cost of medical consultation= N250. Cost of nursing and ancillary services =N200 
 
Table 9.8. Cost of medications (Out-patient) 
Drug Route Most frequent 
dose 
Most 
frequent 
Dosing 
Unit cost 
(Naira) 
Cost per  daily 
dose(Naira) 
Number of 
subjects 
Total 
Cost(Naira) 
Total cost 
in US 
Dollars 
Frusemide Oral 40mg 3 5 15 148 2220 14.8 
Amlodipine Oral 5mg 1 15 15 30 450 3.0 
Lisinopril Oral 10mg 1 15 15 203 3045 20.3 
Spironolactone Oral 25mg 1 10 10 203 2030 13.5 
Digoxin Oral 0.125mg 1 5 5 55 275 1.8 
Carvedilol Oral 6.25mg 1 25 25 30 750 5.0 
Hydrallazine Oral 25mg 1 5 5 30 150 1.0 
Isosorbide dinitrate Oral 10mg 1 220 220 30 6600 44.0 
Warfarin Oral 2.5mg 1 40 40 28 1120 7.5 
Atorvastatin Oral 10mg 1 180 180 41 7380 49.2 
Amiodarone Oral 200mg 2 20 40 5 200 1.3 
Centrally acting 
drugs (Alpha 
methyldopa) 
Oral 500mg 2 10 20 36 720 4.8 
Aspirin Oral 75mg 1 2 2 89 178 1.2 
Antidiabetic agent 
(Metformin) 
Oral 500mg 2 10 20 22 440 2.9 
Antituberculous 
therapy 
Oral Multiple drugs 1 40 40 8 320 2.1 
Total       25878 172.5 
Grand Total (for 365-9 days) OR 356 days except for antiTB which were for 6 months   9154168 61417.1 
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Table 9.9. Cost of transport (Out-patient) 
Residence Number of 
subjects 
Mean Cost per 
visit(to and fro) 
Mean cost for 12 
visits in a year 
Total Cost 
in Naira 
Total Cost 
in Dollars 
Within Abeokuta 138 250 3000 615000 4100 
Outside Abeokuta but 
within Ogun State* 
53 900 10800 2214000 14760 
Outside Ogun State* 48 2800 33600 6888000 45920 
Total 239 3950 47400 9717000 64780 
*Source: Transport fare at the main motor park in the city, 1 US Dollar = 150 Naira,  
Assumptions: Almost all the patients came for follow up 
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9.4.3 Summary of in-patent and out-patient care cost 
The total cost of in-patient care was estimated as N34,996,477 ($US301,230). This comprised of 
N17,899,977 (50.9%, $US114,600) and N17,806,500 (49.1%, $US118,710) for direct and in-direct 
costs respectively. Direct costs were responsible for 61% of in-patient care costs. About 40% of the 
direct cost was due to surgery / procedures. Hospitalization, medical investigations, drug therapy, 
and transportation accounted for 20%, 24%, 15%, and 1% respectively, of costs –see Table  9.10 and 
Figure 9.3. 
Table  9.10 summarizes the components and total estimated cost of out-patient care. It was 
estimated as N41,292,368  ($US 275,282 UD dollars).  Direct and in-direct costs were N20,963,168 
($US139,754) and N20,329,200 ($US135,528) respectively, constituting 51% and 49% of total out-
patient care costs.  Transportation, medications, clinic visits and medical investigations contributed 
46%, 44%, 5% and 5% respectively to these costs (Figure 9.3). 
9.4.4 Total cost 
The total estimated cost of care of HF in Abeokuta for the year 2010 was N76, 288,845 ($US508, 
595) translating to N319,200 ($US2,128) per patient per year.  The proportional contribution of   in-
patient and out-patient cost were 46% and 54% respectively. The contribution of various 
components to the total cost is shown in Figure 9.3. 
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Table  9.10. Summary of various aspects of costs of in-patient/out-patient care 
A. Summary of various aspects of costs of in-patient care   
Item Total cost (in Naira) Total Cost in US Dollars 
Hospitalization 5475100 36500.7 
Investigations 3840750 28005 
Medications 6565527 43770.2 
Surgery and procedures 10920000 72800 
Transportation 216600 1444 
Total Direct Cost 17189977 114600 
Total Indirect Cost 17806500 118710 
Grand total 34996477 233310 
B. Summary of various aspects of costs of out-patient care   Item Total cost (in Naira) Total Cost in US Dollars 
Clinic visit 1107000 7380 
Investigations 985000 6567 
Medications 9154168 61028 
Transportation 9717000 64780 
Total Direct cost 20963168 139754 
Indirect cost 20329200 135528 
Grand total 41292368 275282  
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   Figure 9.1. Components of direct cost (In-patient) 
    
   Figure 9.2. Components of direct cost (out-patient) 
    
    
   Figure 9.3. Percentage contribution of different components to total cost. 
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9.5 Discussion 
To our knowledge this is the first systematic attempt at estimating the cost of HF in Nigeria; a major 
populace of sub-Saharan Africa. We have calculated the cost from an individual perspective whilst 
calculating the total cost per annum overall from a societal perspective. Effort was made to capture 
all the HF patients in the city of Abeokuta during the study period. All cases of HF presenting to the 
two major hospitals in the city were captured into the database. Private health facilities, primary 
health centres   as well as health workers were sensitized on the existence of the registry with good 
response. To a large extent, the sample was representative of the population. During the period, HF 
was responsible for 9% of total medical admission similar to earlier report from other parts of 
Africa.(Stewart et al., 2008, Oyoo and Ogola, 1999, Laabes et al., 2008) The main findings of the 
study are - 1. The total cost of HF or cost per patient per year is enormous considering the context of 
a  developing economy where out-of-pocket expenses is the main means of health care financing;2. 
Furthermore the estimated cost of HF was fairly distributed between in-patient and out-patient 
care; 3.  A large proportion of direct cost for in-patient care was due to surgery and medical 
procedures and; 4. Out-patient medications and transportation was responsible for 90% of direct 
cost of out-patient care. The huge cost of HF has been well documented by several reports both at 
the individual and population levels. Data from the National Heart and Lung Institute of the United 
Kingdom shows that the cost of HF per person is approximately 8500 Pounds. At the national level 
HF costs about 39.2 billion US dollars in America (about 2% of US healthcare budget).(Writing Group 
et al., 2010) Similar data have been reported from other countries.(Ryden-Bergsten and Andersson, 
1999, Stewart et al., 2002) (Araujo et al., 2005, Fagnani et al., 2001)  
The distribution of cost of HF in our setting is different from that observed in high income 
countries(Fagnani et al., 2001, Stewart et al., 2002, Ryden-Bergsten and Andersson, 1999) but similar 
to one report from Brazil.(Araujo et al., 2005) There has not been any report from Africa to compare 
our findings with.  The contribution of hospital care cost in these countries ranged from 53-75%.   
Cost of outpatient care was in the range of 4-31% while the cost of drug therapy was between 6-8% 
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of the total cost of care. The pattern of heart diseases as well as level of technological development 
influences the mode of care as well as utilization of sophisticated and expensive medical equipment, 
procedures and consumables which are obviously needed for the care of HF patients. The 
consumption of these is higher in high income countries than in our setting.  This is clearly shown by 
the impact of surgery/procedures on the cost of hospital care. The few cases (out of the many that 
needed this) that had surgery for valvular diseases or coronary interventions escalated the hospital 
care cost in our study.  
Other determinants of hospital cost will also include length of hospital stay.(Stewart et al., 2002, 
Stewart, 2005) (in which our report is similar to European data but longer than the mean length of 
hospital stay in the USA) Cost of management of co-morbidities has also been shown to account for 
higher cost of hospitalization in high income countries. In one report on Medicare claims, HF 
accounted for only15% of the total in-patient cost while 57% were associated with other co-morbid 
conditions.(Whellan et al., 2010) This may probably be responsible for the huge cost of 
hospitalization in high income countries compared to our environment.  
Due to lack of community based or nurse-led or home care of HF patients in our setting, our patients 
are given shorter out-patient appointments in order to refill their medications. This is responsible for 
the high cost attributable to transportation in our report. Because of the younger age of our 
subjects, HF in our setting is, therefore, associated with longer disability adjusted life years and by 
extension a huge cost to the society at large.  
With the changing demographic and epidemiological landscape in Nigeria coupled with the rising 
burden of cardiovascular risk factors and non-communicable diseases (especially hypertension) in 
the country, the rate of HF is predicted to rise if preventive measures are not put in place at all 
levels. This will put a lot of strain in an already weak health system. The high cost of surgical 
interventions and procedures is out of the reach of the average Nigerian. Prevention of conditions 
requiring this mode of care such as rheumatic heart disease, tuberculosis (because of pericarditis) 
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and coronary artery disease should be a priority for the country at large. Furthermore the need  for  
a functional, effective and efficient social health insurance system in the country cannot be 
overemphasized considering the fact that majority of those afflicted by HF are poor and are not 
likely to sustain the treatment of their illness for a long time. There is also need to develop 
community based HF care in the country as this will reduce the cost of outpatient care which is 
largely contributed by the cost of frequent transport to-and-from the health facility. 
9.5.1 Limitations 
This is a hospital based study. Although we tried as much as possible to capture all the HF cases in 
the city during the study period, there is still the possibility that mild cases may have been missed 
out especially those that were managed in the out-patient clinic.  
“The assumption that the same proportion of patients have investigations (ECG etc.) for the 
outpatients and inpatients, and that almost all the patients came for follow-up may not be correct. It 
is likely that a lower proportion of the outpatients (compared with inpatients) will undergo 
investigations and follow-up (given that the in-patients are not able to miss appointments when in 
hospital)” 
We also did not assess cost based on the severity of HF (NYHA class). Studies have shown that those 
in NYHA class IV were 8-30 times more expensive to manage compared to those in NYHA class 
II.(Czech et al., 2013, McMurray and Davie, 1996, McMurray et al., 1993b)  Age and sex-specific cost 
analysis was also not carried out. We also did not include the cost of co-morbidities neither did we 
capture cost due to alternative medicines (which is common in Africa), over the counter purchases, 
capital cost and indirect cost by care givers as well as the general cost to the society. These are 
potential areas of research in our community in the future. 
9.5.2 Conclusion 
Our data shows the profound impact and importance of HF as a major public health problem in a 
developing economy like Nigeria that is still battling with communicable diseases. The annual 
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individual cost of HF is high coupled with the fact that of pocket expenses in the country is over 90%. 
There is therefore need to reduce this expenditure through control of risk factors for HF in the 
society especially high blood pressure, reduction in hospital as well as out-patient care cost through 
the development of community HF care programmes in the country. 
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Chapter 10: Summary, general discussion, future directions and 
conclusions 
 
 242  
10.1  Summary 
We have been able to explore the contemporary profile(Ogah et al., 2014a), intra-hospital 
outcome(Ogah et al., 2014a), short and medium term outcomes(Ogah et al., 2014c, Ogah et al., 
2014d) as well as the economic cost of acute HF(Ogah et al., 2014e) in Abeokuta, South West 
Nigeria. 
We have documented that acute presentation of HF (predominantly denovo) constitute about 10% 
of all medical admission. We have also shown that the mean age of presentation is about 57-years 
which is 20-years lower that the age of presentation of acute HF in Europe and North 
American.(Nieminen et al., 2006a, Adams et al., 2005a) 
 Individuals with acute HF in the city often present late with severe HF (NYHA III and IV). HF with 
impaired systolic function is commoner and the risk factors for HF are non-ischaemic especially 
hypertensive heart disease, dilated cardiomyopathy, rheumatic valvular heart disease and cor-
pulmonale. Intra-hospital outcome is similar to findings in other regions of the world.(Ogah et al., 
2014a) 
In terms of outcomes, the mean length of hospital stay was about 11.4days. Mortality at one month 
was 4.2% rising to 7.3% at 180-days. Rehospitalization at 180-days was 12.2%. Both socio-
demographic and clinical variables affect mortality as well as readmission rates.(Ogah et al., 2014c, 
Ogah et al., 2014d) 
The economic cost of HF in Abeokuta Nigeria is huge considering the early age of presentation and 
longer disability adjusted life years (DALYs) and paucity of social health insurance in the Nigerian 
milieu. Unlike in high income countries where cost of care is mainly due to hospitalization, this is 
fairly shared between in-patient and outpatient care cost in Nigeria (46% and 54%) 
respectively.(Ogah et al., 2014e) 
10.2 Profile of acute HF in the city 
The work provides the first comprehensive and detailed profile of acute HF in the city in particular 
and in Nigeria in Nigeria. Non-ischaemic causes such as hypertensive HF, dilated cardiomyopathy 
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and rheumatic heart disease constitute a greater proportion of the aetiological risk factor for HF in 
the city. This is consistent with similar studies in Nigerian(Laabes et al., 2008) and SSA.(Damasceno 
et al., 2012) Contrary to the findings in this study, HF in high income countries of Europe and 
America is essentially a disease of the elderly.(Nieminen et al., 2006a) 
This portends a huge public health burden as our subjects have higher disability adjusted life years 
with regards to HF.  The younger age of presentation may not be unrelated to the pattern of heart 
disease in our cohort. Diseases such as rheumatic heart disease and cardiomyopathies are 
essentially problems of young people and those in the middle age. In addition, it has been shown 
that hypertension and hypertensive heart disease present earlier in Africans and people of African 
origin.(Opie and Seedat, 2005) 
 
Secondary valvular dysfunction was a common finding in our cohort. This may explain the severity of 
symptoms at the time of presentation in our subjects.  This may also be due to the severity of 
cardiac damage prior to presentation. This has also been documented by other workers.(Stewart et 
al., 2008, Nieminen et al., 2006a) 
The study documented and provided an area of public health intervention and improvement of care 
in the management of HF in the city and Nigeria. The finding of low use of disease modifying therapy 
in the treatment of HF in out cohort provides opportunity for improvement of care through public 
education especially amongst heart care providers. This also calls for subsidization of cost of 
treatment of a chronic condition such a HF by the Government of Nigeria and other countries in SSA. 
A comparative analysis of our finding with previous study in Nigeria about 40 year ago shows that 
hypertension now appears to play a predominant role in the aetiology of HF in Southern Nigeria; 
infection related heart disease such as rheumatic heart disease, pericardial diseases and 
endomyocardial fibrosis appear to be less prominent.  
The study also provided an in-depth and comprehensive analysis of the commonest aetiology for HF 
in Abeokuta and Nigerian in general: hypertensive heart failure (HHF). 
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Less than half of those afflicted were younger than 60years and majority presented in severe HF. 
Abnormal LV geometric pattern, severe diastolic filling pattern and valvular dysfunction were 
common. Similar to the general HF cohort our subjects were younger than the average HHF patient 
in high income country (Nieminen et al., 2006a) but younger than those in some SSA 
countries.(Tantchou Tchoumi et al., 2011a) 
The burden of CV risk factors and co-morbidity was however lower in our cohort compared to 
finding from high income countries. 
Poor hypertension awareness, treatment and control are possible reasons for the severity of the 
condition in this study. Other factors may include ignorance, weak health system and poor social 
support system. 
10.3 Outcome of acute HF in Abeokuta  
There is generally paucity of data on short/ medium term outcome of acute HF in Nigeria. 
The finding from the study shows that the mean length of hospital stay (LOS) was 10.8 ± 6.1 (range: 
2-61 days medium 9 days).(Ogah et al., 2014c) This is longer than data from the THESUS-HF 
study(Damasceno et al., 2012) but short than data from elsewhere in Africa. LOS in our study was 
generally longer than report from high income countries (4-7days). 
Intrahospital mortality rate of 3-8% was comparable to 3.8-6.7% reported by several studies in 
Europe(Siirila-Waris et al., 2006, Nieminen et al., 2006a) and America(Adams et al., 2005a) but lower 
than several reports from SSA (4.3-9.2%).(Damasceno et al., 2012, Tantchou Tchoumi et al., 2011a) 
The findings of HHF constituting majority of our HF population may be responsible for low 
intrahospital mortality rate. This has been previously documented in the EURO HF survey 
II.(Nieminen et al., 2006a)  
The 30- and 180-days mortality rates were 4.2% (95% CI : 2.4 – 7.3%) and 7.3% (95% CI : 14.7 – 
11.2%) respectively. Mortality was associated with lower systolic blood pressure, higher NYHA 
functional class, lower packed cell volume, higher serum creatinine and larger left atrial area. This is 
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similar to finding from previous studies.(Nieminen et al., 2006a, Siirila-Waris et al., 2006, Rudiger et 
al., 2005)  
In line with the “obesity paradox”, higher BMI was associated with better prognosis.(Fonarow et al., 
2008)  
The fact that this study was conducted in a cardiology service, as well as the young age of our cohort 
many explain the relatively low mortality. 
It is also possible that the longer stay of our patients in hospital may afford them the opportunity to 
recover well and get used to their medication before discharge. 
HF outcome is generally better in Japan(Sato et al., 2010) where the average LOS is 21 days 
compared to 6.1-9.0 days in USA(Adams et al., 2005a) and Western Europe.(Nieminen et al., 2006a, 
Rudiger et al., 2005) 
 
We also report lower rate of readmission (predominantly recurrent HF) at 30days (1.53%) and 180 
days (12.2%).(Ogah et al., 2014b) A higher rate of rehospitalization was commoner in the elderly, 
those with lower BMI, lower literacy and lower serum sodium. Others include presence of atrial 
fibrillation, as well as presence of valvular and renal dysfunction. 
On the other hand, female sex, being single, presence of diabetes mellitus and lower packed cell 
volume were associated with lower rates of readmission. These are similar to findings by other 
workers.(Nieminen et al., 2006a, Rudiger et al., 2005, Siirila-Waris et al., 2006) 
The readmission rate reported in this study is similar to the finding in the THESUS-HF 
study(Damasceno et al., 2012) but lower than reports from high income countries.(Adams et al., 
2005a, Nieminen et al., 2006a) 
The younger age of the cohort, the fact that majority of our subjects had HHF and other forms of 
non-ischaemic HF and the longer LOS may be responsible for the lower readmission rate in our 
study. The conduct of this work in a cardiology service may also be another reason. The findings may 
not reflect the picture in the general population in Nigeria. Nevertheless, the study revealed that 
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simple sociodemographic and laboratory variables such as age, BMI, serum sodium, presence of 
atrial fibrillation and valvular dysfunction could be used to predict HF subjects who ae at increased 
risk of readmission. 
10.4 Cost of HF in Abeokuta 
The study also for the first time in Nigeria estimated the cost of HF in Nigeria using the data of the 
Abeokuta HF registry. 
The cost of HF per patient per year was found to be huge considering the fact that Nigeria is a 
developing economy and out-of-pocket expenses is the main means of health care financing. HF cost 
was fairly and proportionally distributed between in-patient and out-patient care.  
The direct cost of in-patient care becomes very huge when surgery and medical procedures are 
utilized in the care. Medications and transportation constituted over 90% of outpatient care cost. 
The finding of huge cost of HF corroborates previous data from many part of the world such as 
UK(Stewart et al., 2002), Sweden(Ryden-Bergsten and Andersson, 1999) etc. 
The almost equal distribution of in-patient and outpatient care cost is similar to a data from 
Brazil.(Araujo et al., 2005) On the other hand in-patient care cost makes up a large proportion of 
cost of HF in high income countries of Western Europe and North America.(Agvall et al., 2005, 
McMurray et al., 1993b, Cook et al., 2014) 
The pattern of heart diseases (which are predominately non-ischaemic), LOS, burden of co-
morbidities as well as the level of technological development may explain the observed difference. 
The burden of co-morbidities is higher in high income countries than in our study. In one USA report, 
management co-morbid conditions contributed 57% of HF care. 
A significant proportion of the outpatient cost is due to transportation. This is because patients are 
often given short appointments in our setting to refill their drugs. 
The establishment of community based or nurse-led or home care of HF patients in our setting could 
curtail this cost. This has been demonstrated in many high income countries of the world.(Agren et 
al., 2013, Stromberg et al., 2003) 
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On the societal point of view, the cost of HF in Nigeria is huge considering the younger age at 
presentation by our subjects coupled with a longer disability adjusted life years. 
Considering the epidemiologic and demographic transition occurring in Nigeria as well as the risking 
burden of CV risk factors, the burden of HF is likely going to rise. This will put a lot of strain on the 
already weak heath system with catastrophic consequences. 
In view of the high cost of cardiac surgery and cardiac procedures, there is need for government to 
subsidize the cost associated with this. 
Preventive measures are also needed to curtail the burden of conditions such as rheumatic heart 
disease and coronary artery disease that most often require these procedure. 
There is need for implementation of the national health coverage and the health insurance scheme 
in the country must be made to work in order to sustain the treatment of chronic conditions such as 
HF. 
10.5 Limitations of the study 
  The cross-sectional nature of this study is a limitation. In addition subjects were recruited mainly 
from the ward in a tertiary health facility. Individuals with milder forms of HF and those who were 
seen at the out-patient clinic may, therefore, have been under-represented. In addition, cases of 
ischaemic heart disease may also have been under-reported because of possibility of sudden death 
at home and for the fact that the centre does not have facility for coronary angiography. 
Furthermore, since it is a single centre study, the findings may not be extrapolated to the general 
Nigerian population. A regional or national HF registry is therefore needed. 
The Framingham criteria used for the screening of the subjects has the limitation in that it has been 
found to be less effective in the elderly population. Some of the other limitations were highlighted in 
the previous chapters. 
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10.6 Future directions 
 The study is a single centre, single city urban hospital based one. Future study will explore 
the regional as well as national burden of HF in Nigeria using a multicentre regional or 
national registry or survey. 
 There is generally no population based incidence or prevalence data on HF in SSA in general 
and Nigeria in particular. The community or population based data on the burden of systolic 
or diastolic dysfunction using echocardiography is unknown. In addition, apart from high 
blood pressure the community burden of other aetiological risk factors for HF such as EMF, 
rheumatic heart disease and right heart failure is largely unknown. This will also be the focus 
of future studies. 
 The molecular pathobiology of HF in SSA is largely unexplored. This is one area I will to 
explore in the future. 
 The secular trend in HF in the country or in SSA is unknown. This has been well studied in 
high income countries of Europe and North America.(Chen et al., 2011, Stewart et al., 2001b, 
Neumann et al., 2009, McMurray et al., 1993a) This is worth studying in the future. 
 There is also need for research into best strategies for treatment and prevention of common 
causes of HF in the country.  
 More cohort studies and longer follow up of HF patients is needed in the country to fully 
describe the natural history of HF in Nigeria.  
 An in-depth cost analysis or economic analysis as well as data on quality of care are also not 
available and needs exploring.  
 Clinical trials on HF as well as on risk factors for HF in Nigeria are generally lacking. 
 Finally, in-depth scientific approaches to better understand the epidemiology, pathobiology 
socio-cultural factors, treatment patterns as well as outcome of HF and diseases leading to 
HF will be the focus of my future research. As suggested by Fonn, “research conceptualized, 
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conducted, analysed and published by Africans is crucial for Africa to meet the health needs 
of her people”(Fonn et al., 1991)  
The identified gaps/challenges and future directions and possible solutions are summarised 
in table 10.1. 
10.7 Conclusions 
Compared to high income countries, individuals presenting with AHF in Abeokuta, Nigeria are 
relatively younger and still of a working age. It is also commoner in men and associated with severe 
symptoms and severe LV systolic dysfunction. Hypertension is by far the commonest aetiological risk 
factor.  
With the projected increase in hypertension in the region in the coming years, the burden of 
hypertension and other complications is expected to rise. There is therefore need to increase 
awareness, identification, treatment and control of hypertension in the city and Nigeria at large. 
Intra-hospital and short- and medium-term outcomes is similar to findings in other parts of the 
world and has similar clinical and laboratory prognostic factors.  
The economic burden of heart failure in the study setting is high considering the minimum wage of 
18,000 Naira (120 US dollars) per month in the country. This calls for financing reforms for the 
control of the disease, which may include a reduction or waiver of user fees in government hospitals, 
scaling up of financial risk protection pre-payment mechanisms such as health insurance and use of 
primary healthcare centres for follow-up visits for mild cases. The development and adequate 
funding of community HF care programmes in the country is also a possible panacea. 
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10.1. Other identified gaps/challenges and future directions and possible solutions 
GAP/CHALLENGE              FUTURE DIRECTION/POSSIBLE SOLUTION 
Chronic HF case were not included in this study  A study targeting chronic “stable” HF case will be 
one of the future projects 
No data on population based study of HF either in 
urban or rural areas of SSA 
Further study at the population level is needed 
Lack of public health policies in SSA that can 
promote equity in health care delivery 
Multi-dimensional and multi-sectional approach is 
needed to address this. This requires improvement 
in finance, education, health, infrastructure, 
agriculture etc. This will play vital role in primordial 
prevention of CVDs. It will also improve fetal as well 
as early childhood nutrition.   
Lack of access to CVD care in the rural areas and 
among the poor in urban areas. 
There is need for strengthening of primary and 
community health programme. This will include 
training of community health offices and nurses to 
be able to identify and monitor HF cases in the 
community.   
HF related care is associated with catastrophic 
experiences 
Nigeria and other SSA countries which do not have 
universal health coverage should work to achieving 
this. 
Weak health systems and inadequate human 
resources for health  
There is need for improvement in the health system 
especially at the community level. Data is needed to 
assess the usefulness/effectiveness of task sharing/ 
shifting in the management of HF in Nigeria in 
particular and in SSA in general. 
Lack if clinical guidelines and protocols for the 
management of HF and many CVDs in Nigeria and 
SSA. 
There is need for development of locally adapted as 
well as appropriate practice guidelines and 
protocols for management of HF and other NCDs in 
SSA. 
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             Appendix I (Published Review Articles)  
Appendix I is the published review of some of the common risk factors for heart failure in SSA: 
Hypertension and cardiomyopathy. 
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Appendix III: Participant information leaflet and informed consent UNIVERSITY OF THE WITWATERSRAND  
HUMAN RESEARCH ETHICS COMMITTEE  
INFORMED CONSENT  
PARTICIPANT INFORMATION LEAFLET AND INFORMED CONSENT 
Each participant must receive, read and understand this document before any study-related procedure!  
STUDY NUMBER:   
STUDY TITLE: A study of the natural history of heart failure in two African populations  
SPONSOR:   None (PhD Thesis) 
INVESTIGATORS:  Dr O.S Ogah/ Prof. K Sliwa / Prof S Stewart/ Prof A.O Falase 
INSTITUTION/s: Soweto Cardiovascular Research Unit, Chris Hani Baragwanath Hospital, University of 
Witwatersrand, Johannesburg, South Africa / and Cardiology Unit, Department of Medicine, Federal 
Medical Centre, Idi-Aba, Abeokuta, Nigeria 
TELEPHONE NUMBERS:  Prof. K. Sliwa - 083 457 4823 ( for South Africa) 
(24-hour contact)  Dr. O.S Ogah - +234 (0) 8067747121( for Nigeria) 
Time and date of first informed consent discussion: 
Date (dd/mm/yyyy): 
Time: 
To the Participant:   This consent form may contain words that you do not understand.   Please ask the 
study doctor or the study staff to explain any words or information that you do not clearly understand.   
You may take home an unsigned copy of this consent form to think about or discuss with family or friends 
before making your decision. 
INTRODUCTION:  
Good day, my name is Dr Okechukwu Ogah. I am a  postgraduate student at the  Department of 
Cardiology, University of Witwatersrand. I would like to invite you to consider participating in a research 
study, entitled " A study of the natural history of heart failure in two African populations”. 
Before agreeing to participate, it is important that you read and understand the following explanation of 
the purpose of the study, the study procedures, benefits, risks, discomforts, and precautions as well as 
the alternative procedures that are available to you, and your right to withdraw from the study at any 
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time. This information leaflet is to help you to decide if you would like to participate. You should fully 
understand what is involved before you agree to take part in this study.  
If you have any questions, do not hesitate to ask me.  
You should not agree to take part unless you are satisfied about all the procedures involved.  
Please be completely truthful with me regarding your health history.  
If you decide to take part in this study, you will be asked to sign this document to confirm that you 
understand the study. You will be given a copy to keep.  
If you have a personal doctor, please discuss with or inform him/her of your possible participation in this 
study. If you wish, I can also notify your personal doctor in this regard. 
PURPOSE OF THE STUDY:  
You have been admitted to hospital with the diagnosis of heart failure.  
The information surrounding the characteristics, causes, treatment and short term outcome of acute 
heart failure in Africa is largely unknown.  
We are doing an observational study researching these aspects of acute heart failure in order to 
improve our knowledge and future care of patients with acute heart failure.  
We would like to know if you would like to participate in the study to help us improve our knowledge 
about the condition of acute heart failure.  
LENGTH OF THE STUDY AND NUMBER OF PARTICIPANTS:  
The study will be performed in two centres in Africa 
Approximately 400 participants will participate in this study in these two centres 
The participant will be above 18 years of age 
The total amount of time required for your participation in this study will be a maximum of six months 
You will be asked to visit me one month after discharge and on three monthly intervals thereafter  
PROCEDURES:  
If you agree to take part in this study, you will first be asked questions and examined to see if you qualify 
for this study. Upon your cardiac clinic visit or on admission in coronary care unit (CCU) you will be 
evaluated for heart failure and the standard treatments administered.  
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Baseline information, including your age, sex and race will be recorded. A thorough cardiovascular 
examination will be done, including vital sign measurements.  
Present and prior medication details will be obtained and/or previous hospitalization due to heart 
failure. 
Any medical tests that may be indicated will be performed, echocardiogram, electrocardiogram, blood 
tests. 
You will be followed-up for this condition as part of the study for six months.  
WILL ANY OF THESE STUDY PROCEDURES RESULT IN DISCOMFORT OR INCONVENIENCE?  
No discomfort or inconvenience will be caused as it is an observational study. 
BENEFITS:  
While there may be no direct benefit to you by participating in this study, your participation may yield 
information that could benefit other patients in Africa having Heart failure. It may help to improve our 
understanding of patients with heart failure at the time of presentation and during the following six 
months of follow-up as well as insight into its treatment.  
ALTERNATIVE TREATMENT:  
Standard treatment will be used to treat heart failure. 
If you decide not to take part in this study you will still receive the same care from your usual doctor, but 
without us recording your responses as described in this sheet.  
ARE THERE ANY WARNINGS OR RESTRICTIONS CONCERNING MY PARTICIPATION IN THIS STUDY?  
You should not participate in the study if you are already participating in another heart failure study.  
RIGHTS AS A PARTICIPANT IN THIS STUDY: 
Voluntary: Your participation in this study is entirely voluntary and you can decline to participate, or 
stop at any time, without stating any reason. Your withdrawal will not affect your access to other 
medical care.  
Discontinuation of study participation: You may discontinue at any time, you only need to say. I will 
supervise any discontinuation with your health as the first priority.  
WITHDRAWAL FROM THIS STUDY: 
Your withdrawal will not affect your access to other medical care.  
I retain the right to withdraw you from the study if it is considered to be in your best interest.  
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If you did not give an accurate history or did not follow the guidelines of the study and the regulations of 
the study facility, you may be withdrawn from the study.  
REIMBURSEMENT FOR STUDY PARTICIPATION:  
You will not be paid to participate in this study. 
ETHICAL APPROVAL:  
This clinical study protocol has been submitted to the University of the Witwatersrand, Human Research 
Ethics Committee (HREC)  
The study has been structured in accordance with the Declaration of Helsinki (last updated: October 
2000), which deals with the recommendations guiding doctors in biomedical research involving human 
subjects. A copy may be obtained from me should you wish to review it.  
This study is not sponsored by any organization  
SOURCE OF ADDITIONAL INFORMATION:  
For the duration of the study, you will be under the care of Dr. Ogah (Nigeria patients). If at any time you 
feel that any of your symptoms are causing you any problems, or you have any questions during the 
study, please do not hesitate to contact me.  
Doctors from the Department of Cardiology who are working on this study are:  
Dr. O.S Ogah and Dr J.O Adesina 
They can be contacted at the above 24 hour telephone numbers. 
If you want any information regarding your rights as a research participant, or complaints regarding this 
research study, you may contact Dr. A.D Eni-Olorunda, Chairman of the Federal Medical Centre, Human 
Research Ethics Committee, which is an independent committee established to help protect the rights of 
research participants at the following number: +234(0) 8033196560 
For further information relates to queries relevant to the study conducted in Nigeria you can contact:  
Dr. O.S Ogah (08067747121) OR Dr. J.O Adesina (0805842948) 
CONFIDENTIALITY:  
All information obtained during the course of this study, including hospital records, personal data and 
research data will be kept strictly confidential. Data that may be reported in scientific journals will not 
include any information that identifies you as a participant in this study. 
This information will be reviewed by Prof. Sliwa, Prof. Stewart, and Dr. Ogah. You have the right to 
privacy, and all information obtained in the survey that identifies you will remain confidential as much 
as possible within state laws. 
 356  
The information might also be inspected by the University of the Witwatersrand, Human Research Ethics 
Committee (HREC), as well as your personal doctor. Therefore, you hereby authorize me to release your 
medical records to the University of the Witwatersrand, Human Research Ethics Committee (HREC). 
These reviewers may learn of your identity but are required by law to keep it confidential. These records 
will be utilised by them only in connection with carrying out their obligations relating to this clinical 
study.  
Any information uncovered regarding your state of health as a result of your participation in this study 
will be held in strict confidence. You will be informed of any finding of importance to your health in this 
study but this information will not be disclosed to any third party in addition to the ones mentioned 
above without your written permission. The only exception to this rule will be cases of communicable 
diseases where a legal duty of notification of the Department of Health exists. In this case, you will be 
informed of my intent to disclose such information to the authorised state agency.  
PERSONAL DOCTOR / SPECIALIST NOTIFICATION OPTION:  
Please indicate below, whether you want me to notify your personal doctor or your specialist of your 
participation in this study:  
(   ) Yes, I want you to inform my personal doctor / specialist of my participation in this study. 
(   ) No, I do not want you to inform my personal doctor / specialist of my participation in this study  
(   ) I do not have a personal doctor / specialist  
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INFORMED CONSENT:  
I hereby confirm that I have been informed by the study doctor, Dr Okechukwu Ogah/ Prof Karen Sliwa 
about the nature, conduct, benefits and risks of the clinical study A study of the natural history of heart 
failure in two African populations I have also received, read and understood the above written 
information (Patient Information leaflet and Informed Consent) regarding this clinical study.  
I am aware that the results of the study, including personal details regarding my sex, age, date of birth, 
and diagnosis will be anonymously processed into a study report.  
In view of the requirements of research, I agree that the data collected during this study can be 
processed in a computerised system by the Department of Cardiology, Chris Hani Baragwaneth Hospital 
or on its behalf.  
I may, at any stage, without prejudice, withdraw my consent and participation in the study.  
I have had sufficient opportunity to ask questions and of my own free will declare myself prepared to 
participate in the study.  
Participant: 
________________________________________________________________________ 
Printed Name   Signature/Mark/Thumbprint  Date and Time 
I, Dr O.S Ogah/ Prof. Karen Sliwa, herewith confirm that the above patient has been fully informed about 
the nature, conduct, benefits and risks of the above study. 
Study Doctor: 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
Study nurse/translator/other person explaining Informed Consent (Designation): 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
Witness (if applicable): 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
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VERBAL PATIENT INFORMED CONSENT:  
(Applicable when patients cannot read or write or are incapable of giving consent)  
I, the undersigned, Dr Okechukwu Ogah/ Prof. Karen Sliwa /  have read and have explained fully to the 
patient, named ____________________________________ and/or his/her relative/friend/legal 
representative, __________________________ the participant information leaflet.  
The account I have given has explained both the possible risks and benefits of the study as well as the 
alternative treatments available for his/her illness. The patient and/or his/her relative/friend/legal 
representative understand these.  
The patient and/or his/her relative/friend/legal representative indicated that he/she understands that 
the patient will be free to withdraw from the study at any time for any reason and without jeopardising 
his/her subsequent treatment.  
I hereby certify that, the patient and/or his/her relative/friend/legal representative acting on his/her 
behalf have agreed to participate in this study.  
Participant:  
________________________________________________________________________ 
Printed Name   Signature/Mark/Thumbprint  Date and Time 
Study Doctor:  
________________________________________________________________________ 
Printed Name    Signature    Date and Time 
Research nurse/translator/other person explaining Informed Consent (Designation): 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
Legal Representative/Friend:  
________________________________________________________________________ 
Printed Name   Signature/Mark/Thumbprint  Date and Time 
Witness (if applicable): 
________________________________________________________________________ 
Printed Name   Signature    Date and Time 
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